

CORRECTED VERSION

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
27 September 2001 (27.09.2001)

PCT

(10) International Publication Number  
**WO 01/070245 A1**

- (51) International Patent Classification<sup>7</sup>: **A61K 35/28**
- (21) International Application Number: PCT/US01/09616
- (22) International Filing Date: 22 March 2001 (22.03.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/191,274 22 March 2000 (22.03.2000) US  
60/204,249 15 May 2000 (15.05.2000) US  
60/264,003 23 January 2001 (23.01.2001) US
- (71) Applicant (for all designated States except US): **CORIXA CORPORATION** [US/US]; 1124 Columbia Street, Suite 200, Seattle, WA 98104 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **CARTER, Darrick** [US/US]; 321 Summit Avenue East, Seattle, WA 98102 (US). **ZHU, Shirley** [US/US]; 152 Oxford Lane, Apt. 1, San Bruno, CA 94066 (US). **ARIMILLI, Subhashini** [US/US]; 4789 Ridgewood Drive, Fremont, CA 94555 (US). **WANG, Aijun** [CN/US]; 3106 213th Place SE, Issaquah, WA 98029 (US).
- (74) Agents: **PARENT, Annette, S.** et al.; Townsend and Townsend and Crew LLP, Two Embarcadero Center, Eighth Floor, San Francisco, CA 94111-3834 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— with international search report
- (48) Date of publication of this corrected version:  
19 December 2002
- (15) Information about Correction:  
see PCT Gazette No. 51/2002 of 19 December 2002, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/070245 A1

(54) Title: IMMUNE MEDIATORS AND RELATED METHODS

(57) Abstract: The present invention relates to nucleic acids encoding single chain MHC class II molecules that form multimers via inter-chain multimerization domains, and methods of treating autoimmune disease using the same.

**IMMUNE MEDIATORS AND RELATED METHODS****CROSS-REFERENCES TO RELATED APPLICATIONS**

This application is related to U.S. Serial No. 60/191,274, filed March 22, 5 U.S. Serial No. 60/204,249, filed May 15, 2000; and U.S. Serial No. 60/264,003, filed January 23, 2001. Each of the aforementioned applications are herein incorporated by reference in their entirety.

This application is also related to U.S. Serial No. 09/261,811, filed March 3, 1999; which is a continuation of U.S. Serial No. 08/657,581, filed June 7, 1996, now 10 abandoned; which is a continuation in part of U.S. Serial No. 08/480,002, filed June 7, 1995, now abandoned; U.S. Serial No. 09/184,692, filed November 2, 1998, now abandoned; U.S. Serial No. 08/483,241, filed June 7, 1995; U.S. Serial No. 08/482,133, filed June 7, 1995; and U.S. Provisional Application No. 60/005,964, filed October 27, 15 1995.

15

**BACKGROUND OF THE INVENTION**

T cells, unlike B cells, do not directly recognize antigens. Instead, an 20 accessory cell must first process an antigen and present it in association with an MHC molecule in order to elicit a T cell-mediated immunological response. The major function of MHC glycoproteins appears to be the binding and presentation of processed antigen in the form of short antigenic peptides.

In addition to binding foreign or "non-self antigenic peptides," MHC molecules can also bind "self" peptides. If T lymphocytes then respond to cells 25 presenting "self" or autoantigenic peptides, a condition of autoimmunity results. Over 30 autoimmune diseases are presently known, including myasthenia gravis (MG), multiple sclerosis (MS), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), insulin-dependent diabetes mellitus (IDDM) , etc. Characteristic of these diseases is an attack by the immune system on the tissues of the host. In non-diseased individuals, such attack does not occur because the immune system recognizes these tissues as "self." 30 Autoimmunity occurs when a specific adaptive immune response is mounted against self tissue antigens.

There is therefore currently a great interest in developing pharmaceuticals based on the growing understanding of the structure and function of the major

histocompatibility complex (MHC) antigens. Identification of synthetic autoantigenic peptides, and demonstration that these peptides bind selectively to MHC molecules associated with disease and that stimulates T cells would help to implicate a particular peptide or peptide:MHC complex in susceptibility to an autoimmune disease. In particular, the development of single chain MHC class II complexes would be particularly useful in treatment of a number of diseases associated with antigen presentation by MHC molecules. Furthermore, the development of single chain, multimeric complexes would be of interest (*see, e.g.*, WO 93/10220, WO 98/05684, WO 97/35991, WO 98/03552, WO 99/13095, WO 98/06749, WO 99/09064, and U.S. Patent 5,869,270).

10

#### SUMMARY OF THE INVENTION

The present invention provides recombinant nucleic acid constructs that encode single chain, recombinant MHC class II molecules comprising a  $\beta 1$  domain and an  $\alpha 1$  domain that may or may not be further linked to an antigenic peptide. In one embodiment, the single chain polypeptide is a  $\beta 1$  domain and an  $\alpha 1$  domain. In another embodiment, the single chain polypeptide is a  $\beta 1$  domain- $\beta 2$  domain (a  $\beta$  chain) and an  $\alpha 1$  domain-  $\alpha 2$  domain (an  $\alpha$  chain). The single chain constructs of the invention can be further dimerized or multimerized by inter-chain fusion. The fusion sequence (also referred to as a dimerization or multimerization sequence) can be any sequence that allows for covalent or non-covalent linkages between the molecules of the invention. As shown below, a preferred means for carrying this out is through use of segments from immunoglobulin family proteins (e.g., antibodies, MHC molecules, T cell receptors and the like) that have cysteine residues capable of forming interchain disulfide bonds (e.g., constant regions from Ig light chains, e.g. C $\kappa$  or C $\lambda$ , or constant regions from Ig heavy chains, e.g., CH1, hinge, CH2, or CH3). In another embodiment, a leucine zipper domain forms a non-covalent linkage. One of skill will recognize that any of a number of polypeptide sequences can be used for this purpose. The single chain molecules of the invention thus can be multimers wherein each single chain molecule is from a different MHC class II allele. In addition, each single chain molecule in the multimer can be bound to a different antigen.

In one embodiment, monomeric and dimeric forms of recombinant single chain mouse I-AS-peptide complexes, fused to an antigenic MBP 90-101 peptide with

flexible linkers were constructed. The recombinant single chain I-AS proteins share structural similarity to that of crystallized native human MHC class II protein as determined by protein modeling. The recombinant single chain proteins were expressed in *E. coli* and in an insect expression system and purified by affinity chromatography and FPLC. The purified single chain recombinant I-AS proteins showed *in vitro* biological activity as assayed using an antigen-specific mouse T cell clone. The *in vivo* activity of the recombinant single chain I-AS fusion proteins in the EAE model using susceptible SJL mice shows that treatment with the recombinant single chain I-AS proteins prevents mortality and significantly reduces paralysis induced by myelin homogenate.

Histological examination of sections from animal spinal cord reveals that these treatments also reduce the inflammatory lesions. These results demonstrate that the single chain MHC class II molecules have therapeutic benefit as antigen-specific drugs for the treatment of autoimmune diseases.

In another embodiment, novel linkers are provided for forming single chain MHC class II molecules. These linkers can be used with the multimer constructs described above. In another embodiment, the constructs of the invention are optimized for prokaryotic expression, using codons adjusted for *E. coli* codon bias.

The present invention also provides MHC class II heterodimers, wherein a recombinant  $\beta$  chain and a recombinant  $\alpha$  chain are covalently linked using polypeptide fusion segments, e.g., from immunoglobulin family proteins (e.g., antibodies, MHC molecules, T cell receptors and the like) that have cysteine residues capable of forming interchain disulfide bonds (e.g., constant regions from Ig light chains, e.g. C $\kappa$  or C $\lambda$ , or constant regions from Ig heavy chains, e.g., CH1, hinge, CH2, or CH3). Such a heterodimer can also be “dimerized” or “multimerized” by the use of additional fusion domains, such as leucine zipper domains or immunoglobulin domains (see Figure 10).

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1. Schematic structure of the recombinant single chain I-AS .MBP. $\beta$ 1 $\alpha$ 1 (monomer) and I-AS.MBP. $\beta$ 1 $\beta$ 2 $\alpha$ 1 $\alpha$ 2.CK (dimer) proteins.

Figure 2. *In vitro* biological activities of the recombinant I-AS proteins compared with APC+ antigenic peptide in the mouse T cell clone, HS-1.  
A. I-AS.MBP. $\beta$ 1 $\alpha$ 1, monomer, B. I-AS.MBP.Ck, dimer, and C. APC+ antigenic

peptide. The positive (anti-CD3) and the negative (HS-1 cell alone) controls are also shown in each panel.

Figure 3. Diagram of the EAE model and standard for EAE scoring.

Figure 4. The EAE model studies. The recombinant I-AS proteins were  
5 administered to SJL mice on day 1, 4, 7, and II by i.v. injection after inducing the disease  
with myelin emulsified in CFA. The animals were evaluated for neurological  
dysfunction. Panel A: Untreated, injected with same amount of PBS solution. Panel B.  
Treated with the recombinant I-AS.MBP.Ck protein, a dimer form. Panel C: Treated  
with the recombinant I-AS. $\beta$ 1 $\alpha$ 1. This recombinant molecule does not carry the antigenic  
10 peptide. Panel D: Treated with the recombinant I-AS.MBP. $\beta$ 1 $\alpha$ 1, a monomer form.

Figure 5 shows a schematic representation of a  $\beta$ 1- $\alpha$ 1 single chain MHC  
class II peptide complex that is a dimer with two peptide specificities.

Figure 6 shows a schematic representation of a  $\beta$ 1 $\beta$ 2- $\alpha$ 1 $\alpha$ 2 single chain  
MHC class II peptide complex that is a dimer with two peptide specificities.

15 Figure 7 shows a schematic representation of a  $\beta$ 1 $\beta$ 2- $\alpha$ 1 $\alpha$ 2 single chain  
MHC class II peptide complex that is a tetramer with four peptide specificities.

Figure 8 shows a schematic representation of a  $\beta$ 1 $\beta$ 2- $\alpha$ 1 $\alpha$ 2 single chain  
MHC class II peptide complex that is a tetramer with two peptide specificities and two  
different MHC class II alleles.

20 Figure 9 shows the effect of different recombinant MHC class II molecules  
on the development of EAD (day 60+).

Figure 10. Diagram of  $\beta$ 1- $\alpha$ 1 single chain MHC class II peptide complex;  
diagram of recombinant  $\beta$ 1 $\beta$ 2 chains fused to recombinant  $\alpha$ 1 $\alpha$ 2 chains via a fusion  
domain from an immunoglobulin; and diagram of multimerized MHC class II molecules.

25 Figure 11. Sequence comparison of mouse CO608 single chain molecules.

Figure 12. Sequence comparison of mouse CO561 single chain molecules.

## DETAILED DESCRIPTION OF THE INVENTION

### Introduction

30 The present invention provides recombinant DNA constructs that encode  
single chain MHC class II molecules that may or may not be further linked to an antigenic  
peptide. Typically, the constructs comprise a first DNA segment encoding a  $\beta$ 1 domain

of a selected MHC class II molecule; a second DNA segment encoding a  $\alpha$ 1 domain of the selected MHC class II molecule; and a first linker DNA segment connecting in-frame the first and second DNA segments; wherein linkage of the first DNA segment to the second DNA segment by the first linker DNA segment results in a fused first DNA-first 5 linker-second DNA polysegment. The constructs of the invention may also comprise a third DNA segment encoding an antigenic peptide capable of associating with a peptide binding groove of the selected MHC class II molecule and a second linker DNA segment connecting in-frame the third DNA segment to the fused first DNA-first linker-second DNA polysegment.

10 In another embodiment, the present invention also provides recombinant components of an MHC class II heterodimer, which comprise a fusion domain. One recombinant component comprises a  $\beta$ 1 domain, or optionally a  $\beta$ 1 domain- $\beta$ 2 domain (i.e., a  $\beta$  chain). One recombinant component comprises an  $\alpha$ 1 domain, or optionally an  $\alpha$ 1 domain-  $\alpha$ 2 domain (i.e., an  $\alpha$  chain). The two recombinant chains are linked, either 15 covalently, e.g., via a disulfide bond, or non covalently, using the fusion domain. Such molecules can also be made into multimers using additional fusion or multimerization domains. In one embodiment, the invention provides the following recombinant components of an MHC class II heterodimer: pCB220, which is an IAS.MBP.alpha chain fused to an IgG2a CH1 and truncated hinge region; pCB223, which is an IAS.MBP.alpha 20 chain fused to an IgG2a CH1.H.CH2.CH3; and pCB229, which is an IAS.MBP.beta chain fused to a mouse C $\kappa$  domain. These recombinant components can be fused via the fusion domain to form a MHC class II heterodimer molecule that is covalently linked via a disulfide bond at the fusion domain.

25 The present invention provides single chain MHC class II molecules that comprise an additional polypeptide sequence that allows for inter-chain dimerization of the single chain molecules of the invention. The additional polypeptide allows multimerization of the single chain MHC class II molecules, to produce, e.g., dimers and tetramers. The sequence can be any sequence that allows for covalent or non-covalent linkages between the molecules of the invention. In one embodiment, the single chain 30 molecules are covalently linked using chemical methods known to those of skill in the art, e.g., photoaffinity methods or homo-bifunctional protein cross-linkers (*see, e.g., Hermanson et al., Bioconjugate Techniques, (1996)*). In one embodiment, the molecules

are covalently linked using heterobifunctional protein cross-linkers. As shown below, one means for carrying this out is through use of segments from immunoglobulin family proteins (*e.g.*, antibodies, MHC molecules, T cell receptors and the like) that have cysteine residues capable of forming interchain disulfide bonds. An example shown  
5 below is the use of the constant region of the kappa chain of an antibody (C $\kappa$ ), from either a heavy or a light chain. Other dimerization sequences include a leucine zipper, a STAT protein N-terminal domain, or the FK506 binding protein (*see, e.g.*, O'Shea, *Science* 254: 539 (1991), Barahmand-Pour *et al.*, *Curr. Top. Microbiol. Immunol.* 211:121-128 (1996); Klemm *et al.*, *Annu. Rev. Immunol.* 16:569-592 (1998); Ho *et al.*, *Nature* 382:822-826  
10 (1996)). One of skill will recognize that any of a number of polypeptide sequences can be used for this purpose.

In addition, the multimeric, single chain class II molecules of the invention comprise at least two different MHC class II alleles that are associated with an autoimmune disease state, and/or at least two different autoantigenic peptides that are  
15 associated with a particular autoimmune disease state. In one example, the multimeric, single chain class II molecules have chains from different DR2 alleles, *e.g.*, DRB5\*0101 and DRB1\*1501. In another embodiment, the autoantigenic peptides are peptides associated with multiple sclerosis, *e.g.*, MBP (*e.g.*, amino acid residues 83-102Y83), PLP (*e.g.*, amino acid residues 40-60, 89-106, 95-117, and 185-206); and MOG. In addition,  
20 other antigens associated with autoimmune disease, such as acetylcholine receptor and type II collagen, can be linked to the single chain molecules of the invention..

In a further embodiment, the single chain class II molecules of the invention have novel linkers, as described herein. The mammalian MHC class II single chain constructs of the invention may also be constructed to use preferred prokaryotic  
25 codons, for expression, *e.g.*, in *E. coli*, using codon preference tables and methods known to those of skill in the art.

## Definitions

Prior to setting forth the invention, it may be helpful to an understanding  
30 thereof to provide definitions of certain terms to be used hereinafter:

Single chain MHC class II molecule: As used herein this term refers to a fusion protein such as the recombinant single chain MHC class II complex of the

invention, which optionally also is fused to a peptide to form a single chain MHC class:peptide complex. The fusion proteins of the invention can also be multimers, having two, four or more single chain molecules linked covalently or non-covalently through multimerization domains in the single chain molecule. A single chain molecule  
5 of the invention typically comprises at least an MHC class II  $\beta$ 1 domain and an MHC class II  $\alpha$ 1 domain, optionally  $\beta$ 1  $\beta$ 2  $\alpha$ 1  $\alpha$ 2 domains or any combination thereof in any order. Such molecules are also known as "fused heterodimers." Optionally, the single chain molecules are soluble, that is, they lack the naturally occurring cytoplasmic and transmembrane MHC class II domains.

10           A domain of a selected MHC molecule: A portion of an MHC domain which is sufficient to form, either alone, or in combination with another portion of an MHC domain, a peptide binding site which is capable of presenting an antigenic peptide in such a fashion that it is recognized by a T cell receptor. Such MHC domains would include the extracellular portion of the two polypeptide chains of Class II MHC. This  
15 would include the  $\alpha$  chain ( $\alpha$ 1 and  $\alpha$ 2 domains) and  $\beta$  chain ( $\beta$ 1 and  $\beta$ 2 domains) of Class II MHC. This would include  $\beta$ 1 and  $\alpha$ 1,  $\beta$ 1,  $\beta$ 2 and  $\alpha$ 1,  $\alpha$ 2,  $\alpha$ 1 or  $\alpha$ 2 independent of the other, or  $\alpha$ 1 and  $\alpha$ 2 in tandem ( $\alpha$ 1 $\alpha$ 2). It would also include  $\beta$ 1 or  $\beta$ 2 independent of the other, or  $\beta$ 1 and  $\beta$ 2 in tandem ( $\beta$ 1 $\beta$ 2). This would also include any suitable combination  
20 of the  $\alpha$ 1,  $\alpha$ 2,  $\beta$ 1, and  $\beta$ 2 domains. The domains can be directly linked, or can be linked via an amino acid linker.

25           Linker DNA segment: A segment of DNA encoding from about 1 to about 50, preferably from about 5 to about 25 amino acids, which forms a flexible link between two DNA segments. This flexible link allows the two DNA segments to attain a proper configuration, such as an MHC peptide binding groove, or allows a peptide to properly bind into such a groove.

30           Antigenic peptide: The immunological properties of MHC histocompatibility proteins are largely defined by the antigenic peptide that is bound to them. An antigenic peptide is one which contains an epitope (an amino acid sequence) recognized by immune cells, e.g., T cells, and is capable of stimulating an MHC-mediated immune response.. Antigenic peptides for a number of autoimmune diseases are known. For example, in experimentally induced autoimmune diseases, antigens involved in pathogenesis have been characterized: in arthritis in rat and mouse, native type II collagen

is identified in collagen-induced arthritis, and mycobacterial heat shock protein in adjuvant arthritis (Stuart *et al.*, *Ann. Rev. Immunol.* 2:199-218, 1984; and van Eden *et al.*, *Nature* 331:171-173, 1988); thyroglobulin has been identified in experimental allergic thyroiditis (EAT) in mice (Marion *et al.*, *J. Exp. Med.* 152:1115-1120, 1988); acetyl-choline receptor (AChR) in experimental allergic myasthenia gravis (EAMG) (Lindstrom *et al.*, *Adv. Immunol.* 42:233-284, 1988); and myelin basic protein (MBP) and proteolipid protein (PLP) in experimental allergic encephalomyelitis (EAE) in mouse and rat (Acha-Orbea *et al.*, *Ann. Rev. Imm.* 7:377-405, 1989). In addition, target antigens have been identified in humans: type II collagen in human rheumatoid arthritis (Holoshitz *et al.*, *Lancet* ii:305-309, 1986), acetylcholine receptor in myasthenia gravis (Lindstrom *et al.*, *Adv. Immunol.* 42.:233-284, 1988), and MBP, PLP, and MOG in multiple sclerosis in humans.

**MHC:** The major histocompatibility complex (MHC) is a family of highly polymorphic proteins, divided into two classes, Class I and Class II, which are membrane-associated and present antigen to T lymphocytes (T cells). MHC Class I and Class II molecules are distinguished by the types of cells on which they are expressed, and by the subsets of T cells which recognize them. Class I MHC molecules (e.g., HLA-A, -B and -C molecules in the human system) are expressed on almost all nucleated cells and are recognized by cytotoxic T lymphocytes (CTL), which then destroy the antigen-bearing cells. Class II MHC molecules (HLA-DP, -DQ and -DR, for example, in humans) are expressed primarily on the surface of antigen-presenting cells, such as B lymphocytes, dendritic cells, macrophages, and the like. Class II MHC is recognized by CD4<sup>+</sup> T helper lymphocytes (T<sub>H</sub>). T<sub>H</sub> cells induce proliferation of both B and T lymphocytes, thus amplifying the immune response to the particular antigenic peptide that is displayed (Takahashi, *Microbiol. Immunol.*, 37:1-9, 1993).

Two distinct antigen processing pathways are associated with the two MHC classes. Intracellular antigens, synthesized inside of the cell, such as from viral or newly synthesized cellular proteins, for example, are processed and presented by Class I MHC. Exogenous antigens, taken up by the antigen-presenting cell (APC) from outside of the cell through endocytosis, are processed and presented by Class II MHC. After the antigenic material is proteolytically processed by the MHC-bearing cell, the resulting antigenic peptide forms a complex with the antigen binding groove of the MHC molecule

through various noncovalent associations. The MHC-peptide complex on the cell surface is recognized by a specific T cell receptor on a cytotoxic or helper T cell.

The MHC of humans (also referred to as human leukocyte antigens (HLA)) on chromosome 6 has three loci, HLA-A, HLA-B and HLA-C, the first two of which have a large number of alleles encoding alloantigens. An adjacent region, known as HLA-D, is subdivided into HLA-DR, HLA-DQ and HLA-DP. The HLA region is now known as the human MHC region, and is equivalent to the H-2 region in mice. HLA-A, -B and -C resemble mouse H-2K, -D, and -L and are the Class I MHC molecules. HLA-DP, -DQ and -DR resemble mouse I-A and I-E and are the Class II molecules. MHC glycoproteins of both classes have been isolated and characterized (*see Fundamental Immunology*, 2d Ed., Paul (ed.), (1989); and Roitt *et al.*, *Immunology*, 2d Ed., (1989), which are both incorporated herein by reference).

Human MHC Class I molecules consist of a polymorphic type I integral membrane glycoprotein heavy chain of about 46 kD, noncovalently associated with a 12 kD soluble subunit,  $\beta_2$ -microglobulin. The heavy chain consists of two distinct extracellular regions, the membrane distal, peptide binding region formed by the  $\alpha_1$  and  $\alpha_2$  domains, and the membrane proximal, CD8-binding region derived from the  $\alpha_3$  domain.  $\beta_2$ - microglobulin is a single, compact immunoglobulin-like domain that lacks a membrane anchor, and exists either associated with the class I heavy chain or free in plasma (Germain and Margulies, *Annu. Rev. Immunol.* 11:403-50, 1993).

Human MHC Class II is a heterodimeric integral membrane protein. Each dimer consists of one  $\alpha$  and one  $\beta$  chain in noncovalent association. The two chains are similar to each other, with the  $\alpha$  chain having a molecular weight of 32-34 kD and the  $\beta$  chain having a molecular weight of 29-32 kD. Both polypeptide chains contain N-linked oligosaccharide groups and have extracellular amino termini and intracellular carboxy termini.

The extracellular portions of the  $\alpha$  and  $\beta$  chain that comprise the class II molecule have been subdivided into two domains of about 90 amino acids each, called  $\alpha_1$ ,  $\alpha_2$ , and  $\beta_1$ ,  $\beta_2$ , respectively. The  $\alpha_2$  and  $\beta_2$  domains each contain a disulfide-linked loop. The peptide-binding region of the class II molecule is formed by the interaction of the  $\alpha_1$  and  $\beta_1$  domains. This interaction results in an open-ended, antigenic peptide-binding groove made up of two  $\alpha$  helices, and an eight-stranded  $\beta$ -pleated sheet platform.

10

The  $\alpha$  and  $\beta$  chains of Class II molecules are encoded by different MHC genes and are polymorphic (see Addas *et al.*, *Cellular and Molecular Immunology*, 2d Ed. (1994), which is incorporated by reference in its entirety). Within the present invention, a preferred  $\alpha$  chain is DRA\*0101 and a preferred  $\beta$  chain is DR $\beta$ 1\*1501.

5

### MHC Class II alleles

The single chain MHC class II:peptide complexes of the present invention can incorporate cDNA from any allele that predisposes or increases the likelihood of susceptibility to a specific autoimmune disease. Specific autoimmune diseases are

10 correlated with specific MHC types. Specific haplotypes have been associated with many of the autoimmune diseases. For example, HLA-DR2 $^+$  and HLA-DR3 $^+$  individuals are at a higher risk than the general population to develop systemic lupus erythematosus (SLE) (Reinertsen *et al.*, *N. Engl. J. Med.* 299:515-18, 1970). Myasthenia gravis has been linked to HLA-D (Safwenberg *et al.*, *Tissue Antigens* 12:136-42, 1978. Susceptibility to 15 rheumatoid arthritis is associated with HLA-D/DR in humans. Methods for identifying which alleles, and subsequently which MHC-encoded polypeptides, are associated with an autoimmune disease are known in the art. Exemplary alleles for IDDM include DR4, DQ8, DR3, DQ3.2.

20 **Uses of single chain MHC class II molecules**

Single chain MHC class II molecules and/or single chain MHC class II:peptide complexes of the present invention can be used as antagonists to therapeutically block the binding of particular T cells and antigen-presenting cells. In addition, the molecules can induce anergy, or proliferative nonresponsiveness, and possibly apoptosis, 25 in targeted T cells, both *in vivo* and *in vitro*. A single chain MHC class II:peptide molecule directed toward a desired autoimmune disease contains the antigenic peptide implicated for that autoimmune disease properly positioned in the binding groove of the MHC molecule, without need for solubilization of MHC or exogenous loading of an independently manufactured peptide.

30 Previous methods for producing desirable MHC Class II histocompatibility proteins have provided material that contains a mixture of antigenic peptides (Buus *et al.*, *Science* 242:1045-1047, 1988; and Rudensky *et al.*, *Nature* 353:622-627, 1991), which

can be only partially loaded with a defined antigenic peptide (Watts and McConnel, *Proc. Natl. Acad. Sci. USA* 83:9660-64, 1986; and Cappellini *et al.*, *Nature* 339:392-94, 1989). Various methods have been developed to produce heterodimers that do not present endogenous antigens (Stern and Wiley, *Cell* 68:465-77, 1992; Ljunggren *et al.*, *Nature* 346:476-80, 1990; and Schumacher *et al.*, *Cell* 62:563-67, 1990) that can be loaded with a peptide of choice. WO 95/23814 and Kozono *et al.* have described production of soluble murine Class II molecules, I-E<sup>dk</sup> and I-A<sup>d</sup>, each with a peptide attached by a linker to the N terminus of the  $\beta$  chain. Ignatowicz *et al.* (*J. Immunol.* 154:38-62, 1995) have expressed membrane-bound I-A<sup>d</sup> with peptide attached. These methods incorporate the use of both membrane-bound heterodimer and soluble heterodimer.

The current invention offers the advantage of a recombinant single chain MHC class II molecule made up of two or more MHC domains joined together via a flexible linkage, and onto which is tethered (via an additional flexible linkage) an antigenic peptide which is able to bind to the peptide binding groove presented by the single chain MHC class II molecule. Such a complex provides an MHC molecule which is soluble and, because the MHC class II components and corresponding antigenic peptide are permanently linked into a single chain configuration, there is no need for complex heterodimer truncation or formation. These complexes eliminate inefficient and nonspecific peptide loading. Producing the claimed MHC:peptide complexes by recombinant methodology results in specific, high yield protein production, where the final product contains only the properly configured MHC:peptide complex of choice.

As used herein, a soluble MHC class II molecules is one that does not contain the naturally occurring membrane-associated MHC class II sequences. The soluble MHC molecules of the present invention has never been membrane-associated. Further, the soluble MHC class II molecules do not contain an amino acid sequence that acts as a transmembrane domain or as a cytoplasmic domain.

The present invention therefore provides a single chain MHC class II molecule which optionally includes an antigenic peptide covalently attached to the amino terminal portion of an  $\alpha$  or  $\beta$  chain of MHC through a peptide linkage, and the C terminal of the linked  $\alpha$  or  $\beta$  chain may be attached to the N terminal portion of another  $\alpha$  or  $\beta$  chain, thereby creating a two, three, or four domain MHC molecule. The invention further provides a multimerization domain to provide a multimeric single chain MHC

## 12

class II molecules. The invention further provides novel linkers, and multimeric MHC class II molecules that are bound to different antigenic peptides.

The amino acid sequence of each of a number of Class I and Class II proteins are known, and the genes or cDNAs have been cloned. Thus, these nucleic acids can be used to express MHC polypeptides. If a desired MHC gene or cDNA is not available, cloning methods known to those skilled in the art may be used to isolate the genes. One such method that can be used is to purify the desired MHC polypeptide, obtain a partial amino acid sequence, synthesize a nucleotide probe based on the amino acid sequence, and use the probe to identify clones that harbor the desired gene from a cDNA or genomic library.

### Linkers

Linkers of the current invention may be from about 1 to about 50 amino acids in length, depending on the molecular model of the MHC or MHC:peptide complex.

In one embodiment, flexible linkers are made of repeating Gly residues separated by one or more Ser residues to permit a random, flexible motion. In the case of Class II MHC complexes this flexibility accommodates positioning of the  $\alpha$  and  $\beta$  segments to properly configure the binding groove, and also allows for maximum positioning of the peptide in the groove. In another embodiment, the linker comprises a CD4 binding site, as described below in the Example section (see also Table 1). In another embodiment, longer linkers between the chains contain flexible residues (e.g. alanine or glycine) and polar residues (e.g. serine and threonine). To inhibit the continuation of secondary structure across the linker, prolines can be added to bracket the linkers. These prolines are known to inhibit the formation of alpha helices and beta sheets. In another embodiment, flexible regions present in the human MHC and in the murine MHC could be used to make a linker by extending the region of interest and ligating the ends together. Finally, a combination of these types of linkers could also be used.

Linker position and length can be modeled based on the crystal structure of MHC Class II molecules (Brown *et al.*, *Nature* 364:33-39, 1993), where  $\alpha 1$  and  $\beta 1$  are assembled to form the peptide binding groove. Linkers joining segments of the  $\alpha$  and  $\beta$  chains together are based on the geometry of the region in the hypothetical binding site and the distance between the C terminus and the N terminus of the relevant segments.

Molecular modeling based on the X-ray crystal structure of Class II MHC (Stern *et al.*, *Nature* 368:215-221, 1994) dictates the length of linkers joining antigenic peptide,  $\alpha$  chain segments and  $\beta$  chain segments. The recombinant portions of the molecules of the invention can also be directly linked, without additional amino acids linkers.

5

### **Identification of autoantigens**

The invention also provides methods for preparing responder T-cell clones that proliferate when combined with a selected antigenic peptide presented by a stimulator cell. Such clones can be used to identify and map antigenic peptides associated with autoimmune disease. These peptides can then be incorporated into the single chain MHC class II molecule:peptide complexes of the invention. The method provides isolation and enrichment of non-adherent, CD56 $^{+}$ , CD8 $^{+}$  T cells that are reactive with a selected antigenic peptide. These cells are herein referred to as responder cells.

Suitable responder cells can be isolated, for example, from peripheral blood mononuclear cells (PBMNC) obtained from patients prior to or after onset of an autoimmune disease of interest. For example, PBMNCs can be obtained from prediabetic and new onset diabetic patients. These patients can be pre-screened for specific HLA markers, such as DR3-DR4 or DQ3.2, which have the highest association with susceptibility to IDDM. From the collected PBMNCs, a portion is kept to serve as stimulator cells. From the remainder, the desired autoreactive responder cells are purified and isolated by two rounds of plating, to remove adherent cells from the population, followed by removal of monocytes and B cells with nylon wool. Enrichment for non-adherent CD4 $^{+}$  T cells is completed by sequential plating of the cells onto plates coated with anti-CD8 and anti-CD6 antibodies.

The stimulator cells are pulsed or primed with whole GAD or an appropriate antigenic peptide. For example, stimulator cells from the PBMNCs of IDDM patients can be stimulated with antigenic GAD peptides then combined with PBMNCs or responder cells. After seven or 14 days, responder cell (T cell) clones are generated through limiting dilution and tested for antigen reactivity.

These responder cell (T cell) clones can then be used, for example, to map epitopes which bind to MHC and are recognized by a particular T cell. One such method uses overlapping peptide fragments of the autoantigen which are generated by tryptic

digestion, or more preferably, overlapping peptides are synthesized using known peptide synthesis techniques. The peptide fragments are then tested for their ability to stimulate the responder T cell clones or lines (for example, Ota *et al.*, *Nature* 346:183-187, 1990).

Once such a peptide fragment has been identified, synthetic antigenic peptides can be specifically designed, for example, to enhance the binding affinity for MHC and to out-compete any naturally processed peptides. Such synthetic peptides, when combined into a single chain MHC class II molecule:peptide complex, would allow manipulation of the immune system *in vivo*, in order to tolerize or anergize disease-associated activated T cells, thereby ameliorating the autoimmune disease.

Dissecting the functional role of individual peptides and peptide clusters in the interaction of a peptide ligand with an MHC molecule, and also in subsequent T cell recognition and reactivity, is a difficult undertaking due to the degeneracy of peptide binding to the MHC. Changes in T cell recognition or in the ability of an altered peptide to associate with MHC can be used to establish that a particular amino acid or group of amino acids comprises part of an MHC or T cell determinant. The interactions of altered peptides can be further assessed by competition with the parental peptide for presentation to a T cell, or through development of direct peptide-MHC binding assays. Changes to a peptide that do not involve MHC binding could well affect T cell recognition. For example, in a peptide, specific MHC contact points might only occur within a central core of a few consecutive or individual amino acids, whereas those amino acids involved in T cell recognition may include a completely different subset of residues.

In a preferred method, residues that alter T cell recognition are determined by substituting amino acids for each position in the peptide in question, and by assessing whether such change in residues alters the peptide's ability to associate with MHC (Allen *et al.*, *Nature* 327:713-15, 1987; Sette *et al.*, *Nature* 328:395-99, 1987; O'Sullivan *et al.*, *J. Immunol.* 147:2663-69, 1991; Evavold *et al.*, *J. Immunol.* 148:347-53, 1992; Jorgensen *et al.*, *Annu. Rev. Immunol.* 10:835-73, 1992; Hammer *et al.*, *Cell* 74:197-203, 1993; Evavold *et al.*, *Immunol. Today* 14:602-9, 1993; Hammer *et al.*, *Proc. Natl. Acad. Sci. USA* 91:4456-60, 1994; and Reich *et al.*, *J. Immunol.* 154:2279-88, 1994). One method would involve generating a panel of altered peptides wherein individual or groups of amino acid residues are substituted with conservative, semi-conservative or non-conservative residues. A preferred variant of this method is an alanine scan (Ala scan)

where a series of synthetic peptides are synthesized wherein each individual amino acid is substituted with L-alanine (L-Ala scan). Alanine is the amino acid of choice because it is found in all positions (buried and exposed), in secondary structure, it does not impose steric hindrances, or add additional hydrogen bonds or hydrophobic side chains. Alanine  
5 substitutions can be done independently or in clusters depending on the information desired. Where the information pertains to specific residues involved in binding, each residue in the peptide under investigation can be converted to alanine and the binding affinity compared to the unsubstituted peptide. Additional structural and conformational information regarding each residue and the peptide as a whole can be gained, for  
10 example, by synthesizing a series of analogs wherein each residue is substituted with a D-amino acid such as D-alanine (D-Ala scan) (Galantino *et al.*, in Smith, J. and Rivier, J. (eds.), *Peptides Chemistry and Biology (Proceedings of the Twelfth American Peptide Symposium)*, ESCOM, Leiden, 1992, pp. 404-05). Essential residues can be identified, and nonessential residues targeted for modification, deletion or replacement by other  
15 residues that may enhance a desired quality (Cunningham and Wells, *Science* 244:1081-1085, 1989; Cunningham and Wells, *Natl. Acad. Sci. USA*, 88:3407-3411, 1991; Ehrlich *et al.*, *J. Biol. Chem.* 267:11606-11, 1992; Zhang *et al.*, *Proc. Natl. Acad. Sci. USA* 90:4446-50, 1993; see also "Molecular Design and Modeling: Concepts and Applications Part A Proteins, Peptides, and Enzymes," *Methods in Enzymology*, Vol. 202, Langone  
20 (ed.), Academic Press, San Diego, CA, 1991).

Truncated peptides can be generated from the altered or unaltered peptides by synthesizing peptides wherein amino acid residues are truncated from the N- or C-terminus to determine the shortest active peptide, or between the N- and C-terminus to determine the shortest active sequence. Such peptides could be specifically developed to  
25 stimulate a response when joined to a particular MHC to form a peptide ligand to induce anergy in appropriate T cells *in vivo* or *in vitro*.

#### **Analysis of single chain MHC class II molecule:peptide complexes**

The physical and biological properties of the single chain MHC class II molecule:peptide complexes may be assessed in a number of ways. Mass spectral analysis methods such as electrospray and Matrix-Assisted Laser Desorption/Ionization Time Of Flight mass spectrometry (MALDI TOF) analysis are routinely used in the art to  
30

provide such information as molecular weight and confirm disulfide bond formation. FACS analysis can be used to determine proper folding of the single chain complex.

An ELISA (Enzyme-linked Immunosorbent Assay) can be used to measure concentration and confirm correct folding of the single chain MHC class II molecule:peptide complexes. This assay can be used with either whole cells; solubilized MHC, removed from the cell surface; or free single chain MHC class II molecule:peptide complexes of the current invention. In an exemplary ELISA, an antibody that detects the recombinant MHC haplotype is coated onto wells of a microtiter plate. In a preferred embodiment, the antibody is L243, a monoclonal antibody that recognizes only correctly folded HLA-DR MHC dimers. One of skill in the art will recognize that other MHC Class II-specific antibodies are known and available. Alternatively, there are numerous routine techniques and methodologies in the field for producing antibodies (for example, Hurrell, (ed.), *Monoclonal Hybridoma Antibodies: Techniques and Applications*, CRC Press Inc., Boca Raton, FL, 1982), if an appropriate antibody for a particular haplotype does not exist. Anti-MHC Class II antibodies can also be used to purify Class II molecules through techniques such as affinity chromatography, or as a marker reagent to detect the presence of Class II molecules on cells or in solution. Such antibodies are also useful for Western analysis or immunoblotting, particularly of purified cell-secreted material. Polyclonal, affinity purified polyclonal, monoclonal and single chain antibodies are suitable for use in this regard. In addition, proteolytic and recombinant fragments and epitope binding domains can be used herein. Chimeric, humanized, veneered, CDR-replaced, reshaped or other recombinant whole or partial antibodies are also suitable.

In the ELISA format, bound MHC molecules can be detected using an antibody or other binding moiety capable of binding MHC molecules. This binding moiety or antibody may be tagged with a detectable label, or may be detected using a detectably labeled secondary antibody or binding reagent. Detectable labels or tags are known in the art, and include fluorescent, colorimetric and radiolabels, for instance.

Other assay strategies can incorporate specific T-cell receptors to screen for their corresponding MHC-peptide complexes, which can be done either *in vitro* or *in vivo*. For example, an *in vitro* anergy assay determines if non-responsiveness has been induced in the T cells being tested. Briefly, an MHC molecule containing antigenic peptide in the peptide binding groove can be mixed with responder cells, preferably

5 peripheral blood mononuclear cells (PBMN) (a heterogeneous population including B and T lymphocytes, monocytes and dendritic cells), PBMNC lymphocytes, freshly isolated T lymphocytes, *in vivo* primed splenocytes, cultured T cells, or established T cell lines or clones. Responder cells from mammals immunized with, or having a demonstrable cellular immune response to, the antigenic peptide are particularly preferred.

Subsequently, these responder cells are combined with stimulator cells (antigen presenting cells; APCs) that have been pulsed or primed with the same antigenic peptide. In a preferred embodiment, the stimulator cells are antigenic peptide-presenting cells, such as PBMNCs, PBMNCs that have been depleted of lymphocytes, appropriate antigenic peptide-presenting cell lines or clones (such as EBV-transformed B cells), EBV transformed autologous and non-autologous PMNCs, genetically engineered antigen presenting cells, such as mouse L cells or bare lymphocyte cells BLS-1, in particular, DRB1\*0401, DRB1\*0404 and DRB1\*0301 (Kovats *et al.*, *J. Exp. Med.* 179:2017-22, 1994), or *in vivo* or *in vitro* primed or pulsed splenocytes. Stimulator cells from 10 mammals immunized with, or having a demonstrable cellular immune response to, the antigenic peptide are particularly preferred. For certain assay formats, it is preferred to inhibit the proliferation of stimulator cells prior to mixing with responder cells. This inhibition may be achieved by exposure to gamma irradiation or to an anti-mitotic agent, such as mitomycin C, for instance. Appropriate negative controls are also included 15 (nothing; syngeneic APC; experimental peptide; APC + Peptide; MHC:peptide complex; control peptide +/- APC). Further, to assure that non-responsiveness represents anergy, the proliferation assay may be set up in duplicate, +/- recombinant IL-2 since it has been demonstrated that IL-2, can rescue anergized cells.

20 After an approximately 72 hour incubation, the activation of responder cells in response to the stimulator cells is measured. In a preferred embodiment, responder cell activation is determined by measuring proliferation using <sup>3</sup>H-thymidine uptake (Crowley *et al.*, *J. Immunol. Meth.* 133:55-66, 1990). Alternatively, responder cell activation can be measured by the production of cytokines, such as IL-2, or by 25 determining the presence of responder cell-specific, and particularly T cell-specific, activation markers. Cytokine production can be assayed by testing the ability of the stimulator + responder cell culture supernatant to stimulate growth of cytokine-dependent 30

cells. Responder cell- or T cell-specific activation markers may be detected using antibodies specific for such markers.

Preferably, the single chain MHC class II molecule:peptide complex induces non-responsiveness (for example, anergy) in the antigenic peptide-reactive responder cells. In addition to single chain MHC class II molecule:peptide complex recognition, responder cell activation requires the involvement of co-receptors on the stimulator cell (the APC) that have been stimulated with co-stimulatory molecules. By blocking or eliminating stimulation of such co-receptors (for instance, by exposing responder cells to purified single chain MHC class II molecule:peptide complex, by blocking with anti-receptor or anti-ligand antibodies, or by "knocking out" the gene(s) encoding such receptors), responder cells can be rendered non-responsive to antigen or to single chain MHC class II molecule:peptide complex.

In a preferred embodiment, responder cells are obtained from a source manifesting an autoimmune disease or syndrome. Alternatively, autoantigen-reactive T cell clones or lines are preferred responder cells. In another preferred embodiment, stimulator cells are obtained from a source manifesting an autoimmune disease or syndrome. Alternatively, APC cell lines or clones that are able to appropriately process and/or present autoantigen to responder cells are preferred stimulator cells. In a particularly preferred embodiment, responder and stimulator cells are obtained from a source with diabetes or multiple sclerosis.

At this point, the responder T cells can be selectively amplified and/or stimulated, thereby producing a subset of T cells that are specific for the antigenic peptide. For instance, antigenic peptide-reactive responder cells may be selected by flow cytometry, and particularly by fluorescence activated cell sorting. This subset of responder cells can be maintained by repetitive stimulation with APCs presenting the same antigenic peptide. Alternatively, responder cell clones or lines can be established from this responder cell subset. Further, this subset of responder cells can be used to map epitopes of the antigenic peptide and the protein from which it is derived.

Other methods to assess the biological activity of the single chain MHC class II molecule:peptide complexes are known in the art and can be used herein, such as using a microphysiometer, to measure production of acidic metabolites in T cells following interaction with antigenic peptide. Other assay methods include competition

assays, comparing single chain MHC class II molecule:complex response with that to the normal antigen. Also measurement production of such indicators as cytokines or  $\gamma$  interferon can provide an indication of complex response.

5   **Animal models of autoimmune disease**

Similar assays and methods can be developed for and used in animal models. For instance, the therapeutic effect of a pharmaceutical composition of the single chain molecule or multimer or a polynucleotide encoding the single chain molecule or multimer can be tested *in vivo* in a number of animal models of HLA-DR-associated 10 autoimmunity disease. These diseases include, but are not limited to, insulin-dependent diabetes mellitus, multiple sclerosis, myasthenia gravis, pernicious anemia, rheumatoid arthritis, and systemic lupus erythematosus.

For example, NOD mice are a spontaneous model of IDDM. Treatment with the pharmaceutical compositions prior to or after onset of disease can be monitored 15 by assay of urine glucose levels in the NOD mouse, as well as by *in vitro* T cell proliferation assays to assess reactivity to known autoantigens (*see, e.g.,* Kaufman *et al.*, *Nature* 366:69-72 (1993)) for example). Alternatively, induced models of autoimmune disease, such as EAE, can be treated with pharmaceutical composition. Treatment in a preventive or intervention mode can be followed by monitoring the clinical symptoms of 20 EAE.

Following is a description of several other animal models of HLA-DR-associated autoimmune disease which can be used to assay *in vivo* effects of the peptide. It will be obvious to one of skill in the art that other suitable animal models for 25 autoimmune diseases can be utilized in a similar manner.

Systemic Lupus Erythematosus (SLE)

F<sub>1</sub> hybrids of autoimmune New Zealand black (NZB) mice and the phenotypically normal New Zealand White (NZW) mouse strain develop severe systemic 30 autoimmune disease, more fulminant than that found in the parental NZB strain. These mice manifest several immune abnormalities, including antibodies to nuclear antigens and subsequent development of a fatal, immune complex-mediated glomerulonephritis with

20

female predominance, remarkably similar to SLE in humans (Knight *et al.*, *J. Exp. Med.* 147:1653 (1978)), which is incorporated hereby by reference.

In both the human and murine forms of the disease, a strong association with MHC gene products has been reported. HLA-DR2 and HLA-DR3 individuals are at 5 a higher risk than the general population to develop SLE (Reinertsen *et al.*, *N. Engl. J. Med.* 299:515 (1970)), while in NZB/W F<sub>1</sub> mice (H-2<sup>d/u</sup>), a gene linked to the h-2<sup>u</sup> haplotype derived from the NZW parent contributes to the development of the lupus-like nephritis.

The effect of the invention can be measured by survival rates and by the 10 progress of development of the symptoms, such as proteinuria and appearance of anti-DNA antibodies.

Proteinuria can be measured by any method known to those of skill in the art, *e.g.* colorimetrically by the use of Uristix (Miles Laboratories, Inc., Elkhart, IN), giving an approximation of proteinuria as follows: trace, 10 mg/dl; 1+, 30 mg/dl; 100 15 mg/dl; 3+, 300 mg/dl; and 4+, 1000 mg/dl.

The presence of anti-DNA specific antibodies in NZB/W F<sub>1</sub> mice can be determined by using a modification of a linked immunosorbent assay (ELISA) described by Zouali *et al.*, *J. Immunol. Methods* 90:105 (1986) which is incorporated herein by reference.

20

#### Myasthenia Gravis (MG)

Myasthenia gravis is one of several human autoimmune diseases linked to HLA-D (Safenberg, *et al.*, *Tissue Antigens* 12:136 (1978); McDevitt *et al.*, *Arth. Rheum.* 20:59 (1977)) which are incorporated herein by reference. In MG antibodies to the acetyl 25 choline receptors (AcChoR) impair neuromuscular transmission by mediating loss of AcChoR in the postsynaptic membrane.

SJL/J female mice are a model system for human MG. In these animals, experimental autoimmune myasthenia gravis (EAMG) can be induced by immunizing the mice with soluble AcChoR protein from another species. Susceptibility to EAMG is 30 linked in part to the MHC and has been mapped to the region within H-2 (Christadoss *et al.*, *J. Immunol.* 123:2540 (1979)).

21

AcChoR protein can be purified from *Torpedo californica* and assayed according to the method of Waldor *et al.*, *Proc. Natl. Acad. Sci. USA* 80:2713 (1983), incorporated by reference. For example, emulsified AcChoR, 15 µg in complete Freund adjuvant, is injected intradermally among six sites on the back, the hind foot pads, and the 5 base of the tail. Animals are reimmunized with this same regimen 4 weeks later.

Evaluation can be made by measurement of anti-AcChoR antibodies by any method known to those of skill in the art, *e.g.*, a microtiter ELISA assay as described in Waldor *et al.*, *supra*. In an exemplary assay, the standard reagent volume is 50 µl per well. Reagents are usually incubated in the wells for 2 hr at RT. Five µg of AcChoR 10 diluted in bicarbonate buffer, pH 9.6, is added to each well. After incubation with AcChoR, the plates are rinsed four times with a wash solution consisting of phosphate-buffer saline containing 0.05% Tween and 0.05% NaN<sub>3</sub>. Mouse sera are diluted in 0.01M PBS (pH 7.2), 1.5 mfr MgCl<sub>2</sub>, 2.0 mM 2-mercaptoethanol, 0.05% Tween-80, 0.05% NaN<sub>3</sub> (p-Tween buffer) and incubated on the plate. After the plate is washed, beta- 15 galactosidase-conjugated sheep anti-mouse antibody diluted in P-Tween buffer is added to each well. After a final washing, the enzyme substrate, p-nitrophenylgalactopyranoside is added to the plate, and the degree of substrate catalysis is determined from the absorbance at 405 nm after 1 hr.

Anti-AcChoR antibodies are expected to be present in the mice immunized 20 with AcChoR as compared to nonimmunized mice. Treatment with complex is expected to significantly reduce the titer of anti-AcChoR antibodies in the immunized mice.

The effect of treatment with the invention on clinical EAMG can also be assessed by any method known to those of skill in the art. Myasthenia symptoms include a characteristic hunched posture with drooping of the head and neck, exaggerated arching 25 of the back, splayed limbs, abnormal walking, and difficulty in righting. Mild symptoms are present after a standard stress test, and should be ameliorated by administration of complex.

#### Rheumatoid Arthritis (RA)

In humans, susceptibility to rheumatoid arthritis is associated with HLA 30 D/DR. The immune response in mice to native type II collagen has been used to establish D/DR. The immune response in mice to native type II collagen has been used to establish an experimental model for arthritis with a number of histological and pathological

22

features resembling human RA. Susceptibility to collagen-induced arthritis (CIA) in mice has been mapped to the H-2 I region, particularly the I-A subregion (Huse *et al.*, *Fed. Proc.* 43:1820 (1984)).

Mice from a susceptible strain, DEA-1 can be caused to have CIA by  
5 treatment of the mice with native type II collagen, using the technique described in Wooley *et al.*, *J. Immunol.* 134:2366 (1985), incorporated herein by reference.

In another model adjuvant arthritis in rats is an experimental model for human arthritis, and a prototype of autoimmune arthritis triggered by bacterial antigens (Holoschitz *et al.*, *Prospects of Immunology* (1986); Pearson, *Arthritis Rheum.* 7:80  
10 (1964)). The disease is the result of a cell-mediated immune response, as evidenced by its transmissibility by a clone of T cells which were reactive against the adjuvant (MT); the target self-antigen in the disease, based upon studies with the same cloned cells, appears to be part(s) of a proteoglycan molecule of cartilage.

Adjuvant disease in rats is produced as described by Pearson *supra*, i.e., by  
15 a single injection of Freund's adjuvant (killed tubercle bacilli or chemical fractions of it, mineral oil, and an emulsifying agent) given into several depot sites, preferably intracutaneously or into a paw or the base of the tail. The adjuvant is given in the absence of other antigens.

The effect of the invention treatment on manifestations of the disease can  
20 be monitored by any method known to those of skill in the art. These manifestations are histopathological, and include an acute and subacute synovitis with proliferation of synovial lining cells, predominantly a mononuclear infiltration of the articular and particular tissues, the invasion of bone and articular cartilage by connective tissue pannus, and periosteal new bone formation, especially adjacent to affected joints. In severe or  
25 chronic cases, destructive changes occur, as do fibrous or bony ankylosis. These histopathological symptoms are expected to appear in control animals at about 12 days after sensitization to the Freund's adjuvant.

#### Insulin Dependent Diabetes Mellitus (IDDM)

IDDM is observed as a consequence of the selective destruction of insulin-secreting cells within the Islets of Langerhans of the pancreas. Involvement of the  
30 immune system in this disease is suggested by morphologic evidence of early infiltration

23

of the Islets by mononuclear cells, by the detection of anti-islet cell antibodies, by the high frequency of HLA-DR3 and -DR4 alleles in IDDM populations, and by clinical associations between IDDM and various autoimmune diseases. An animal model for spontaneous IDDM and thyroiditis has been developed in the BB rat. As in humans, the  
5 rat disease is controlled in part by the genes encoding the MHC antigens, is characterized by islet infiltration, and is associated with the presence of anti-islet antibodies. The I-E equivalent class II MHC antigens appear to be involved in manifestation of the autoimmune diseases in the BB rat. Biotard *et al.*, *Proc. Natl. Acad. Sci. USA* 82:6627 (1985).

10 In morphologic evaluation, insulitis is characterized by the presence of mononuclear inflammatory cells within the islets. Thyroiditis is characterized by focal interstitial lymphocytic infiltrate within the thyroid gland, as a minimum criterion. Most severe cases show diffuse extensive lymphocytic infiltrates, disruption of acini, fibrosis, and focal Hurthle cell change. See Biotard *et al. supra*.

15 Treatment of the BB rats with the invention is expected to ameliorate or prevent the manifestation of the clinical and morphological symptoms associated with IDDM and thyroiditis.

In another model, the NOD mouse strain (H-2K<sup>d</sup> D<sup>b</sup>) is a murine model for autoimmune IDDM. The disease in these animals is characterized by anti-islet cell  
20 antibodies, severe insulitis, and evidence for autoimmune destruction of the beta-cells (Kanazawa, *et al.*, *Diabetologica* 27:113 (1984)). The disease can be passively transferred with lymphocytes and prevented by treatment with cyclosporin-A (Ikehara *et al.*, *Proc. Natl. Acad. Sci. USA* 82:7743 (1985)); Mori *et al.*, *Diabetologica* 29:244 (1986).

Untreated animals develop profound glucose intolerance and ketosis and succumb within  
25 weeks of the onset of the disease. Seventy to ninety percent of female and 20-30% of male animals develop diabetes within the first six months of life. Breeding studies have defined at least two genetic loci responsible for disease susceptibility, one of which maps to the MHC. Characterization of NOD Class II antigens at both the serologic and molecular level suggest that the susceptibility to autoimmune disease is linked to I-A<sub>B</sub>  
30 (Acha-Orbea and McDevitt, *Proc. Natl. Acad. Sci. USA* 84:235 (1907)).

Treatment of Female NOD mice with complex is expected to lengthen the time before the onset of diabetes and/or to ameliorate or prevent the disease.

Experimental Allergic Encephalomyelitis (EAE)

Experimental allergic encephalomyelitis (EAE) is an induced autoimmune disease of the central nervous system which is a model for multiple sclerosis (MS). The  
5 disease can be induced in many species, including mice and rats.

The disease is characterized by the acute onset of paralysis. Perivascular infiltration by mononuclear cells in the CNS is observed in both mice and rats. Methods of inducing the disease, as well as symptomology, are reviewed in Aranson, *The Autoimmune Diseases* (Rose and Mackay, eds., 1985), and in Acha-Orbea *et al.*, *Ann. Rev. Imm.* 7:377-405 (1989).

One of the genes mediating susceptibility is localized in the MHC class II region (Moore *et al.*, *J. Immunol.* 124:1815-1820 (1980)). The best analyzed encephalitogenic protein is myelin basic protein (MBP), but other encephalitogenic antigens are found in the brain. The immunogenic epitopes have been mapped (*see*, Acha-  
15 Orbea *et al.*, *supra*). In the PL mouse strains (H-2<sup>u</sup>) two encephalitogenic peptides in MBP have been characterized: MBP peptide p35-47 (MBP 35-47), and acetylated NSF p1-9 (MBP 1-9).

The effect of the invention on ameliorating disease symptoms in individuals in which EAE has been induced can be measured by survival rates, and by the  
20 progress of the development of symptoms.

**Methods of making the complexes of the invention**

Expression systems suitable for production of appropriate recombinant single chain MHC class II molecule:peptide complexes are available and known in the  
25 art. Various prokaryotic, fungal, and eukaryotic host cells are suitable for expression of recombinant, single chain MHC class II molecule:peptide complexes, as well as for individual recombinant alpha and beta MHC class II chains.

Prokaryotes that are useful as host cells, according to the present invention, most frequently are represented by various strains of *Escherichia coli*.  
30 However, other microbial strains can also be used, such as bacilli, for example *Bacillus subtilis*, various species of *Pseudomonas*, or other bacterial strains.

According to the invention, the single chain MHC class II molecule:peptide complexes are expressed from recombinantly engineered nucleotide sequences that encode the single chain MHC class II molecule:peptide polypeptides by operably linking the engineered nucleic acid coding sequence to signals that direct gene expression in prokaryotes. A nucleic acid is “operably linked” when it is placed into a functional relationship with another nucleic acid sequence. For instance, a promoter or enhancer is operably linked to a coding sequence if it effects the transcription of the sequence. Generally, operably linked means that the nucleic acid sequences being linked are contiguous and, where necessary to join two protein coding regions, contiguous and in reading frame.

The genes encoding the single chain MHC class II molecule:peptide complexes may be inserted into an “expression vector,” “cloning vector,” or “vector,” terms which are used interchangeably herein and usually refer to plasmids or other nucleic acid molecules that are able to replicate in a chosen host cell. Expression vectors may replicate autonomously, or they can replicate by being inserted into the genome of the host cell, by methods well known in the art. Vectors that replicate autonomously will have an origin of replication or autonomous replicating sequence (ARS) that is functional in the chosen host cell(s).

Plasmid vectors that contain replication sites and control sequences derived from a species compatible with the chosen host are used. For example, *E. coli* is typically transformed using derivatives of pBR322, a plasmid derived from *E. coli* species by Bolivar *et al.*, *Gene* 2:95-113, 1977. Often, it is desirable for a vector to be usable in more than one host cell, e.g., in *E. coli* for cloning and construction, and in a *Bacillus* cell for expression.

The expression vectors typically contain a transcription unit or expression cassette that contains all the elements required for the expression of the DNA encoding the MHC molecule in the host cells. A typical expression cassette contains a promoter operably linked to the DNA sequence encoding a single chain MHC class II molecule:peptide complex and a ribosome binding site. The promoter is preferably positioned about the same distance from the heterologous transcription start site as it is from the transcription start site in its natural setting. As is known in the art, however, some variation in this distance can be accommodated without loss of promoter function.

In addition to a promoter sequence, the expression cassette can also contain a transcription termination region downstream of the structural gene to provide for efficient termination. The termination region may be obtained from the same gene as the promoter sequence or may be obtained from a different gene.

5 Commonly used prokaryotic control sequences which are defined herein to include promoters for transcription initiation, optionally with an operator, along with ribosome binding site sequences, include such commonly used promoters as the beta-lactamase (penicillinase) and lactose (lac) promoter systems (Change *et al.*, *Nature* 198:1056, 1977) and the tryptophan (trp) promoter system (Goeddel *et al.*, *Nucleic Acids Res.* 8:4057-74, 1980) and the lambda-derived P<sub>L</sub> promoter and N-gene ribosome binding site (Shimatake *et al.*, *Nature* 292:128-32, 1981). Any available promoter system that functions in prokaryotes can be used.

10

15 Either constitutive or regulated promoters can be used in the present invention. Regulated promoters can be advantageous because the host cells can be grown to high densities before expression of the single chain MHC class II molecule:peptide complexes is induced. High level expression of heterologous proteins slows cell growth in some situations. Regulated promoters especially suitable for use in *E. coli* include the bacteriophage lambda P<sub>L</sub> promoter, the hybrid trp-lac promoter (Amann *et al.*, *Gene* 25:167-78 1983; and the bacteriophage T7 promoter.

20 For expression of single chain MHC class II molecule:peptide complexes in prokaryotic cells other than *E. coli*, a promoter that functions in the particular prokaryotic species is required. Such promoters can be obtained from genes that have been cloned from the species, or heterologous promoters can be used. For example, the hybrid trp-lac promoter functions in Bacillus in addition to *E. coli*.

25 A ribosome binding site (RBS) is also necessary for expression of single chain MHC class II molecule:peptide complexes in prokaryotes. An RBS in *E. coli*, for example, consists of a nucleotide sequence 3-9 nucleotides in length located 3-11 nucleotides upstream of the initiation codon (Shine and Dalgarno, *Nature*, 254:34-40, 1975; Steitz, *In Biological regulation and development: Gene expression* (ed., Goldberger), vol. 1, p. 349, 1979).

30 Translational coupling may be used to enhance expression. The strategy uses a short upstream open reading frame derived from a highly expressed gene native to

the translational system, which is placed downstream of the promoter, and a ribosome binding site followed after a few amino acid codons by a termination codon. Just prior to the termination codon is a second ribosome binding site, and following the termination codon is a start codon for the initiation of translation. The system dissolves secondary structure in the RNA, allowing for the efficient initiation of translation. See Squires, et. al., *J. Biol. Chem.* 263:16297-16302, 1988.

The single chain MHC class II molecule:peptide complexes can be expressed intracellularly, or can be secreted from the cell. Intracellular expression often results in high yields. However, some of the protein may be in the form of insoluble inclusion bodies. Although some of the intracellularly produced MHC polypeptides of the present invention may be active upon being harvested following cell lysis, the amount of soluble, active MHC polypeptide may be increased by performing refolding procedures using methods known to those of skill in the art (see, e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual Second Edition*, Cold Spring Harbor, NY, 1989.; Marston et al., *Bio/Technology* 2:800-804, 1985; Schoner et al., *Bio/Technology* 3:151-54, 1985). In one embodiment, for purification and refolding the cell pellet is lysed and refolded in urea-borate-DTT buffer followed by urea-borate buffer and reverse phase HPLC purification using either silica gel based Vydac (Hewlett Packard, Wilmington, DE) or polymer based Poros-R2 (PerSeptive Biosystems) resins, with bead size varying based on the scale of the culture and is described in further detail below. In one embodiment, e.g., for large scale refolding, the sample can be ultrafiltered into a urea-borate buffer to which is then added 0.2  $\mu$ M to 1 mM copper sulfate, preferably 0.2 to 20  $\mu$ M, after which folding occurs immediately.

More than one MHC:peptide complex may be expressed in a single prokaryotic cell by placing multiple transcriptional cassettes in a single expression vector, or by utilizing different selectable markers for each of the expression vectors which are employed in the cloning strategy.

A second approach for expressing the MHC:peptide complexes of the invention is to cause the polypeptides to be secreted from the cell, either into the periplasm or into the extracellular medium. The DNA sequence encoding the MHC polypeptide is linked to a cleavable signal peptide sequence. The signal sequence directs translocation of the MHC:peptide complex through the cell membrane. An example of a

suitable vector for use in *E. coli* that contains a promoter-signal sequence unit is pTA1S29, which has the *E. coli* phoA promoter and signal sequence *see*, e.g., Sambrook *et al.*, *supra*; Oka *et al.*, *Proc. Natl. Acad. Sci. USA* 82:7212-16, 1985; Talmadge *et al.*, *Proc. Natl. Acad. Sci. USA* 77:39892, 1980; Takahara *et al.*, *J. Biol. Chem.* 260: 2670-74, 5 1985). Once again, multiple polypeptides can be expressed in a single cell for periplasmic association. Eukaryotic signal sequences are also well known to those of skill in the art, and cause the MHC:peptide complexes of the invention to be secreted into the extracellular medium.

The MHC:peptide complexes of the invention can also be produced as 10 fusion proteins. This approach often results in high yields, because normal prokaryotic control sequences direct transcription and translation. In *E. coli*, lacZ fusions are often used to express heterologous proteins. Suitable vectors are readily available, such as the pUR, pEX, and pMR100 series (*see*, e.g., Sambrook *et al.*, *supra*). For certain 15 applications, it may be desirable to cleave the non-MHC amino acids from the fusion protein after purification. This can be accomplished by any of several methods known in the art, including cleavage by cyanogen bromide, a protease, or by Factor X, (*see*, e.g., Sambrook *et al.*, *supra*; Goeddel *et al.*, *Proc. Natl. Acad. Sci. USA* 76:106-10, 1979; Nagai *et al.*, *Nature* 309:810-12, 1984; Sung *et al.*, *Proc. Natl. Acad. Sci. USA* 83:561-65, 1986). Cleavage sites can be engineered into the gene for the fusion protein at the desired 20 point of cleavage.

Foreign genes, such as single chain MHC class II molecule:peptide complexes, can be expressed in *E. coli* as fusions with binding partners, such as 25 glutathione-S-transferase (GST), maltose binding protein, or thioredoxin. These binding partners are highly translated and can be used to overcome inefficient initiation of translation of eukaryotic messages in *E. coli*. Fusion to such binding partner can result in high-level expression, and the binding partner is easily purified and then excised from the protein of interest. Such expression systems are available from numerous sources, such as Invitrogen Inc. (San Diego, CA) and Pharmacia LKB Biotechnology Inc. (Piscataway, NJ).

A method for obtaining recombinant proteins from *E. coli* which maintains 30 the integrity of their N-termini has been described by Miller *et al.* *Biotechnology* 7:698-704 (1989). In this system, the gene of interest is produced as a C-terminal fusion to the

first 76 residues of the yeast ubiquitin gene containing a peptidase cleavage site.

Cleavage at the junction of the two moieties results in production of a protein having an intact authentic N-terminal residue.

The vectors containing the nucleic acids that code for the single chain

- 5 MHC class II molecule:peptide complexes are transformed into prokaryotic host cells for expression. "Transformation" refers to the introduction of vectors containing the nucleic acids of interest directly into host cells by well known methods. The particular procedure used to introduce the genetic material into the host cell for expression of the single chain MHC class II molecule:peptide complex is not particularly critical. Any of the well  
10 known procedures for introducing foreign nucleotide sequences into host cells may be used. It is only necessary that the, particular host cell utilized be capable of expressing the gene.

Transformation methods, which vary depending on the type of the prokaryotic host cell, include electroporation; transfection employing calcium chloride, rubidium chloride calcium phosphate, or other substances; microprojectile bombardment; infection (where the vector is an infectious agent); and other methods. See, generally, Sambrook *et al., supra*, and Ausubel *et al.*, (eds.) *Current Protocols in Molecular Biology*, John Wiley and Sons, Inc., NY, 1987. Reference to cells into which the nucleic acids described above have been introduced is meant to also include the progeny of such cells.

- 20 Transformed prokaryotic cells that contain expression vectors for single chain MHC class II molecule:peptide complexes are also included in the invention.

After standard transfection or transformation methods are used to produce prokaryotic cell lines that express large quantities of the single chain MHC class II molecule:peptide complex polypeptide, the polypeptide is then purified using standard techniques. See, e.g., Colley *et al., J. Chem.* 64:17619-22, 1989; and *Methods in Enzymology*, "Guide to Protein Purification", Deutscher, ed., Vol. 182 (1990). The recombinant cells are grown and the single chain MHC class II molecule:peptide complex is expressed. The purification protocol will depend upon whether single chain MHC class II molecule:peptide complex is expressed intracellularly, into the periplasm, or secreted from the cell. For intracellular expression, the cells are harvested, lysed, and the polypeptide is recovered from the cell lysate (Sambrook *et al., supra*). Periplasmic MHC polypeptide is released from the periplasm by standard techniques (Sambrook *et al.,*

30

*supra*). If the MHC polypeptide is secreted from the cells, the culture medium is harvested for purification of the secreted protein. The medium is typically clarified by centrifugation or filtration to remove cells and cell debris.

5 The MHC polypeptides can be concentrated by adsorption to any suitable resin (such as, for example, CDP-Sepharose, Asialoprothrombin-Sepharose 4B, or Q Sepharose), or by use of ammonium sulfate fractionation, polyethylene glycol precipitation, or by ultrafiltration. Other means known in the art may be equally suitable.

10 Further purification of the MHC polypeptides can be accomplished by standard techniques, for example, affinity chromatography, ion exchange chromatography, sizing chromatography, reverse phase HPLC, or other protein purification techniques used to obtain homogeneity. The purified proteins are then used to produce pharmaceutical compositions.

15 For secretion of a polypeptide or protein of interest, recombinant nucleic acid constructs of the invention may include sequences that encode signal sequences or other sequences that direct secretion. Secretory signal sequences, also called leader sequences, prepro sequences and/or pre sequences, are amino acid sequences that play a role in secretion of mature polypeptides or proteins from a cell. Such sequences are characterized by a core of hydrophobic amino acids and are typically (but not exclusively) found at the amino termini of newly synthesized proteins. The secretory 20 signal sequence may be that of the protein of interest, or may be derived from another secreted protein (e.g., t-PA, a preferred mammalian secretory leader) or synthesized de novo. The secretory signal sequence is joined to the DNA sequence encoding a protein of the present invention in the correct reading frame. Secretory signal sequences are commonly positioned 5' to the DNA sequence encoding the polypeptide of interest, 25 although certain signal sequences may be positioned elsewhere in the DNA sequence of interest (see, e.g., Welch *et al.*, U.S. Patent No. 5,037,743; Holland *et al.*, U.S. Patent No. 5,143,830). Very often the secretory peptide is cleaved from the mature protein during secretion. Such secretory peptides contain processing sites that allow cleavage of the secretory peptide from the mature protein as it passes through the secretory pathway. An 30 example of such a processing site is a dibasic cleavage site, such as that recognized by the *Saccharomyces cerevisiae* KEX2 gene or a Lys-Arg processing site. Processing sites

may be encoded within the secretory peptide or may be added to the peptide by, for example, *in vitro* mutagenesis.

Secretory signals include the  $\alpha$  factor signal sequence (prepro sequence: Kurjan & Herskowitz, *Cell* 3:933-943, 1982; Kurjan *et al.*, U.S. Patent No. 4,546,082; 5 Brake, EP 116, 201), the *PHO5* signal sequence (Beck *et al.*, WO 86/00637) , the *BAR1* secretory signal sequence (MacKay *et al.*, U.S. Patent No. 4,613,572; MacKay, WO 87/002670), the *SUC2* signal sequence (Carlsen *et al.*, *Molecular and Cellular Biology* 3: 439-447 , 1983) , the  $\alpha$ -l-antitrypsin signal sequence (Kurachi *et al.*, *Proc. Natl. Acad. Sci. USA* 78: 6826-6830, 1981) , the  $\alpha$ -2 plasmin inhibitor signal sequence (Tone *et al.*, *J. Biochem. (Tokyo)* 102: 1033-1042, 1987) and the tissue plasminogen activator signal sequence (Pennica *et al.*, *Nature* 301: 214-221, 1983). Alternately, a secretory signal sequence may be synthesized according to the rules established, for example, by von Heinje (*European Journal of Biochemistry* 133: 17-21, 1983; *Journal of Molecular Biology* 184: 99-105, 1985; *Nucleic Acids Research* 14: 4683-4690; 1986). Another 10 signal sequence is the synthetic signal LaC212 spx (1-47). ERLE described in WO 90/10075.

Secretory signal sequences may be used singly or may be combined. For example, a first secretory signal sequence may be used in combination with a sequence encoding the third domain of barrier (described in U.S. Patent No. 5,037,243, which is 20 incorporated by reference herein in its entirety). The third domain of barrier may be positioned in proper reading frame 3' of the DNA segment of interest or 5' to the DNA segment and in proper reading frame with both the secretory signal sequence and a DNA segment of interest.

The choice of suitable promoters, terminators and secretory signals for all 25 expression systems, is well within the level of ordinary skill in the art. Methods for expressing cloned genes in *Saccharomyces cerevisiae* are generally known in the art (see, “Gene Expression Technology,” *Methods in Enzymology*, Vol. 185, Goeddel (ed.), Academic Press, San Diego, CA, 1990 and “Guide to Yeast Genetics and Molecular Biology,” *Methods in Enzymology*, Guthrie and Fink (eds.), Academic Press, San Diego, 30 CA, 1991; which are incorporated herein by reference). Proteins of the present invention can also be expressed in filamentous fungi, for example, strains of the fungi *Aspergillus* (McKnight *et al.*, U.S. Patent No. 4,935,349, which is incorporated herein by reference).

Expression of cloned genes in cultured mammalian cells and in *E. coli*, for example, is discussed in detail in Sambrook *et al.* (*Molecular Cloning: A Laboratory Manual. Second Edition*, Cold Spring Harbor, NY, 1989; which is incorporated herein by reference). As would be evident to one skilled in the art, one could express the proteins 5 of the instant invention in other host cells such as avian, insect and plant cells using regulatory sequences, vectors and methods well established in the literature.

In yeast, suitable yeast vectors for use in the present invention include YRp7 (Struhl *et al.*, *Proc. Natl. Acad. Sci. USA* 76:1035-1039, 1978), YEpl3 (Broach *et al.*, *Gene* 8: 121-133, 1979), POT vectors (Kawasaki *et al.*, U.S. Patent No. 4,931,373, 10 which is incorporated by reference herein), pJDB249 and pJDB219 (Beggs, *Nature* 275:104-108, 1978) and derivatives thereof. Preferred promoters for use in yeast include promoters from yeast glycolytic genes (Hitzeman *et al.*, *J. Biol. Chem.* 255: 12073-12080, 15 1980; Alber and Kawasaki, *J. Mol. Appl. Genet.* 1: 419-434, 1982; Kawasaki, U.S. Patent No. 4,599,311) or alcohol dehydrogenase genes (Young *et al.*, in *Genetic Engineering of Microorganisms for Chemicals*, Hollaender *et al.*, (eds.), p. 355, 1982; Ammerer, *Meth. Enzymol.* 101: 192-201, 1983). Other promoters are the TPI1 promoter (Kawasaki, U.S. Patent No. 4,599,311, 1986) and the ADH2-4<sup>c</sup> promoter (Russell *et al.*, *Nature* 304: 652-654, 1983; Irani and Kilgore, U.S. Patent Application Serial No. 07/784,653, CA 1,304,020 and EP 284 044, which are incorporated herein by reference). The expression 20 units may also include a transcriptional terminator such as the TPI1 terminator (Alber and Kawasaki, *ibid.*).

Yeast cells, particularly cells of the genus *Pichia* or *Saccharomyces*, are a preferred host for use in producing compound of the current invention. Methods for transforming yeast cells with exogenous DNA and producing recombinant proteins 25 therefrom are disclosed by, for example, Kawasaki, U.S. Patent No. 4,599,311; Kawasaki *et al.*, U.S. Patent No. 4,931,373; Brake, U.S. Patent No. 4,870,008; Welch *et al.*, U.S. Patent No. 5,037,743; and Murray *et al.*, U.S. Patent No. 4,845,075, which are 30 incorporated herein by reference. Transformed cells are selected by phenotype determined by a selectable marker, commonly drug resistance or the ability to grow in the absence of a particular nutrient (e.g., leucine). A preferred vector system for use in yeast is the POT1 vector system disclosed by Kawasaki *et al.* (U.S. Patent No. 4,931,373), which allows transformed cells to be selected by growth in glucose-containing media. A

preferred secretory signal sequence for use in yeast is that of the *S. cerevisiae* MF $\alpha$ 1 gene (Brake, *ibid.*; Kurjan *et al.*, U.S. Patent No. 4,546,082). Suitable promoters and terminators for use in yeast include those from glycolytic enzyme genes (*see, e.g.*, Kawasaki, U.S. Patent No. 4,599,311; Kingsman *et al.*, U.S. Patent No. 4,615,974; and 5 Bitter, U.S. Patent No. 4,977,092, which are incorporated herein by reference) and alcohol dehydrogenase genes. See also U.S. Patent Nos. 4,990,446; 5,063,154; 5,139,936 and 4,661,454, which are incorporated herein by reference. Transformation systems for other yeasts, including *Hansenula polymorpha*, *Schizosaccharomyces pombe*, *Kluyveromyces lactis*, *Kluyveromyces fragilis*, *Ustilago maydis*, *Pichia pastoris*, *Pichia methanolica*, *Pichia guillermondii* and *Candida maltosa* are known in the art. See, for 10 example, Gleeson *et al.*, *J. Gen. Microbiol.* 132:3459-65, 1986; Cregg, U.S. Patent No. 4,882,279; and Stroman *et al.*, U.S. Patent No. 4,879,231.

Other fungal cells are also suitable as host cells. For example, *Aspergillus* cells may be utilized according to the methods of McKnight *et al.*, U.S. Patent No. 15 4,935,349, which is incorporated herein by reference. Methods for transforming *Acremonium chrysogenum* are disclosed by Sumino *et al.*, U.S. Patent No. 5,162,228, which is incorporated herein by reference. Methods for transforming *Neurospora* are disclosed by Lambowitz, U.S. Patent No. 4,486,533, which is incorporated herein by reference.

20 Host cells containing DNA constructs of the present invention are then cultured to produce the heterologous proteins. The cells are cultured according to standard methods in a culture medium containing nutrients required for growth of the particular host cells. A variety of suitable media are known in the art and generally include a carbon source, a nitrogen source, essential amino acids, vitamins, minerals and 25 growth factors. The growth medium will generally select for cells containing the DNA construct by, for example, drug selection or deficiency in an essential nutrient which is complemented by a selectable marker on the DNA construct or co-transfected with the DNA construct.

Yeast cells, for example, are preferably cultured in a chemically defined 30 medium, comprising a non-amino acid nitrogen source, inorganic salts, vitamins and essential amino acid supplements. The pH of the medium is preferably maintained at a pH greater than 2 and less than 8, preferably at pH 6.5. Methods for maintaining a stable

pH include buffering and constant pH control, preferably through the addition of sodium hydroxide. Preferred buffering agents include succinic acid and Bis-Tris (Sigma Chemical Co., St. Louis, MO). Yeast cells having a defect in a gene required for asparagine-linked glycosylation are preferably grown in a medium containing an osmotic stabilizer. A preferred osmotic stabilizer is sorbitol supplemented into the medium at a concentration between 0.1 M and 1.5 M, preferably at 0.5 M or 1.0 M. Cultured mammalian cells are generally cultured in commercially available serum-containing or serum-free media. Selection of a medium appropriate for the particular host cell used is within the level of ordinary skill in the art.

Methods for introducing exogenous DNA into mammalian host cells include calcium phosphate-mediated transfection (Wigler *et al.*, *Cell* 14:725, 1978; Corsaro and Pearson, *Somatic Cell Genetics* 7:603, 1981; Graham and Van der Eb, *Virology* 52:456, 1973), electroporation (Neumann *et al.*, *EMBO J.* 1:841-45, 1982) and DEAE-dextran mediated 'transfection' (Ausubel *et al.*, (eds), *Current Protocols in Molecular Biology*, John Wiley and Sons, Inc., NY, 1987), which are incorporated herein by reference. Cationic lipid transfection using commercially available reagents, including the Boehringer Mannheim TRANSFECTION-REAGENT (N-[1-(2,3-dioleoyloxy)propyl] -N,N,N-trimethyl ammoniummethylsulfate; Boehringer Mannheim, Indianapolis, IN) or LIPOFECTIN reagent (N-[l-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride and dioleoyl phosphatidylethanolamine; GIBCO-BRL, Gaithersburg, MD) using the manufacturer-supplied directions, may also be used. A preferred mammalian expression plasmid is Zem229R (deposited under the terms of the Budapest Treaty with American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD on September 28, 1993 as an *E. coli* HB101 transformant and assigned Accession Number 69447). The production of recombinant proteins in cultured mammalian cells is disclosed, for example, by Levinson *et al.*, U.S. Patent No. 4,713,339; Hagen *et al.*, U.S. Patent No. 4,784,950; Palmiter *et al.*, U.S. Patent No. 4,579,821; and Ringold, U.S. Patent No. 4,656,134, which are incorporated herein by reference. Preferred cultured mammalian cells include the COS-1 (ATCC No. CRL 1650), COS-7 (ATCC No. CRL 1651), BHK (ATCC No. CRL 1632), BHK 570 (ATCC No. CRL 10314), DG44, and 293 (ATCC No. CRL 1573; Graham *et al.*, *J. Gen. Virol.* 36:59-72, 1977) cell lines. Additional suitable cell lines are known in the art and available from

public depositories such as the American Type Culture Collection, Rockville, Maryland. In general, strong transcription promoters are preferred, such as promoters from SV-40 or cytomegalovirus. *See, e.g.*, U.S. Patent No. 4,956,288. Other suitable promoters include those from metallothionein genes (U.S. Patents Nos. 4,579,821 and 4,601,978, which are 5 incorporated herein by reference) and the adenovirus major late promoter.

Drug selection is generally used to select for cultured mammalian cells into which foreign DNA has been inserted. Such cells are commonly referred to as “transfectants.” Cells that have been cultured in the presence of the selective agent and are able to pass the gene of interest to their progeny are referred to as “stable 10 transfectants.” A preferred selectable marker is a gene encoding resistance to the antibiotic neomycin. Selection is carried out in the presence of a neomycin-type drug, such as G-418 or the like. Selection systems may also be used to increase the expression level of the gene of interest, a process referred to as “amplification.” Amplification is carried out by culturing transfectants in the presence of a low level of the selective agent 15 and then increasing the amount of selective agent to select for cells that produce high levels of the products of the introduced genes. A preferred amplifiable selectable marker is dihydrofolate reductase, which confers resistance to methotrexate. Other drug resistance genes (e.g. hygromycin resistance, multi-drug resistance, puromycin acetyltransferase) can also be used.

20 The soluble, fused MHC:peptide complexes of the present invention can be purified by first isolating the polypeptides from the cells followed by conventional purification methods, such as by ion-exchange and partition chromatography as described by, for example, Coy *et al.* (*Peptides Structure and Function*, Pierce Chemical Company, Rockford, IL, pp 369-72, 1983) or by reverse-phase chromatography as described, for 25 example, by Andreu and Merrifield (*Eur. J. Biochem.* 164: 585-90, 1987), or by HPLC as described, for example, by Kofod *et al.* (*Int. J. Peptide and Protein Res.* 32.: 436-40, 1988). Additional purification can be achieved by additional conventional purification means, such as liquid chromatography, gradient centrifugation, and gel electrophoresis, among others. Methods of protein purification are known in the art (see generally, 30 Scopes, R., *Protein Purification*, Springer-Verlag, NY, 1982, which is incorporated by reference herein) and can be applied to the purification of the recombinant polypeptides described herein. Single chain MHC class II molecule:peptide complexes of at least

about 50% purity are preferred, at least about 70-80% purity more preferred, and about 95-99% or more purity most preferred, particularly for pharmaceutical uses. Once purified, either partially or to homogeneity, as desired, the single chain MHC class II molecule:peptide complexes may then be used diagnostically or therapeutically, as further described below.

5

### Methods of using single chain MHC class II molecule:peptide complexes

The single chain MHC class II molecule:peptide complexes of the present invention may be used within methods for down-regulating parts of the immune system 10 that are reactive in autoimmune diseases. The single chain MHC class II molecule:peptide complexes of the present invention are contemplated to be advantageous for use as immunotherapeutics to induce immunological tolerance or nonresponsiveness (anergy) in patients predisposed to mount or already mounting an immune response those particular autoantigens. A patient having or predisposed to a 15 particular autoimmune disease is identified and MHC type is determined by methods known in the art. The patient's T cells can be examined *in vitro* to determine autoantigenic peptide(s) recognized by the patient's autoreactive T cells using complexes and methods described herein. The patient can then be treated with complexes of the invention. Such methods will generally include administering single chain MHC class II 20 molecule:peptide complex in an amount sufficient to lengthen the time period before onset of the autoimmune disease and/or to ameliorate or prevent that disease. Single chain MHC class II molecule:peptide complexes of the present invention are therefore contemplated to be advantageous for use in both therapeutic and diagnostic applications related to auto immune diseases.

25

Kits can also be supplied for therapeutic or diagnostic uses. Thus, the subject composition of the present invention may be provided, usually in a lyophilized form, in a container. The single chain MHC class II molecule:peptide complex is included in the kits with instructions for use, and optionally with buffers, stabilizers, biocides, and inert proteins. Generally, these optional materials will be present at less 30 than about 5% by weight, based on the amount of single chain MHC class II molecule:peptide complex, and will usually be present in a total amount of at least about 0.001% by weight, based on the single chain MHC class II molecule:peptide complex

concentration. It may be desirable to include an inert extender or excipient to dilute the active ingredients, where the excipient may be present in from about 1 to 99% weight of the total composition.

Within one aspect of the present invention, single chain MHC class II molecule:peptide complexes are utilized to prepare antibodies for diagnostic or therapeutic uses. As used herein, the term "antibodies" includes polyclonal antibodies, monoclonal antibodies, antigen-binding fragments thereof such as F(ab')<sub>2</sub> and Fab fragments, as well as recombinantly produced binding partners. These binding partners incorporate the variable or CDR regions from a gene which encodes a specifically binding antibody. The affinity of a monoclonal antibody or binding partner may be readily determined by one of ordinary skill in the art (see, Scatchard, *Ann. NY Acad. Sci.* 51: 660-72, 1949)

Methods for preparing polyclonal and monoclonal antibodies have been well described in the literature (see, for example, Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual, Second Edition*, Cold Spring Harbor, NY, 1989; and Hurrell, J. G. R., Ed., *Monoclonal Hybridoma Antibodies: Techniques and Applications*, CRC Press, Ind., Boca Raton, FL, 1982, which is incorporated herein by reference). As would be evident to one of ordinary skill in the art, polyclonal antibodies may be generated from a variety of warm-blooded animals, such as horses, cows, goats, sheep, dogs, chickens, rabbits, mice, or rats, for example. The immunogenicity of the single chain MHC class II molecule:peptide complexes may be increased through the use of an adjuvant, such as Freund's complete or incomplete adjuvant. A variety of assays known to those skilled in the art may be utilized to detect antibodies which specifically bind to a single chain MHC class II molecule:peptide complex. Exemplary assays are described in detail in *Antibodies: A Laboratory Manual*, Harlow and Lane (Eds.), Cold Spring Harbor Laboratory Press, 1988. Representative examples of such assays include: concurrent immunoelectrophoresis, radio-immunoassays, radio-immunoprecipitations, enzyme-linked immuno-sorbent assays, dot blot assays, inhibition or competition assays, and sandwich assays.

Additional techniques for the preparation of monoclonal antibodies may be utilized to construct and express recombinant monoclonal antibodies. Briefly, mRNA is isolated from a B cell population and used to create heavy and light chain

immunoglobulin cDNA expression libraries in a suitable vector such as the λIMMUNOZAP(H) and λIMMUNOZAP(L) vectors, which may be obtained from Stratagene Cloning Systems (La Jolla, CA). These vectors are then screened individually or are co-expressed to form Fab fragments or antibodies (Huse *et al.*, *Science* 246 1275-5 81, 1989; Sastry *et al.*, *Proc. Natl. Acad. Sci. USA* 86: 5728-32, 1989). Positive plaques are subsequently converted to a non-lytic plasmid which allows high level expression of monoclonal antibody fragments in *E. coli*.

Antibodies of the present invention may be produced by immunizing an animal selected from a wide variety of warm-blooded animals, such as horses, cows, goats, sheep, dogs, chickens, rabbits, mice, and rats, with a recombinant single chain MHC class II molecule:peptide complex. Serum from such animals are a source of polyclonal antibodies. Alternatively antibody producing cells obtained from the immunized animals are immortalized and screened. As the generation of human monoclonal antibodies to a human antigen, such as a single chain MHC class II molecule:peptide complex, may be difficult with conventional immortalization techniques, it may be desirable to first make non-human antibodies. Using recombinant DNA techniques, the antigen binding regions of the non-human antibody is transferred to the corresponding site of a human antibody coding region to produce a substantially human antibody molecules. Such methods are generally known in the art and are described in, for example, U.S. Patent No. 4,816,397, and EP publications 173,494 and 239,400, which are incorporated herein by reference.

In another aspect of the invention, the single chain MHC class II molecule:peptide complexes can be used to clone T cells which have specific receptors for the single chain MHC class II molecule:peptide complex. Once the single chain MHC class II molecule:peptide complex-specific T cells are isolated and cloned using techniques generally available to the skilled artisan, the T cells or membrane preparations thereof can be used to immunize animals to produce antibodies to the single chain MHC class II molecule:peptide complex receptors on T cells. The antibodies can be polyclonal or monoclonal. If polyclonal, the antibodies can be murine, lagomorph, equine, ovine, or from a variety of other mammals. Monoclonal antibodies will typically be murine in origin, produced according to known techniques, or human, as described above, or combinations thereof, as in chimeric or humanized antibodies. The anti-single chain

MHC class II molecule:peptide complex receptor antibodies thus obtained can then be administered to patients to reduce or eliminate T cell subpopulations that display such receptor. This T-cell population recognizes and participates in the immunological destruction of cells bearing the autoantigenic peptide in an individual predisposed to or  
5 already suffering from a disease, such as an autoimmune disease related to the autoantigenic peptide.

The coupling of antibodies to solid supports and their use in purification of proteins is well known in the literature (*see, for example, Methods in Molecular Biology. Vol. I*, Walker (Ed.), Humana Press, New Jersey, 1984, which is incorporated by  
10 reference herein in its entirety). Antibodies of the present invention may be used as a marker reagent to detect the presence of MHC heterodimer:peptide complexes on cells or in solution. Such antibodies are also useful for Western analysis or immunoblotting, particularly of purified cell-secreted material. Polyclonal, affinity purified polyclonal, monoclonal and single chain antibodies are suitable for use in this regard. In addition,  
15 proteolytic and recombinant fragments and epitope binding domains can be used herein. Chimeric, humanized, veneered, CDR-replaced, reshaped or other recombinant whole or partial antibodies are also suitable.

### Pharmaceutical compositions

20 Pharmaceutically acceptable carriers are determined in part by the particular composition being administered (*e.g., nucleic acid, protein*) as by the particular method used to administer the composition. Accordingly, there are a wide variety of suitable formulations of pharmaceutical compositions of the present invention (*see, e.g., Remington's Pharmaceutical Sciences* (17<sup>th</sup> ed., 1989)). Administration can be in any  
25 convenient manner, *e.g., by injection, oral administration, inhalation, or transdermal application.*

Formulations suitable for oral administration can consist of (a) liquid solutions, such as an effective amount of the packaged nucleic acid or polypeptide suspended in diluents, such as water, saline or PEG 400; (b) capsules, sachets or tablets,  
30 each containing a predetermined amount of the active ingredient, as liquids, solids, granules or gelatin; (c) suspensions in an appropriate liquid; and (d) suitable emulsions. Tablet forms can include one or more of lactose, sucrose, mannitol, sorbitol, calcium

40

phosphates, corn starch, potato starch, microcrystalline cellulose, gelatin, colloidal silicon dioxide, talc, magnesium stearate, stearic acid, and other excipients, colorants, fillers, binders, diluents, buffering agents, moistening agents, preservatives, flavoring agents, dyes, disintegrating agents, and pharmaceutically compatible carriers. Lozenge forms can 5 comprise the active ingredient in a flavor, *e.g.*, sucrose, as well as pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin or sucrose and acacia emulsions, gels, and the like containing, in addition to the active ingredient, carriers known in the art.

The compound of choice, alone or in combination with other suitable 10 components, can be made into aerosol formulations (*i.e.*, they can be “nebulized”) to be administered via inhalation. Aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like.

Formulations suitable for parenteral administration, such as, for example, by intraarticular (in the joints), intravenous, intramuscular, intradermal, intraperitoneal, 15 and subcutaneous routes, include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. In the practice of this invention, compositions can 20 be administered, for example, by intravenous infusion, orally, topically, intraperitoneally, intravesically or intrathecally. Parenteral administration and intravenous administration are the preferred methods of administration. The formulations of commends can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials.

Injection solutions and suspensions can be prepared from sterile powders, 25 granules, and tablets of the kind previously described. Cells transduced by nucleic acids for *ex vivo* therapy can also be administered intravenously or parenterally as described above.

The polypeptides of the invention are administered prophylactically or to an individual already suffering from the disease. The compositions are administered to a 30 patient in an amount sufficient to elicit an effective immune response. An amount adequate to accomplish this is defined as “therapeutically effective dose” or “immunogenically effective dose.” Amounts effective for this use will depend on, *e.g.*,

the peptide composition, the manner of administration, the stage and severity of the disease being treated, the weight and general state of health of the patient, and the judgment of the prescribing physician, but generally range for the initial immunization dose (that is for therapeutic or prophylactic administration) from about 0.01 mg to about 5 50 mg per 70 kilogram patient, more commonly from about 0.5-1 mg to about 10-15 mg per 70 kg of body weight. Boosting dosages are typically from about 0.01 mg to about 50 mg of peptide, more commonly about 0.5-1 mg to about 10-15 mg, using a boosting regimen over weeks to months depending upon the patient's response and condition. A suitable protocol would include injection at time 0, 2, 6, 8, 10 and 14 weeks, followed by 10 booster injections at 24 and 28 weeks. Booster injections can be from one, two, three, four, five or more. Initial and booster injection amounts and timing are determined based on the judgment of the physician and the antigen being administered. In one embodiment, the initial and booster dose is 1.3 mg, 4 mg, or 13 mg, administered via intramuscular injection, with at least one and up to 3 booster injections at 8 week 15 intervals, or at least one and up to 4 booster injections at 6 week intervals.

The therapeutic methods of the present invention may involve oral tolerance (Weiner *et al.*, *Nature* 376: 177-80, 1995), or intravenous tolerance, for example. Tolerance can be induced in mammals, although conditions for inducing such tolerance will vary according to a variety of factors. To induce immunological tolerance 20 in an adult susceptible to or already suffering from an autoantigen-related disease such as IDDM, the precise amounts and frequency of administration will also vary. For instance for adults about 20-80 µg/kg can be administered by a variety of routes, such as parenterally, orally, by aerosols, intradermal injection, and the like. For neonates, tolerance can be induced by parenteral injection or more conveniently by oral 25 administration in an appropriate formulation. The precise amount administrated, and the mode and frequency of dosages, will vary.

The single chain MHC class II molecule:peptide complexes will typically be more tolerogenic when administered in a soluble form, rather than in an aggregated or particulate form. Persistence of a single chain MHC class II molecule:peptide complex of 30 the invention is generally needed to maintain tolerance in an adult, and thus may require more frequent administration of the complex, or its administration in a form which

extends the half-life of the complex. See for example, Sun *et al.*, *Proc. Natl. Acad. Sci. USA* 91: 10795-99, 1994.

Within another aspect of the invention, a pharmaceutical composition is provided which comprises a single chain MHC class II molecule:peptide complex of the present invention contained in a pharmaceutically acceptable carrier or vehicle for parenteral, topical, oral, or local administration, such as by aerosol or transdermally, for prophylactic and/or therapeutic treatment, according to conventional methods. The composition may typically be in a form suited for systemic injection or infusion and may, as such, be formulated with sterile water or an isotonic saline or glucose solution.

Formulations may further include one or more diluents, fillers, emulsifiers, preservatives, buffers, excipients, and the like, and may be provided in such forms as liquids, powders, emulsions, suppositories, liposomes, transdermal patches and tablets, for example.

Pharmaceutical compositions of the present invention are administered at daily to weekly intervals. An "effective amount" of such a pharmaceutical composition is an amount that provides a clinically significant decrease in a deleterious T cell-mediated immune response to an autoantigen, for example, those associated with IDDM, or provides other pharmacologically beneficial effects. Such amounts will depend, in part, on the particular condition to be treated, age, weight, and general health of the patient, and other factors evident to those skilled in the art. Preferably the amount of the single chain MHC class II molecule:peptide complex administered will be within the range of 20-80 µg/kg. Compounds having significantly enhanced half-lives may be administered at lower doses or less frequently.

#### Adjuvants

An immunostimulant refers to essentially any substance that enhances or potentiates an immune response (antibody and/or cell-mediated) to an exogenous antigen. One preferred type of immunostimulant comprises an adjuvant. Many adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a stimulator of immune responses, such as lipid A, *Bordetella pertussis* or *Mycobacterium tuberculosis* derived proteins. Certain adjuvants are commercially available as, for example, Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, MI); Merck Adjuvant 65 (Merck and Company,

Inc., Rahway, NJ); AS-2 (SmithKline Beecham, Philadelphia, PA); aluminum salts such as aluminum hydroxide gel (alum) or aluminum phosphate; salts of calcium, iron or zinc; an insoluble suspension of acylated tyrosine; acylated sugars; cationically or anionically derivatized polysaccharides; polyphosphazenes; biodegradable microspheres;

- 5 monophosphoryl lipid A and quil A. Cytokines, such as GM-CSF, interleukin-2, -7, -12, and other like growth factors, may also be used as adjuvants.

The compositions may also include a *Mycobacterium* species CWS adjuvant, as described above. The effectiveness of an adjuvant may be determined by measuring the amount of antibodies directed against the immunogenic peptide.

10 Certain adjuvants for eliciting a predominantly Th1-type response include, for example, a combination of monophosphoryl lipid A, preferably 3-de-O-acylated monophosphoryl lipid A, together with an aluminum salt. MPL® adjuvants are available from Corixa Corporation (Seattle, WA; *see*, for example, US Patent Nos. 4,436,727; 4,877,611; 4,866,034 and 4,912,094). CpG-containing oligonucleotides (in which the 15 CpG dinucleotide is unmethylated) also induce a predominantly Th1 response. Such oligonucleotides are well known and are described, for example, in WO 96/02555, WO 99/33488 and U.S. Patent Nos. 6,008,200 and 5,856,462. Immunostimulatory DNA sequences are also described, for example, by Sato *et al.*, *Science* 273:352, 1996.

Another preferred adjuvant comprises a saponin, such as Quil A, or derivatives thereof, 20 including QS21 and QS7 (Aquila Biopharmaceuticals Inc., Framingham, MA); Escin; Digitonin; or *Gypsophila* or *Chenopodium quinoa* saponins. Other preferred formulations include more than one saponin in the adjuvant combinations of the present invention, for example combinations of at least two of the following group comprising QS21, QS7, Quil A, β-escin, or digitonin.

25 Alternatively the saponin formulations may be combined with vaccine vehicles composed of chitosan or other polycationic polymers, polylactide and polylactide-co-glycolide particles, poly-N-acetyl glucosamine-based polymer matrix, particles composed of polysaccharides or chemically modified polysaccharides, liposomes and lipid-based particles, particles composed of glycerol monoesters, etc. The 30 saponins may also be formulated in the presence of cholesterol to form particulate structures such as liposomes or ISCOMs. Furthermore, the saponins may be formulated together with a polyoxyethylene ether or ester, in either a non-particulate solution or

suspension, or in a particulate structure such as a paucilamellar liposome or ISCOM. The saponins may also be formulated with excipients such as Carbopol<sup>R</sup> to increase viscosity, or may be formulated in a dry powder form with a powder excipient such as lactose.

In one embodiment, the adjuvant system includes the combination of a monophosphoryl lipid A and a saponin derivative, such as the combination of QS21 and 3D-MPL<sup>®</sup> adjuvant, as described in WO 94/00153, or a less reactogenic composition where the QS21 is quenched with cholesterol, as described in WO 96/33739. Other formulations comprise an oil-in-water emulsion and tocopherol. Another adjuvant formulation employs QS21, 3D-MPL<sup>®</sup> adjuvant and tocopherol in an oil-in-water emulsion is described in WO 95/17210.

Another enhanced adjuvant system involves the combination of a CpG-containing oligonucleotide and a saponin derivative particularly the combination of CpG and QS21 as disclosed in WO 00/09159. Preferably the formulation additionally comprises an oil in water emulsion and tocopherol.

Additional illustrative adjuvants for use in the pharmaceutical compositions of the invention include Montanide ISA 720 (Seppic, France), SAF (Chiron, California, United States), ISCOMS (CSL), MF-59 (Chiron), the SBAS series of adjuvants (*e.g.*, SBAS-2 or SBAS-4, available from SmithKline Beecham, Rixensart, Belgium), Detox (Enhanzyn<sup>®</sup>) (Corixa, Hamilton, MT), RC-529 (Corixa, Hamilton, MT) and other aminoalkyl glucosaminide 4-phosphates (AGPs), such as those described in pending U.S. Patent Application Serial Nos. 08/853,826 and 09/074,720, the disclosures of which are incorporated herein by reference in their entireties, and polyoxyethylene ether adjuvants such as those described in WO 99/52549A1.

Other preferred adjuvants include adjuvant molecules of the general formula (I): HO(CH<sub>2</sub>CH<sub>2</sub>O)<sub>n</sub>-A-R,  
wherein, n is 1-50, A is a bond or -C(O)-, R is C<sub>1-50</sub> alkyl or Phenyl C<sub>1-50</sub> alkyl.

One embodiment of the present invention consists of a vaccine formulation comprising a polyoxyethylene ether of general formula (I), wherein n is between 1 and 50, preferably 4-24, most preferably 9; the R component is C<sub>1-50</sub>, preferably C<sub>4</sub>-C<sub>20</sub> alkyl and most preferably C<sub>12</sub> alkyl, and A is a bond. The concentration of the polyoxyethylene ethers should be in the range 0.1-20%, preferably from 0.1-10%, and most preferably in the range 0.1-1%. Preferred polyoxyethylene ethers are selected from the following

group: polyoxyethylene-9-lauryl ether, polyoxyethylene-9-stearyl ether, polyoxyethylene-8-stearyl ether, polyoxyethylene-4-lauryl ether, polyoxyethylene-35-lauryl ether, and polyoxyethylene-23-lauryl ether. Polyoxyethylene ethers such as polyoxyethylene lauryl ether are described in the Merck index (12<sup>th</sup> edition: entry 7717). These adjuvant molecules are described in WO 99/52549.

The polyoxyethylene ether according to the general formula (I) above may, if desired, be combined with another adjuvant. For example, a preferred adjuvant combination is preferably with CpG as described in the pending UK patent application GB 9820956.2.

10

#### Liposome-, Nanocapsule-, and Microparticle-Mediated Delivery

In certain embodiments, the inventors contemplate the use of liposomes, nanocapsules, microparticles, microspheres, lipid particles, vesicles, and the like, for the introduction of the compositions of the present invention into the subjects. In particular, the compositions of the present invention may be formulated for delivery either encapsulated in a lipid particle, a liposome, a vesicle, a nanosphere, or a nanoparticle or the like.

Such formulations may be preferred for the introduction of pharmaceutically-acceptable formulations of the compositions disclosed herein. The formation and use of liposomes is generally known to those of skill in the art (see, for example, Couvreur *et al.*, 1977; Couvreur, 1988; Lasic, 1998; which describes the use of liposomes and nanocapsules in the targeted antibiotic therapy for intracellular bacterial infections and diseases). Recently, liposomes were developed with improved serum stability and circulation half-times (Gabizon & Papahadjopoulos, 1988; Allen and Choun, 1987; U. S. Patent 5,741,516, specifically incorporated herein by reference in its entirety). Further, various methods of liposome and liposome-like preparations as potential drug carriers have been reviewed (Takakura, 1998; Chandran *et al.*, 1997; Margalit, 1995; U. S. Patent 5,567,434; U. S. Patent 5,552,157; U. S. Patent 5,565,213; U. S. Patent 5,738,868 and U. S. Patent 5,795,587, each specifically incorporated herein by reference in its entirety).

Liposomes have been used effectively to introduce genes, drugs (Heath & Martin, 1986; Heath *et al.*, 1986; Balazssovits *et al.*, 1989; Fresta & Puglisi, 1996),

radiotherapeutic agents (Pikul *et al.*, 1987), enzymes (Imaizumi *et al.*, 1990a; Imaizumi *et al.*, 1990b), viruses (Faller & Baltimore, 1984), transcription factors and allosteric effectors (Nicolau & Gersonde, 1979) into a variety of cultured cell lines and animals. In addition, several successful clinical trials examining the effectiveness of liposome-mediated drug delivery have been completed (Lopez-Berestein *et al.*, 1985a; 1985b; Coune, 1988; Sculier *et al.*, 1988). Furthermore, several studies suggest that the use of liposomes is not associated with autoimmune responses, toxicity or gonadal localization after systemic delivery (Mori & Fukatsu, 1992).

Liposomes are formed from phospholipids that are dispersed in an aqueous medium and spontaneously form multilamellar concentric bilayer vesicles (also termed multilamellar vesicles (MLVs). MLVs generally have diameters of from 25 nm to 4  $\mu\text{m}$ . Sonication of MLVs results in the formation of small unilamellar vesicles (SUVs) with diameters in the range of 200 to 500 Å, containing an aqueous solution in the core.

Liposomes bear resemblance to cellular membranes and are contemplated for use in connection with the present invention as carriers for the compositions. They are widely suitable as both water- and lipid-soluble substances can be entrapped, *i.e.*, in the aqueous spaces and within the bilayer itself, respectively. It is possible that the drug-bearing liposomes may even be employed for site-specific delivery of active agents by selectively modifying the liposomal formulation.

In addition to the teachings of Couvreur *et al.* (1977, 1988), the following information may be utilized in generating liposomal formulations. Phospholipids can form a variety of structures other than liposomes when dispersed in water, depending on the molar ratio of lipid to water. At low ratios the liposome is the preferred structure. The physical characteristics of liposomes depend on pH, ionic strength and the presence of divalent cations. Liposomes can show low permeability to ionic and polar substances, but at elevated temperatures undergo a phase transition which markedly alters their permeability. The phase transition involves a change from a closely packed, ordered structure, known as the gel state, to a loosely packed, less-ordered structure, known as the fluid state. This occurs at a characteristic phase-transition temperature and results in an increase in permeability to ions, sugars and drugs.

In addition to temperature, exposure to proteins can alter the permeability of liposomes. Certain soluble proteins, such as cytochrome c, bind, deform and penetrate

the bilayer, thereby causing changes in permeability. Cholesterol inhibits this penetration of proteins, apparently by packing the phospholipids more tightly. It is contemplated that the most useful liposome formations for antibiotic and inhibitor delivery will contain cholesterol.

5       The ability to trap solutes varies between different types of liposomes. For example, MLVs are moderately efficient at trapping solutes, but SUVs are extremely inefficient. SUVs offer the advantage of homogeneity and reproducibility in size distribution. However, a compromise between size and trapping efficiency is offered by large unilamellar vesicles (LUVs). These are prepared by ether evaporation and are three  
10      to four times more efficient at solute entrapment than MLVs.

In addition to liposome characteristics, an important determinant in entrapping compounds is the physicochemical properties of the compound itself. Polar compounds are trapped in the aqueous spaces and nonpolar compounds bind to the lipid bilayer of the vesicle. Polar compounds are released through permeation or when the  
15      bilayer is broken, but nonpolar compounds remain affiliated with the bilayer unless it is disrupted by temperature or exposure to lipoproteins. Both types show maximum efflux rates at the phase transition temperature.

Liposomes interact with cells *via* four different mechanisms: endocytosis  
20      by phagocytic cells of the reticuloendothelial system such as macrophages and neutrophils; adsorption to the cell surface, either by nonspecific weak hydrophobic or electrostatic forces, or by specific interactions with cell-surface components; fusion with the plasma cell membrane by insertion of the lipid bilayer of the liposome into the plasma membrane, with simultaneous release of liposomal contents into the cytoplasm; and by transfer of liposomal lipids to cellular or subcellular membranes, or vice versa, without  
25      any association of the liposome contents. It often is difficult to determine which mechanism is operative and more than one may operate at the same time.

The fate and disposition of intravenously injected liposomes depend on their physical properties, such as size, fluidity, and surface charge. They may persist in tissues for hours or days, depending on their composition, and half lives in the blood  
30      range from minutes to several hours. Larger liposomes, such as MLVs and LUVs, are taken up rapidly by phagocytic cells of the reticuloendothelial system, but physiology of the circulatory system restrains the exit of such large species at most sites. They can exit

only in places where large openings or pores exist in the capillary endothelium, such as the sinusoids of the liver or spleen. Thus, these organs are the predominant site of uptake. On the other hand, SUVs show a broader tissue distribution but still are sequestered highly in the liver and spleen. In general, this *in vivo* behavior limits the potential targeting of liposomes to only those organs and tissues accessible to their large size. These include the blood, liver, spleen, bone marrow, and lymphoid organs.

Targeting is generally not a limitation in terms of the present invention. However, should specific targeting be desired, methods are available for this to be accomplished. Antibodies may be used to bind to the liposome surface and to direct the antibody and its drug contents to specific receptors located on a particular cell-type surface. Carbohydrate determinants (glycoprotein or glycolipid cell-surface components that play a role in cell-cell recognition, interaction and adhesion) may also be used as recognition sites as they have potential in directing liposomes to particular cell types. Mostly, it is contemplated that intravenous injection of liposomal preparations would be used, but other routes of administration are also conceivable.

Alternatively, the invention provides for pharmaceutically-acceptable nanocapsule formulations of the compositions of the present invention. Nanocapsules can generally entrap compounds in a stable and reproducible way (Henry-Michelland *et al.*, 1987; Quintanar-Guerrero *et al.*, 1998; Douglas *et al.*, 1987). To avoid side effects due to intracellular polymeric overloading, such ultrafine particles (sized around 0.1  $\mu\text{m}$ ) should be designed using polymers able to be degraded *in vivo*. Biodegradable polyalkyl-cyanoacrylate nanoparticles that meet these requirements are contemplated for use in the present invention. Such particles may be easily made, as described (Couvreur *et al.*, 1980; 1988; zur Muhlen *et al.*, 1998; Zambaux *et al.* 1998; Pinto-Alphandry *et al.*, 1995 and U. S. Patent 5,145,684, specifically incorporated herein by reference in its entirety).

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to one of ordinary skill in the art in light of the teachings of this invention that

certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

The following example is provided by way of illustration only and not by way of limitation. Those of skill in the art will readily recognize a variety of noncritical parameters that could be changed or modified to yield essentially similar results.

### EXAMPLES

Example 1: Construction of DNA sequences encoding human single chain MHC class II peptide complexes, HLA-DR4 molecules(CO563 and CO564).

10 DNA constructs encoding gp39 β1/α1 human molecules were prepared from a cDNA encoding the gp39 peptide fused to the β1/α1 domains of HLA-DR4 according to standard techniques. For the production of “empty” β1/α1 DR4 molecules, a cDNA encoding the fused β1/α1 domains of HLA-DR4 was prepared using cloned α and β chains from DR4.

15 Amino acid sequence of the gp39-β1/α1 HLA-DR4 human single chain molecule (linkers are shown in bold)

MGDTGRSFTLASSETGVGASGGGGSGGGDTRPRFLEQVKHECH  
FFNGTERVRFLDRYFYHQEEYVRFDSDVGEYRAVTELGRPDAEYWNSQKDLLEQ  
KRAAVDTYCRHNYGVGESFTVQRRGGIKEEHVIIQAEFYLNPDQSGEFMFDG  
20 DEIFHVVDMAKKETVWRLEEFGRFASFEAQGALANIAVDKANLEIMTKRSNYTPIT  
N\*

aa1 – aa4: leader sequence

aa5 - aa18: gp39 peptide

aa19 - aa28: linker

25 aa29 - aa122: HLA-DR4 β1 domain

aa123 – aa124: linker

aa125 – aa 208: HLA-DR4 α1 domain

Amino acid sequence of the “empty” β1/α1 HLA-DR4 human single chain molecule (linkers in bold):

30 MGDTRPRFLEQVKHECHFFNGTERVRFLDRYFYHQEEYVRFDSDVGEYRAVTEL  
GRPDAEYWNSQRDLLEQKRAAVDTYCRHNYGVGESFTVQRRGGIKEEHVIIQAE

50

FYLNPDQSGEFMFDFDGDEIFHVDMAKKETVWRLEEFGRFASFEAQGALANIAV  
DKANLEIMTKRSNYTPITN\*

aa 1 – aa95: HLA-DR4  $\beta$ 1 domain

aa96- aa97: linker

5 aa98- aa181: HLA-DR4  $\alpha$ 1 domain

For the production of recombinant proteins, the bacteria (pLysS) were grown in LB (containing ampicillin (50  $\mu$ g / ml) and chloramphenicol (5  $\mu$ g / ml)) at 37°C until OD 600 = 0.5. IPTG was added at the final concentration of 0.5 mM final and the bacteria were further incubated for 3 hours at 37°C with shaking. The bacteria were 10 centrifuged at 4°C, 4000xg for 20 min and the pellet was frozen at -80°C. The following day, the pellet was resuspended in 40 ml of lysis buffer (50 mM Tris-HCl pH 8, 50 mM NaCl, 2 mM EDTA, 1 protease inhibitor cocktail tablet, 1% Triton X100 and 1% deoxycholate), and incubated for 1 hour at 4°C under continuous agitation with a magnetic stirrer. The sample was then homogenized using a French Press with a 16,000 15 psi setting, and centrifuged at 4°C, 9000g for 20 min. The pellet was then resuspended in 30 ml of lysis buffer without Triton and deoxycholate and centrifuged at 4°C, 9000 g for 20 min. The new pellet was resuspended in 10 ml of 20 mM ethanolamine/6 M urea pH 10, and eventually frozen at -80°C. The recombinant protein was then purified by FPLC 20 ion-exchange chromatography using Source 30Q anion-exchange media in an XK26/20 column using a step gradient going from 1 mM to 1 M NaCl in 20 mM ethanolamine/6M urea pH 10. Fractions were analyzed by SDS/PAGE and those corresponding to the proteins of interest are pooled and dialyzed against PBS 1X.

Example 2: Production of additional single chain constructs

25 Additional constructs with different composition and length of the 2<sup>nd</sup> linker (between  $\beta$ 1 and  $\alpha$ 1) were engineered by using standard techniques using CO567 as the template. Specifically, PCR primers were designed to replace the old sequence in CO567 with the new sequence. For example, to make CO581, the primers were designed with the following sequences (note these primers were phosphorylated at 5').

30 Primer 1:

5' pCACCAAGGAGGGAGGCCGCCACGCCGGTCTCGCTGG

Primer 2:

51

5' pGACCACCTGGATCTGGGGACACCCGACCACGTTTC

PCR reaction (100 µl) was made of the following components: 2 µl CO567 (80 ng) as template, 2 µl each of primer 1 and primer 2 (10 µM), 2 µl of dNTP mix (20 mM each), 10 µl of 10X pfu buffer, and 80 µl of sterile water. After all the  
5 components were mixed, 2 µl of Turbo pfu (5U total ) was added, mixed and put on PCR machine. The PCR cycles has a pre-denaturation at 95°C for 30 sec, then 10 cycles of 95°C for 30°C, 60°C for 1 min, and 72°C for 7 min. Then another 22 cycles of 95°C for 30°C, 65°C for 1 min and 72°C for 7 min, followed by a final 10 min at 72°C.

The PCR mixture was digested with 2 µl of DpnI (10U) for 2h at 37°C.  
10 Then the PCR product at ~6 kb was purified from agarose gel after electrophoresis. The purified PCR product was ligated by T4 DNA ligase for 1 h at room temperature then used to transform into NovaBlue (Novagen)competent cells by standard protocol. Cells were plated on LB (+Carb) and grow overnight at 37°C.

15 Next day, about a dozen single colony from the transformation were randomly picked for overnight culture in 5 ml LB (+Carb) at 37°C. Plasmids from these culture were purified with Wizard Miniprep kit, and analyzed by Xho I digestion. A few plasmids that passed the Xho I digestion were further confirmed by DNA sequencing.

To express the recombinant proteins, a clone with confirmed DNA sequence was used to transform BL21(DE3)CodonPlus-RIL (Stratagene) by standard  
20 transformation protocol and plated on LB (Carb+Cam) plates overnight at 37°C. Next morning, a single colony was picked to inoculate 100 ml LB (+Carb +Cam) and the culture was grown till OD reach between 0.8-1.0, and stored overnight at 4°C. Next day, the culture was pellet down and used to inoculate into 2xYT (+Carb+Cam) at ratio of 25 ml culture per liter new media. These large cultures were grown at 37°C till OD=0.5-0.6,  
25 and IPTG was added to induce recombinant protein at 37°C for 3 h. The induced cultures were pellet and stored at -80°C till purification.

Table 1 provides a listing of various constructs made according to the invention.

TABLE I

<b>Construct</b>	<b>peptide</b>	<b>upstream linker</b>	<b>downstream linker</b>
C0523	yes	GGGG	GG
C0543	none	none	GG
C0563	yes	ASGGGSGGG	GG
C0567	yes	ASGGGSGGG	TSGGGGSGGGSSS
C0580	yes	ASGGGSGGG	GSPGGGSGGPGS
C0581	yes	ASGGGSGGG	GSPPGGPPGS
C0582	yes	ASGGGSGGG	GSPGGGPAGS
C0583	yes	ASGGGSGGG	TSGGGGS
C0584	yes	ASGGGSGGG	SGGSGGS
C0585	yes	ASGGGSGGG	FDAPSPLP
C0586	none	none	TSGGGGSGGGSSS
C0587	none	none	GSPGGGSGGPGS
C0588	none	none	GSPPGGPPGS
C0589	none	none	GSPGGGPAGS
C0590	none	none	TSGGGGS
C0591	none	none	SGGSGGS
C0592	none	none	FDAPSPLP
C0593	yes	ASGGGSGGG	VYPEVTV
C0594	none	none	VYPEVTV
C0595	yes	ASGGGSGGG	GGGG
C0596	yes	ASGGGSGGG	GGGGS
C0597	yes	ASGGGSGGG	GGGSAG

Example 3: Four classes of novel linkers for MHC class II single chain molecules

Inspection of circular dichroism spectra of purified, refolded single chain constructs indicated that novel linkers could be used for the constructs. The atomic structures of the various murine and human MHC class II molecules, as determined by X-ray crystallography, indicated that these molecules have a high degree of structural similarity. The circular dichroism results were consistent with two folded molecules of clearly different secondary structure. Careful inspection of the structures reveals that the human MHC has a longer distance between chains than the equivalent murine molecule. This results led to proposing longer linkers between the chains which would contain flexible residues (e.g. alanine or glycine) and polar residues (e.g. serine and threonine). These constructs make up the first class of linkers. To inhibit the continuation of secondary structure across the linker, prolines were added to bracket the linkers. These prolines are known to inhibit the formation of alpha helices and beta sheets. These linkers make up the second class of linkers disclosed here.

Next, flexible regions present in the human MHC and in the murine MHC could be used to make a linker by extending the region of interest and ligating the ends together. These are the third class of linkers. Finally, a combination of these types of linkers could also be used. These are the fourth class of linkers.

Example 4: Human MHC class II single chain molecule with murine linkers

Another linker has been suggested based on a combination of murine and human MHC class II single chain molecules. This fusion would incorporate linker residues from the functional murine single chain MHC class II molecule and the alpha and beta chains of the human molecule. The protein sequence of the single chain molecule is provided below (the linker residues from the mouse construct are in bold):

MGDTGRSFTLASSETGVGASGGGGSGGGDTRPRFLEQVKHECHFFNGTERVRF  
LDRYFYHQEEYVRFSDVGEYRAVTELGRPDAEYWNSQKDLLEQKRAAVDTYC  
RHNYGVGESFTVL**RRLGGEDDEADHHVIIQAEFYLNPDQSGEFMFDGDEIFH**  
**VDMAKKETVWRLEFGRFASFEAQGALANIAVDKANLEIMTKRSNYTPITN\***

Further MHC class II hybrid single chain molecules may be designed by fusing other portions of the alpha chain and the beta chain together using linkers as described elsewhere. A properly folded molecule may be obtained by putting appropriate

54

linkers between portions of the human MHC class II which are proximal to each other as determined by visual inspection of the atomic coordinates of residues of the native MHC available in the publicly accessible protein structure database. These structures would predict possible fusion proteins which covalently attach any part of the beta chain  
5 between residues 82 to 123 or between residues 148 to 164 to portions of the alpha chain such as the N-terminal residues, residues 79 to 84, or 92 to 106. The numbering system of residues in this example corresponds to those found in the coordinates of the structure described in: DESSEN, *et al.* *Immunity* 7:473 (1997). Other, homologous residues could be used to create equivalent constructs for genotypic and allelic variants of these  
10 molecules e.g. equivalent residues in DR2 or such. DNAs for such hybrids would be prepared and expressed in a recombinant expression system by someone skilled in the art and could be assayed for structure and function in appropriate assays.

15 Example 5: Use of CD4 binding site(s) of MHC class II molecules as linkers for the production of bioactive recombinant MHC class II:peptide complexes

HLA class II molecules present antigenic peptides to the T cell receptor of the CD4+ T lymphocytes and interact with CD4 during the antigen recognition process. Native MHC class II-peptide complexes have been shown to bind to MHC class II restricted and antigen specific TCRs on a particular T cell and induce T cell  
20 nonresponsiveness. It is proposed that the CD4 binding site is important in the docking of MHC class II-peptide complex with the TCR and induce nonresponsiveness. Since the binding of CD4 to MHC class II-peptide is important in antigen presentation and/or induction of T cell nonresponsiveness, it is proposed that recombinant MHC class II-peptide molecules (truncated or whole) containing CD4 binding site will be biologically active. Furthermore, a polypeptide fragment from MHC class II which binds the CD4,  
25 when used as a linker in preparation of MHC class II-peptide truncated molecules, provides resulting recombinant molecules that will be biologically active.

The following describes the concept of different linkers. Peptide is attached to a linker 1 (L1) which is attached to N-terminus of  $\beta$ 1 domain that is linked to L2. L2 is linked to L3, which in turn is linked to N-terminus of  $\alpha$ 1 chain of MHC class II. Here L2 represents the human CD4 binding sequences. It should be noted that L2 could also be directly linked to N-terminus of  $\alpha$ 1 domain by completely deleting L3.

55

Specific examples of L1 and L3 are given in a examples. The sequences of L2 are given below. These sequences are applicable to most of the DR-Peptide molecules.

RNGQEEKAGVVSTGLI, RNGQETKAGVVSTGLI, YNQQEEKAGGVSTGLI,  
FRNGQEEKAGVVSTGLI, FRNGQETKAGVVSTGLI, FYNQQEEKAGGVSTGLI,

5 and LNGQEEKAGMVSTGLI.

Example 6: I-As MBP. $\beta$ 1 $\beta$ 2 $\alpha$ 1 $\alpha$ 2.C $\kappa$  construct and activity

The “full anergix” single chain molecule, mouse I-As MBP. $\beta$ 1 $\beta$ 2 $\alpha$ 1 $\alpha$ 2.C $\kappa$ , was generated by overlap PCR using standard methodology. The molecules was expressed in 293T cells and baculoviral cells according to standard methodology, and purified according to standard methodology using affinity chromatography using goat-anti mouse antibodies. The structure of I-As MBP. $\beta$ 1 $\beta$ 2 $\alpha$ 1 $\alpha$ 2.C $\kappa$  is shown in Figure 1.

The amino acid sequence of the I-As MBP. $\beta$ 1 $\beta$ 2 $\alpha$ 1 $\alpha$ 2.C $\kappa$  shown in Figure 1 is as follows:

METDTLLLWVLLWVPGSTGDFKNIVTPRTPPPASGGGGSGGGGDSERHFVFQF  
KGECYFTNGTQRIRSVDRYIYNREEYLRFDSDVGEYRAVTELGRPDPEYYNKQY  
LEQTRAELDTVCRHNYEGVETHTSLRRLEQPNVISLSRTEALNHHTLVCSVTD  
FYPAKIKVRWFRNGQEETVGVSSTQLIRNGDWTQVLVMLEMPRRGEVYTCH  
VEHPSLKSPITVEWTSGGGGSGGGGSGGGSGGGSSSEDDIEADHVGVYGTIV  
YQSPGDIGQYTHEFDGDEWFYVDLDKKETIWMLPEFGQLTSFDPQGGLQNIATG  
KYTLGILTKRSNSTPATNEAPQATVFPKSPVLLGQPNTLICFVDNIFPPVINITWLR  
NSKSVTDGVYETSFLVNRDHSHFKLSYLTFIPSDDDIYDCKVEHWGLEEPVLKHW  
ASGGGGSGGGADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVWKIDG  
SERQNGVLNSWTDQDSKDSTYSMSSTLTKEYERHNSYTCEATHKTSTSPIVK  
SFNRNEC

The *in vitro* activity of recombinant I-As MBP. $\beta$ 1 $\beta$ 2 $\alpha$ 1 $\alpha$ 2.C $\kappa$  was tested using MBP90-101 specific IAs restricted mouse T cell clone HS1. This clone was prepared by the immunization of SJL mice with the MBP90-101 peptide, followed by cloning out CD4+ T cells by limited dilution techniques. These cells were maintained by stimulation every 10 days with irradiated SJF splenocytes and PBP90-101 peptide. The T cells are activated by a combination of soluble recombinant I-As MBP. $\beta$ 1 $\beta$ 2 $\alpha$ 1 $\alpha$ 2.C $\kappa$  and plate bound anti-CD28 antibody. T cell activation was assayed by  $^3$ H-thymidine

incorporation according to standard methodology. Figure 2 shows the results of this assay.

MS is a T cell dependent autoimmune disease caused by localized demyelination in the central nervous system. Experimental autoimmune encephalomyelitis is accepted animal model of MS. The following results demonstrate that administration of I-As MBP. $\beta$ 1 $\beta$ 2 $\alpha$ 1 $\alpha$ 2.Ck reduces the incidence and severity of EAE. EAE was induced according to standard methodology according to the myelin model. Ten  $\mu$ g of recombinant I-As MBP. $\beta$ 1 $\beta$ 2 $\alpha$ 1 $\alpha$ 2.Ck was given intravenously in 100  $\mu$ l of PBS at days 1, 4, 7, and 11 after disease induction. 12 days after immunization, animals are observed daily for the onset of neurological dysfunction. Disease is graded by trained technicians according to standard methods (see Figure 3). Mice are followed for up to 60-70 days. The data shown in Figure 4 demonstrate that administration of the recombinant I-As MBP. $\beta$ 1 $\beta$ 2 $\alpha$ 1 $\alpha$ 2.Ck significantly reduced the incidence of myelin-induced EAE in SJL mice. In one experiment, 11 out of 20 mice developed EAE in the untreated group (55%), whereas only 2 out of 21 animal showed sign of the disease in the treated group (16.6%). Similarly, in another experiment, 12 out of 16 mice developed EAE in the untreated group (75%), while only 2 out of 16 developed EAE in the treated group (12.5%).

Histological examination from SJL mice in the EAE model studies: spinal cords were removed, fixed in formalin solution and embedded in paraffin. Sections were cut, stained with hematoxylin, eosin and graded for inflammatory lesions. A. Section of spinal cord from untreated mouse, score = 2.5; B. Section of spinal cord from mouse treated with the recombinant I-AS.MBP.Ck, score = 0; C. Section of spinal cord from mouse treated with the recombinant I-AS. $\beta$ 1 $\alpha$ 1 without antigenic peptide fusion, score = 2.0; D. Section of spinal cord from mouse treated with the recombinant I-AS.MBP. $\beta$ 1 $\alpha$ 1, score = 0.5. The histology score for each section is marked.

Example 7: Functional human anergix molecules optimized for *E. coli* expression with *E. coli* codons

Two human single chain MHC class II molecules (CO528-AC and CO608-AC) have been optimized for *E. coli* expression using "artificial codons," e.g.,

preferred *E. coli* codons encoding the mammalian protein. CO528-AC and CO608-AC were made according to standard PCR overlap technology.

Example 7: Recombinant MHC class II IAs.MBP.Ig multimeric complexes

5           Recombinant MHC class II (IAs)-peptide-Ig fusion complexes were constructed by fusing the mIgG leader, MBP 90-101, or MBP1-14 (as a control) to IAs single chain (b1b2a1a2), and mIgG.Ck, mIgG.CH1.H, mIgG.CH1.H.CH2, or mIgG.CH1.H.CH2.CH3 with flexible linkers, according to standard methodology. The recombinant IAs fusion proteins were expressed in both mammalian and insect cells and  
10          detected by western analysis and ELISA. The overexpressed and secreted recombinant IAs fusion proteins from both human 293 cell cultures or from insect culture medium were purified by affinity chromatography. The purified dimeric and tetrameric recombinant IAs proteins have *in vitro* biological activity as assayed using an antigen-specific mouse T cell clone. The *in vivo* activity of the recombinant IAs fusion proteins  
15          were studied with the experimental autoimmune encephalomyelitis (EAE) model using susceptible SJL mice. In these EAE studies, recombinant IAs fusion protein was delivered on days 1, 4, 7, and 11 by I.V. injections after induction of the disease with myelin. The animals were then examined for neurological dysfunction. The results indicate that treatment with the recombinant IAs fusion proteins prevents mortality and  
20          significantly reduces paralysis induced by myelin homogenate in CFA. In conclusion, these studies suggest that the recombinant MHC class II fusion protein has therapeutic benefit as antigen-specific drugs for the treatment of autoimmune diseases.

Example 8: Synthesis of mouse model equivalent of CO608

25          Four forms of the murine MHC Class II IAs  $\beta 1\alpha 1$  with MBP peptide linkers analogous to CO608 human were made. These constructs can be used, e.g., as murine clinical control for human 608. mCO608 (mouse CO608, lacking the first five amino acids, GDSER, as compared to native beta 1 domain), MCO608-A (same as m608 except lacking four amino acids, GSER, after the methionine as compared to m608), *B.*  
30          *megaterium*-mCO608-A (expressed in *Bacillus megaterium*), and mCO608-B (same as m608 except lacking first four amino acids, GSER, after the methionine as compared to m608; also lacking second amino acid, D, as compared to native beta 1 domain).

To make mCO608, the upstream linker of mouse CO521 (GGGS) was replaced with the human CO608 linker (ASGGGGSGGG) and the downstream linker of mouse CO521 (GG) was replaced with the downstream linker of CO608 (TSGGGGS), using PCR according to standard methodology. mCO608-A and m6O8-B were made  
5 from mCO608 using PCR according to standard methodology.

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.

10 Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to one of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

59

5 <210> CO602  
 <211> 558  
 <212> DNA  
 <213> Homo sapiens

10 atgggggaca cccgaccacg tttcttggag caggttaaac atgagtgtca tttcttcaac 60  
 gggacggagc ggggtgcgggtt cctggacaga tacttctatc accaagagga gtacgtgcgc 120  
 ttgcacagcg acgtggggga gtaccgggagc gtgacggagc tggggcggcc tgatgccgag 180  
 tactggaaaca gccagaagga cctcctggag cagaagcggg ccgcgggtgga cacctactgc 240  
 agacacaact acggggttgg tgagagcttc acagtgcgc gcccactcgg aggtgaagat 300  
 15 gacgaggcag atcaccatgt gatcatccag gccgagttct atctgaatcc tgaccaaatac 360  
 ggcgagtttta tgtttgactt tgatggtgat gagattttcc atgtggatat ggaaagaag 420  
 gagacggctt ggcggcttga agaatttggc cgatttgcca gctttgaggc tcaagggtgca 480  
 ttggccaaaca tagctgtggc caaagccaaac ctggaaatca tgacaaaagcg ctccaaactat 540  
 actccgatca ccaattaa 558

20 <210> CO601  
 <211> 558  
 <212> DNA  
 <213> Homo sapiens

25 atgggggaca cccgaccacg tttcttggag caggttaaac atgagtgtca tttcttcaac 60  
 gggacggagc ggggtgcgggtt cctggacaga tacttctatc accaagagga gtacgtgcgc 120  
 ttgcacagcg acgtggggga gtaccgggagc gtgacggagc tggggcggcc tgatgccgag 180  
 tactggaaaca gccagaagga cctcctggag cagaagcggg ccgcgggtgga cacctactgc 240  
 agacacaact acggggttgg tgagagcttc acagtgcgc ggcgaggagg tggaaagcggc 300  
 30 gaaatcaaag aagaacatgt gatcatccag gccgagttct atctgaatcc tgaccaaatac 360  
 ggcgagtttta tgtttgactt tgatggtgat gagattttcc atgtggatat ggaaagaag 420  
 gagacggctt ggcggcttga agaatttggc cgatttgcca gctttgaggc tcaagggtgca 480  
 ttggccaaaca tagctgtggc caaagccaaac ctggaaatca tgacaaaagcg ctccaaactat 540  
 actccgatca ccaattaa 558

35 <210> CO600  
 <211> 555  
 <212> DNA  
 <213> Homo sapiens

40 atgggggaca cccgaccacg tttcttggag caggttaaac atgagtgtca tttcttcaac 60  
 gggacggagc ggggtgcgggtt cctggacaga tacttctatc accaagagga gtacgtgcgc 120  
 ttgcacagcg acgtggggga gtaccgggagc gtgacggagc tggggcggcc tgatgccgag 180  
 tactggaaaca gccagaagga cctcctggag cagaagcggg ccgcgggtgga cacctactgc 240  
 45 agacacaact acggggttgg tgagagcttc acagtgcgc ggcgaggagg tggaggcaggc 300  
 atcaaagaag aacatgttat gatccaggcc gagttctatc tgaatccatg ccaatcaggc 360  
 gagtttatgt ttgactttga tggtgatgag attttccatg tggatatggc aaagaaggag 420  
 acggctctggc ggcttgaaga atttggacga ttgcgcagct ttgaggctca aggtgcattt 480  
 50 gccaacatag ctgtggacaa agccaaacctg gaaatcatga caaagcgctc caactatact 540  
 ccgatcacca attaa 555

<210> CO599  
 <211> 552  
 <212> DNA  
 <213> Homo sapiens

55 atgggggaca cccgaccacg tttcttggag caggttaaac atgagtgtca tttcttcaac 60

60

gggacggagc gggtgcggtt cctggacaga tacttctatc accaagagga gtacgtgcgc 120  
 ttcgacagcg acgtggggga gtaccggggcg gtgacggagc tggggcggcc tgatgccgag 180  
 tactgaaca gccagaagga cctcctggag cagaagcggg ccgcgggtgga cacctactgc 240  
 5 agacacaact acggggtttg tgagagcttc acagtgcagc ggcgaggagg tggaggcatc 300  
 aaagaagaac atgtgatcat ccaggccgag ttctatctga atcctgacca atcaggcgag 360  
 tttatgtttg actttgatgg tgatgagatt ttccatgtgg atatggcaaa gaaggagacg 420  
 gtctggcggc ttgaagaatt tggacgattt gccagctttg aggctcaagg tgcattggcc 480  
 aacatagctg tggacaaagc caacctggaa atcatgacaa agcgctccaa ctatactccg 540  
 atcacaatt aa 552

10

&lt;210&gt; C0594

&lt;211&gt; 561

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

15

atgggggaca cccgaccacg tttcttggag caggtaaac atgagtgtca tttcttcaac 60  
 gggacggagc gggtgcggtt cctggacaga tacttctatc accaagagga gtacgtgcgc 120  
 ttcgacagcg acgtggggga gtaccggggcg gtgacggagc tggggcggcc tgatgccgag 180  
 tactgaaca gccagaagga cctcctggag cagaagcggg ccgcgggtgga cacctactgc 240  
 20 agacacaact acggggtttg tgagagcttc acagtgcagc ggcgagtcta ccctgaggta 300  
 actgtcatca aagaagaaca tgtgatcatc caggccgagt tctatctgaa tcctgaccaa 360  
 tcaggcgagt ttatgtttga ctttgatggt gatgagattt tccatgtgga tatggcaaag 420  
 aaggagacgg tctggcggct tgaagaattt ggacgattt ccagctttga ggctcaaggt 480  
 25 gcattggcca acatagctgt ggacaaagcc aacctggaaa tcatgacaaa gcgctccaac 540  
 tatactccga tcaccaatta a 561

&lt;210&gt; C0592

&lt;211&gt; 564

&lt;212&gt; DNA

30

&lt;213&gt; Homo sapiens

atgggggaca cccgaccacg tttcttggag caggtaaac atgagtgtca tttcttcaac 60  
 gggacggagc gggtgcggtt cctggacaga tacttctatc accaagagga gtacgtgcgc 120  
 ttcgacagcg acgtggggga gtaccggggcg gtgacggagc tggggcggcc tgatgccgag 180  
 tactgaaca gccagaagga cctcctggag cagaagcggg ccgcgggtgga cacctactgc 240  
 35 agacacaact acggggtttg tgagagcttc acagtgcagc ggcgattcga cgcaccttagc 300  
 ccactcccaa tcaaagaaga acatgtgatc atccaggccg agttctatct gaatcctgac 360  
 caatcaggcg agtttatgtt tgactttgat ggtgatgaga tttccatgt ggatatggca 420  
 aagaaggaga cggtctggcg gcttgaagaa tttggacgat ttgccagctt tgaggctcaa 480  
 40 ggtgcattgg ccaacatagc tgtggacaaa gccaacctgg aaatcatgac aaagcgctcc 540  
 aactatactc cgatcaccaa ttaa 564

&lt;210&gt; C0591

&lt;211&gt; 561

45

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

atgggggaca cccgaccacg tttcttggag caggtaaac atgagtgtca tttcttcaac 60  
 gggacggagc gggtgcggtt cctggacaga tacttctatc accaagagga gtacgtgcgc 120  
 50 ttcgacagcg acgtggggga gtaccggggcg gtgacggagc tggggcggcc tgatgccgag 180  
 tactgaaca gccagaagga cctcctggag cagaagcggg ccgcgggtgga cacctactgc 240  
 agacacaact acggggtttg tgagagcttc acagtgcagc ggcgaagtgg cggtagttgc 300  
 ggttagtatca aagaagaaca tgtgatcatc caggccgagt tctatctgaa tcctgaccaa 360  
 tcaggcgagt ttatgtttga ctttgatggt gatgagattt tccatgtgga tatggcaaag 420  
 55 aaggagacgg tctggcggct tgaagaattt ggacgattt ccagctttga ggctcaaggt 480  
 gcattggcca acatagctgt ggacaaagcc aacctggaaa tcatgacaaa gcgctccaac 540  
 tatactccga tcaccaatta a 561

&lt;210&gt; C0590

<211> 561  
 <212> DNA  
 <213> Homo sapiens

5 atgggggaca cccgaccacg tttcttggag caggttaaac atgagtgtca tttcttcaac 60  
 gggacggagc ggggtgcgggtt cctggacaga tacttctatc accaagagga gtacgtgcgc 120  
 ttcgacagcg acgtggggga gtaccgggagc gtgacggagc tggggcgccc tgatgccgag 180  
 tactgaaaca gccagaagga cctcctggag cagaagcggg ccgcgggtgga cacctactgc 240  
 agacacaact acggggtgtgg tgagagcttc acagtgcagc ggcgaactag tggtgccggt 300  
 10 ggcagcatca aagaagaaca tttgtatcatc caggcccgagt tctatctgaa tcctgacc 360  
 tcagggcgagt ttatgttga ctttgatggt gatgagattt tccatgtgga tatggcaaag 420  
 aaggagacgg tctggcggt tgaagaattt ggacgatttgc ccagcttga ggctcaaggt 480  
 gcattggcca acatagctgt ggacaaagcc aacctggaaa tcatgacaaa gcgctccaac 540  
 tatactccga tcaccaatta a 561

15 <210> C0589  
 <211> 570  
 <212> DNA  
 <213> Homo sapiens

20 atgggggaca cccgaccacg tttcttggag caggttaaac atgagtgtca tttcttcaac 60  
 gggacggagc ggggtgcgggtt cctggacaga tacttctatc accaagagga gtacgtgcgc 120  
 ttcgacagcg acgtggggga gtaccgggagc gtgacggagc tggggcgccc tgatgccgag 180  
 tactgaaaca gccagaagga cctcctggag cagaagcggg ccgcgggtgga cacctactgc 240  
 25 agacacaact acggggtgtgg tgagagcttc acagtgcagc ggcgaggcgc tcctggaggt 300  
 ggaggtcctg gatctatcaa agaagaacat gtgatcatcc aggcccgagggt ctatctgaaat 360  
 cctgaccaat cagggcgagtt tatgttgc tttgtatgggt atgagattt ccatgtggat 420  
 atggcaaaga aggagacggc ctggcggtt gaagaatttgc gacgatttgc cagctttag 480  
 gctcaaggtg cattggccaa catagctgtg gacaaagcc acctggaaat catgacaaaag 540  
 30 cgctccaact atactccgat caccattaa 570

<210> C0588  
 <211> 570  
 <212> DNA  
 <213> Homo sapiens

35 atgggggaca cccgaccacg tttcttggag caggttaaac atgagtgtca tttcttcaac 60  
 gggacggagc ggggtgcgggtt cctggacaga tacttctatc accaagagga gtacgtgcgc 120  
 ttcgacagcg acgtggggga gtaccgggagc gtgacggagc tggggcgccc tgatgccgag 180  
 tactgaaaca gccagaagga cctcctggag cagaagcggg ccgcgggtgga cacctactgc 240  
 agacacaact acggggtgtgg tgagagcttc acagtgcagc ggcgaggcgc tcctcctgggt 300  
 40 ggaccacctg gatctatcaa agaagaacat gtgatcatcc aggcccgagggt ctatctgaaat 360  
 cctgaccaat cagggcgagtt tatgttgc tttgtatgggt atgagattt ccatgtggat 420  
 atggcaaaga aggagacggc ctggcggtt gaagaatttgc gacgatttgc cagctttag 480  
 gctcaaggtg cattggccaa catagctgtg gacaaagcc acctggaaat catgacaaaag 540  
 45 cgctccaact atactccgat caccattaa 570

<210> C0587  
 <211> 582  
 <212> DNA  
 <213> Homo sapiens

50 atgggggaca cccgaccacg tttcttggag caggttaaac atgagtgtca tttcttcaac 60  
 gggacggagc ggggtgcgggtt cctggacaga tacttctatc accaagagga gtacgtgcgc 120  
 55 ttcgacagcg acgtggggga gtaccgggagc gtgacggagc tggggcgccc tgatgccgag 180  
 tactgaaaca gccagaagga cctcctggag cagaagcggg ccgcgggtgga cacctactgc 240  
 agacacaact acggggtgtgg tgagagcttc acagtgcagc ggcgaggaggag tccagggcggt 300  
 ggcgggagcg gcggtggtcc tgggagtttgc aaagaagaac atgtgatcat ccagggcgag 360  
 ttctatctgaa atcctgacca atcaggcgag tttatgttgc actttgtatgg tgatgagatt 420

62

ttccatgtgg atatggcaaa gaaggagacg gtctggcggc ttgaagaatt tggacgattt 480  
 gccagcttg aggctcaagg tgcattggcc aacatagctg tggacaaagc caacctggaa 540  
 atcatgacaa agcgctccaa ctatactccg atcaccaatt aa 582

5 &lt;210&gt; CO586

&lt;211&gt; 582

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

10 atggggaca cccgaccacg tttcttggag caggttaaac atgagtgtca tttcttcaac 60  
 gggacggagc ggggtgcggtt cctggacaga tacttctatc accaagagga gtacgtgcgc 120  
 ttcgacagcg acgtggggga gtaccgggacg tgacggagc tggggcggcc tgatgccgag 180  
 tactgaaca gccagaagga cctcctggag cagaagcggg cccgcgtgga cacctactgc 240  
 agacacaact acggggttgg tgagagctc acagtgcagc ggcgaactag tggtggcggt 300  
 15 ggcagcggcg gtgggtgttc ctcgagtatc aaagaagaac atgtgatcat ccaggccgag 360  
 ttctatctga atcctgacca atcaggcggag tttatgtttg actttatgg tgatgagatt 420  
 ttccatgtgg atatggcaaa gaaggagacg gtctggcggc ttgaagaatt tggacgattt 480  
 gccagcttg aggctcaagg tgcattggcc aacatagctg tggacaaagc caacctggaa 540  
 atcatgacaa agcgctccaa ctatactccg atcaccaatt aa 582

20

&lt;210&gt; CO602

&lt;211&gt; 186

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

25

Met	Gly	Asp	Thr	Arg	Pro	Arg	Phe	Leu	Glu	Gln	Val	Lys	His	Glu	Cys
5														15	

30

His	Phe	Phe	Asn	Gly	Thr	Glu	Arg	Val	Arg	Phe	Leu	Asp	Arg	Tyr	Phe
20														30	

40

Tyr	His	Gln	Glu	Glu	Tyr	Val	Arg	Phe	Asp	Ser	Asp	Val	Gly	Glu	Tyr
35													45		

45

Arg	Ala	Val	Thr	Glu	Leu	Gly	Arg	Pro	Asp	Ala	Glu	Tyr	Trp	Asn	Ser
50											60				

Gln	Lys	Asp	Leu	Leu	Glu	Gln	Lys	Arg	Ala	Ala	Val	Asp	Thr	Tyr	Cys
65											75				80

50

Arg	His	Asn	Tyr	Gly	Val	Gly	Glu	Ser	Phe	Thr	Val	Leu	Arg	Arg	Leu
85											90		95		

55

Gly	Gly	Glu	Asp	Asp	Glu	Ala	Asp	His	His	Val	Ile	Ile	Gln	Ala	Glu
100										105			110		

Phe	Tyr	Leu	Asn	Pro	Asp	Gln	Ser	Gly	Glu	Phe	Met	Phe	Asp	Phe	Asp
115											120		125		

60

Gly	Asp	Glu	Ile	Phe	His	Val	Asp	Met	Ala	Lys	Lys	Glu	Thr	Val	Trp
130											135		140		

Arg	Leu	Glu	Glu	Phe	Gly	Arg	Phe	Ala	Ser	Phe	Glu	Ala	Gln	Gly	Ala
145										150		155		160	

65

Leu	Ala	Asn	Ile	Ala	Val	Asp	Lys	Ala	Asn	Leu	Glu	Ile	Met	Thr	Lys
165										170			175		

Arg	Ser	Asn	Tyr	Thr	Pro	Ile	Thr	Asn
-----	-----	-----	-----	-----	-----	-----	-----	-----



64

Arg Ala Val Thr Glu Leu Gly Arg Pro Asp Ala Glu Tyr Trp Asn Ser  
 50 55 60

5 Gln Lys Asp Leu Leu Glu Gln Lys Arg Ala Ala Val Asp Thr Tyr Cys  
 65 70 75 80

Arg His Asn Tyr Gly Val Gly Glu Ser Phe Thr Val Gln Arg Arg Gly  
 85 90 95

10 Gly Gly Gly Ser Ile Lys Glu Glu His Val Ile Ile Gln Ala Glu Phe  
 100 105 110

Tyr Leu Asn Pro Asp Gln Ser Gly Glu Phe Met Phe Asp Phe Asp Gly  
 115 120 125

15 Asp Glu Ile Phe His Val Asp Met Ala Lys Lys Glu Thr Val Trp Arg  
 130 135 140

20 Leu Glu Glu Phe Gly Arg Phe Ala Ser Phe Glu Ala Gln Gly Ala Leu  
 145 150 155 160

Ala Asn Ile Ala Val Asp Lys Ala Asn Leu Glu Ile Met Thr Lys Arg  
 165 170 175

25 Ser Asn Tyr Thr Pro Ile Thr Asn  
 180

30 <210> CO599

<211> 184

<212> PRT

<213> Homo sapiens

35 Met Gly Asp Thr Arg Pro Arg Phe Leu Glu Gln Val Lys His Glu Cys  
 5 10 15

His Phe Phe Asn Gly Thr Glu Arg Val Arg Phe Leu Asp Arg Tyr Phe  
 20 25 30

40 Tyr His Gln Glu Glu Tyr Val Arg Phe Asp Ser Asp Val Gly Glu Tyr  
 35 40 45

Arg Ala Val Thr Glu Leu Gly Arg Pro Asp Ala Glu Tyr Trp Asn Ser  
 50 55 60

45 Gln Lys Asp Leu Leu Glu Gln Lys Arg Ala Ala Val Asp Thr Tyr Cys  
 65 70 75 80

50 Arg His Asn Tyr Gly Val Gly Glu Ser Phe Thr Val Gln Arg Arg Gly  
 85 90 95

Gly Gly Gly Ile Lys Glu Glu His Val Ile Ile Gln Ala Glu Phe Tyr  
 100 105 110

55 Leu Asn Pro Asp Gln Ser Gly Glu Phe Met Phe Asp Phe Asp Gly Asp  
 115 120 125

Glu Ile Phe His Val Asp Met Ala Lys Lys Glu Thr Val Trp Arg Leu  
 130 135 140

65

Glu Glu Phe Gly Arg Phe Ala Ser Phe Glu Ala Gln Gly Ala Leu Ala  
 145 150 155 160

5 Asn Ile Ala Val Asp Lys Ala Asn Leu Glu Ile Met Thr Lys Arg Ser  
 165 170 175

Asn Tyr Thr Pro Ile Thr Asn  
 180

10

&lt;210&gt; CO594

&lt;211&gt; 187

&lt;212&gt; PRT

15 &lt;213&gt; Homo sapiens

Met Gly Asp Thr Arg Pro Arg Phe Leu Glu Gln Val Lys His Glu Cys  
 5 10 15

20 His Phe Phe Asn Gly Thr Glu Arg Val Arg Phe Leu Asp Arg Tyr Phe  
 20 25 30

Tyr His Gln Glu Glu Tyr Val Arg Phe Asp Ser Asp Val Gly Glu Tyr  
 35 40 45

25 Arg Ala Val Thr Glu Leu Gly Arg Pro Asp Ala Glu Tyr Trp Asn Ser  
 50 55 60

30 Gln Lys Asp Leu Leu Glu Gln Lys Arg Ala Ala Val Asp Thr Tyr Cys  
 65 70 75 80

Arg His Asn Tyr Gly Val Gly Glu Ser Phe Thr Val Gln Arg Arg Val  
 85 90 95

35 Tyr Pro Glu Val Thr Val Ile Lys Glu Glu His Val Ile Ile Gln Ala  
 100 105 110

Glu Phe Tyr Leu Asn Pro Asp Gln Ser Gly Glu Phe Met Phe Asp Phe  
 115 120 125

40 Asp Gly Asp Glu Ile Phe His Val Asp Met Ala Lys Lys Glu Thr Val  
 130 135 140

45 Trp Arg Leu Glu Glu Phe Gly Arg Phe Ala Ser Phe Glu Ala Gln Gly  
 145 150 155 160

Ala Leu Ala Asn Ile Ala Val Asp Lys Ala Asn Leu Glu Ile Met Thr  
 165 170 175

50 Lys Arg Ser Asn Tyr Thr Pro Ile Thr Asn  
 180 185

55 &lt;210&gt; CO592

&lt;211&gt; 188

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

Met Gly Asp Thr Arg Pro Arg Phe Leu Glu Gln Val Lys His Glu Cys

		66		
	5		10	15
	His Phe Phe Asn Gly Thr Glu Arg Val Arg Phe Leu Asp Arg Tyr Phe			
	20 25 30			
5	Tyr His Gln Glu Glu Tyr Val Arg Phe Asp Ser Asp Val Gly Glu Tyr			
	35 40 45			
10	Arg Ala Val Thr Glu Leu Gly Arg Pro Asp Ala Glu Tyr Trp Asn Ser			
	50 55 60			
	Gln Lys Asp Leu Leu Glu Gln Lys Arg Ala Ala Val Asp Thr Tyr Cys			
	65 70 75 80			
15	Arg His Asn Tyr Gly Val Gly Glu Ser Phe Thr Val Gln Arg Arg Phe			
	85 90 95			
	Asp Ala Pro Ser Pro Leu Pro Ile Lys Glu Glu His Val Ile Ile Gln			
	100 105 110			
20	Ala Glu Phe Tyr Leu Asn Pro Asp Gln Ser Gly Glu Phe Met Phe Asp			
	115 120 125			
25	Phe Asp Gly Asp Glu Ile Phe His Val Asp Met Ala Lys Lys Glu Thr			
	130 135 140			
	Val Trp Arg Leu Glu Glu Phe Gly Arg Phe Ala Ser Phe Glu Ala Gln			
	145 150 155 160			
30	Gly Ala Leu Ala Asn Ile Ala Val Asp Lys Ala Asn Leu Glu Ile Met			
	165 170 175			
	Thr Lys Arg Ser Asn Tyr Thr Pro Ile Thr Asn			
	180 185			
35	<210> CO591			
	<211> 187			
	<212> PRT			
40	<213> Homo sapiens			
	Met Gly Asp Thr Arg Pro Arg Phe Leu Glu Gln Val Lys His Glu Cys			
	5 10 15			
45	His Phe Phe Asn Gly Thr Glu Arg Val Arg Phe Leu Asp Arg Tyr Phe			
	20 25 30			
	Tyr His Gln Glu Glu Tyr Val Arg Phe Asp Ser Asp Val Gly Glu Tyr			
	35 40 45			
50	Arg Ala Val Thr Glu Leu Gly Arg Pro Asp Ala Glu Tyr Trp Asn Ser			
	50 55 60			
	Gln Lys Asp Leu Leu Glu Gln Lys Arg Ala Ala Val Asp Thr Tyr Cys			
	65 70 75 80			
	Arg His Asn Tyr Gly Val Gly Glu Ser Phe Thr Val Gln Arg Arg Ser			
	85 90 95			

67

Gly Gly Ser Gly Gly Ser Ile Lys Glu Glu His Val Ile Ile Gln Ala  
 100 105 110

5      Glu Phe Tyr Leu Asn Pro Asp Gln Ser Gly Glu Phe Met Phe Asp Phe  
 115 120 125

Asp Gly Asp Glu Ile Phe His Val Asp Met Ala Lys Lys Glu Thr Val  
 130 135 140

10     Trp Arg Leu Glu Glu Phe Gly Arg Phe Ala Ser Phe Glu Ala Gln Gly  
 145 150 155 160

Ala Leu Ala Asn Ile Ala Val Asp Lys Ala Asn Leu Glu Ile Met Thr  
 165 170 175

15     Lys Arg Ser Asn Tyr Thr Pro Ile Thr Asn  
 180 185

20     <210> CO590  
 <211> 187  
 <212> PRT  
 <213> Homo sapiens

25     Met Gly Asp Thr Arg Pro Arg Phe Leu Glu Gln Val Lys His Glu Cys  
 5 10 15

His Phe Phe Asn Gly Thr Glu Arg Val Arg Phe Leu Asp Arg Tyr Phe  
 20 25 30

30     Tyr His Gln Glu Glu Tyr Val Arg Phe Asp Ser Asp Val Gly Glu Tyr  
 35 40 45

Arg Ala Val Thr Glu Leu Gly Arg Pro Asp Ala Glu Tyr Trp Asn Ser  
 35 50 55 60

Gln Lys Asp. Leu Leu Glu Gln Lys Arg Ala Ala Val Asp Thr Tyr Cys  
 65 70 75 80

40     Arg His Asn Tyr Gly Val Gly Glu Ser Phe Thr Val Gln Arg Arg Thr  
 85 90 95

Ser Gly Gly Gly Ser Ile Lys Glu Glu His Val Ile Ile Gln Ala  
 100 105 110

45     Glu Phe Tyr Leu Asn Pro Asp Gln Ser Gly Glu Phe Met Phe Asp Phe  
 115 120 125

Asp Gly Asp Glu Ile Phe His Val Asp Met Ala Lys Lys Glu Thr Val  
 50 130 135 140

Trp Arg Leu Glu Glu Phe Gly Arg Phe Ala Ser Phe Glu Ala Gln Gly  
 145 150 155 160

55     Ala Leu Ala Asn Ile Ala Val Asp Lys Ala Asn Leu Glu Ile Met Thr  
 165 170 175

Lys Arg Ser Asn Tyr Thr Pro Ile Thr Asn  
 180 185

<210> CO589  
 <211> 190  
 <212> PRT  
 <213> Homo sapiens

5	Met Gly Asp Thr Arg Pro Arg Phe Leu Glu Gln Val Lys His Glu Cys	5	10	15	
10	His Phe Phe Asn Gly Thr Glu Arg Val Arg Phe Leu Asp Arg Tyr Phe	20	25	30	
15	Tyr His Gln Glu Glu Tyr Val Arg Phe Asp Ser Asp Val Gly Glu Tyr	35	40	45	
20	Arg Ala Val Thr Glu Leu Gly Arg Pro Asp Ala Glu Tyr Trp Asn Ser	50	55	60	
25	Gln Lys Asp Leu Leu Glu Gln Lys Arg Ala Ala Val Asp Thr Tyr Cys	65	70	75	80
30	Arg His Asn Tyr Gly Val Gly Glu Ser Phe Thr Val Gln Arg Arg Gly	85	90	95	
35	Ser Pro Gly Gly Gly Pro Gly Ser Ile Lys Glu Glu His Val Ile	100	105	110	
40	Ile Gln Ala Glu Phe Tyr Leu Asn Pro Asp Gln Ser Gly Glu Phe Met	115	120	125	
45	Phe Asp Phe Asp Gly Asp Glu Ile Phe His Val Asp Met Ala Lys Lys	130	135	140	
50	Glu Thr Val Trp Arg Leu Glu Glu Phe Gly Arg Phe Ala Ser Phe Glu	145	150	155	160
55	Ala Gln Gly Ala Leu Ala Asn Ile Ala Val Asp Lys Ala Asn Leu Glu	165	170	175	
60	Ile Met Thr Lys Arg Ser Asn Tyr Thr Pro Ile Thr Asn	180	185		
65	<210> CO588 <211> 190 <212> PRT <213> Homo sapiens				
70	Met Gly Asp Thr Arg Pro Arg Phe Leu Glu Gln Val Lys His Glu Cys	5	10	15	
75	His Phe Phe Asn Gly Thr Glu Arg Val Arg Phe Leu Asp Arg Tyr Phe	20	25	30	
80	Tyr His Gln Glu Glu Tyr Val Arg Phe Asp Ser Asp Val Gly Glu Tyr	35	40	45	
85	Arg Ala Val Thr Glu Leu Gly Arg Pro Asp Ala Glu Tyr Trp Asn Ser				

		69	
	50	55	60
	Gln Lys Asp Leu Leu Glu Gln Lys Arg Ala Ala Val Asp Thr Tyr Cys		
	65	70	75
5	Arg His Asn Tyr Gly Val Gly Ser Phe Thr Val Gln Arg Arg Gly		
	85	90	95
10	Ser Pro Pro Gly Gly Pro Pro Gly Ser Ile Lys Glu Glu His Val Ile		
	100	105	110
	Ile Gln Ala Glu Phe Tyr Leu Asn Pro Asp Gln Ser Gly Glu Phe Met		
	115	120	125
15	Phe Asp Phe Asp Gly Asp Glu Ile Phe His Val Asp Met Ala Lys Lys		
	130	135	140
	Glu Thr Val Trp Arg Leu Glu Glu Phe Gly Arg Phe Ala Ser Phe Glu		
	145	150	155
20	Ala Gln Gly Ala Leu Ala Asn Ile Ala Val Asp Lys Ala Asn Leu Glu		
	165	170	175
25	Ile Met Thr Lys Arg Ser Asn Tyr Thr Pro Ile Thr Asn		
	180	185	
	<210> CO587		
	<211> 194		
30	<212> PRT		
	<213> Homo sapiens		
	Met Gly Asp Thr Arg Pro Arg Phe Leu Glu Gln Val Lys His Glu Cys		
	5	10	15
35	His Phe Phe Asn Gly Thr Glu Arg Val Arg Phe Leu Asp Arg Tyr Phe		
	20	25	30
40	Tyr His Gln Glu Glu Tyr Val Arg Phe Asp Ser Asp Val Gly Glu Tyr		
	35	40	45
	Arg Ala Val Thr Glu Leu Gly Arg Pro Asp Ala Glu Tyr Trp Asn Ser		
	50	55	60
45	Gln Lys Asp Leu Leu Glu Gln Lys Arg Ala Ala Val Asp Thr Tyr Cys		
	65	70	75
	Arg His Asn Tyr Gly Val Gly Ser Phe Thr Val Gln Arg Arg Gly		
	85	90	95
50	Ser Pro Gly Gly Gly Ser Gly Gly Pro Gly Ser Ile Lys Glu		
	100	105	110
55	Glu His Val Ile Ile Gln Ala Glu Phe Tyr Leu Asn Pro Asp Gln Ser		
	115	120	125
	Gly Glu Phe Met Phe Asp Phe Asp Gly Asp Glu Ile Phe His Val Asp		
	130	135	140

70

Met Ala Lys Lys Glu Thr Val Trp Arg Leu Glu Glu Phe Gly Arg Phe			
145	150	155	160
Ala Ser Phe Glu Ala Gln Gly Ala Leu Ala Asn Ile Ala Val Asp Lys			
5	165	170	175
Ala Asn Leu Glu Ile Met Thr Lys Arg Ser Asn Tyr Thr Pro Ile Thr			
180	185	190	

10 Asn

<210> CO586  
 15 <211> 194  
 <212> PRT  
 <213> Homo sapiens

Met Gly Asp Thr Arg Pro Arg Phe Leu Glu Gln Val Lys His Glu Cys			
20	5	10	15
His Phe Phe Asn Gly Thr Glu Arg Val Arg Phe Leu Asp Arg Tyr Phe			
25	20	25	30
Tyr His Gln Glu Glu Tyr Val Arg Phe Asp Ser Asp Val Gly Glu Tyr			
30	35	40	45
Arg Ala Val Thr Glu Leu Gly Arg Pro Asp Ala Glu Tyr Trp Asn Ser			
35	50	55	60
Gln Lys Asp Leu Leu Glu Gln Lys Arg Ala Ala Val Asp Thr Tyr Cys			
40	65	70	75
Arg His Asn Tyr Gly Val Gly Glu Ser Phe Thr Val Gln Arg Arg Thr			
45	85	90	95
Ser Gly Gly Gly Ser Gly Gly Gly Ser Ser Ser Ile Lys Glu			
50	100	105	110
Glu His Val Ile Ile Gln Ala Glu Phe Tyr Leu Asn Pro Asp Gln Ser			
55	115	120	125
Gly Glu Phe Met Phe Asp Phe Asp Gly Asp Glu Ile Phe His Val Asp			
60	130	135	140
Met Ala Lys Lys Glu Thr Val Trp Arg Leu Glu Glu Phe Gly Arg Phe			
65	145	150	155
Ala Ser Phe Glu Ala Gln Gly Ala Leu Ala Asn Ile Ala Val Asp Lys			
70	165	170	175
Ala Asn Leu Glu Ile Met Thr Lys Arg Ser Asn Tyr Thr Pro Ile Thr			
75	180	185	190

55 Asn

&lt;210&gt; CO598

<211> 639  
 <212> DNA  
 <213> Homo sapiens

5 atgggggaca ccggtcgcag cttcaccctg gcctccagcg agaccggcgt gggcgctagc 60  
 ggagggggcg gaagcggcg aggaaaaaac acccgaccac gtttcttggaa gcaggtaaa 120  
 catgagtgtc atttcttcaa cggacggag cgggtgcgggt tcctggacag atacttctat 180  
 caccaagagg agtacgtgcg cttcgacagc gacgtggggg agtaccgggc ggtgacggag 240  
 ctggggcggc ctgatgccga gtactggAAC agccagaagg acctcctggaa gcagaagcgg 300  
 10 gcccgggtgg acacctaactg cagacacaac tacgggttg gtgagagctt cacagtgtc 360  
 cggcactcg gaggtgaaga tgacgaggca gatcacatg tgatcatcca ggccgagttc 420  
 tatctgaatc ctgaccaatc aggcgagttt atgtttgact ttgatggta tgagattttc 480  
 catgtggata tggcaaagaa ggagacggtc tggcggcttg aagaatttgg acgatttgcc 540  
 15 agcttgagg ctcaagggtgc attggccaaac atagctgtgg acaaagccaa cctgaaaatc 600  
 atgacaaagc gctccaacta tactccgatc accaattaa 639

<210> CO597  
 <211> 639  
 <212> DNA  
 <213> Homo sapiens

20 atgggggaca ccggtcgcag cttcaccctg gcctccagcg agaccggcgt gggcgctagc 60  
 ggagggggcg gaagcggcg aggaaaaaac acccgaccac gtttcttggaa gcaggtaaa 120  
 catgagtgtc atttcttcaa cggacggag cgggtgcgggt tcctggacag atacttctat 180  
 25 caccaagagg agtacgtgcg cttcgacagc gacgtggggg agtaccgggc ggtgacggag 240  
 ctggggcggc ctgatgccga gtactggAAC agccagaagg acctcctggaa gcagaagcgg 300  
 gcccgggtgg acacctaactg cagacacaac tacgggttg gtgagagctt cacagtgcag 360  
 cggcaggaggt gttggaaaggcg cggaaatcaaa gaagaacatg tgatcatcca ggccgagttc 420  
 tatctgaatc ctgaccaatc aggcgagttt atgtttgact ttgatggta tgagattttc 480  
 30 catgtggata tggcaaagaa ggagacggtc tggcggcttg aagaatttgg acgatttgcc 540  
 agcttgagg ctcaagggtgc attggccaaac atagctgtgg acaaagccaa cctgaaaatc 600  
 atgacaaagc gctccaacta tactccgatc accaattaa 639

<210> CO596  
 35 <211> 636  
 <212> DNA  
 <213> Homo sapiens

40 atgggggaca ccggtcgcag cttcaccctg gcctccagcg agaccggcgt gggcgctagc 60  
 ggagggggcg gaagcggcg aggaaaaaac acccgaccac gtttcttggaa gcaggtaaa 120  
 catgagtgtc atttcttcaa cggacggag cgggtgcgggt tcctggacag atacttctat 180  
 caccaagagg agtacgtgcg cttcgacagc gacgtggggg agtaccgggc ggtgacggag 240  
 ctggggcggc ctgatgccga gtactggAAC agccagaagg acctcctggaa gcagaagcgg 300  
 45 gcccgggtgg acacctaactg cagacacaac tacgggttg gtgagagctt cacagtgcag 360  
 cggcaggaggt gttggaggcg catcaaagaa gaacatgtgatc tcatccaggc cgagttctat 420  
 ctgaatctg accaatcagg cgagttatg tttgactttg atggatgtgatc gattttccat 480  
 gtggatatgg caaagaagga gacggctgg cggcttggaa aatggacg atttggccagc 540  
 tttgaggctc aaggtgcatt ggcaacata gctgtggaca aagccaaacct ggaatcatg 600  
 50 acaaagcgct ccaactatac tccgatcacc aattaa 636

<210> CO595  
 <211> 633  
 <212> DNA  
 <213> Homo sapiens

55 atgggggaca ccggtcgcag cttcaccctg gcctccagcg agaccggcgt gggcgctagc 60  
 ggagggggcg gaagcggcg aggaaaaaac acccgaccac gtttcttggaa gcaggtaaa 120  
 catgagtgtc atttcttcaa cggacggag cgggtgcgggt tcctggacag atacttctat 180  
 caccaagagg agtacgtgcg cttcgacagc gacgtggggg agtaccgggc ggtgacggag 240

72

ctggggcggc ctgatgccga gtactggAAC agccAGAAAG acctcctggA gcagaAGCGG 300  
 ggcgcggTgg acacctaCTg cagacaCAAC tacggggTTg gtgagAGCTt cacagtgcag 360  
 cggcgaggAG gtggaggGCAT caaaAGAAAG catgtatca tccaggCCGA gtttatCTG 420  
 5 aatccTGacc aatcaggCga gtttatGTT gactttGATg gtgatgAGAT ttccatGTG 480  
 gatatGGcaa agaaggAGAC ggtctggCGG cttGAAGAAAT ttggacGATT tgccAGCTT 540  
 gaggctcaag gtgcattGGC caacataGCT gtggacaAAAG ccaacctggA aatcatgaca 600  
 aagcgtcca actataCTC GATCACCAAT taa 633

10 <210> CO593  
 <211> 642  
 <212> DNA  
 <213> Homo sapiens

atgggggaca ccggTCgcAG cttcacCCtG gcctccAGCG agaccGGCGT gggcgCTAGC 60  
 15 ggagggggcg gaagcggCGG aggGGGGGAC acccgaccAC gtttcttggA gcaggTTAAA 120  
 catgagtgtc atttcttcaa cggacggAG cgggtgcggT tcctggacAG atacttctat 180  
 caccaagagg agtacgtgcG cttcgacAGC gacgtggggG agtaccGGGC ggtgacGGAG 240  
 ctggggcggc ctgatGCCGA gtactggAAC agccAGAAAG acctcctggA gcagaAGCGG 300  
 20 gcccgcggTgg acacctaCTg cagacaCAAC tacggggTTg gtgagAGCTt cacagtgcag 360  
 cggcgagtct accctgaggt aactgtcAtC aaagaAGAAAC atgtgatCAT ccaggCCGAG 420  
 ttctatctGA atcctgacca atcaggcGAG tttatGTTG actttGATGG tgatgAGATT 480  
 ttccatgtgg atatGGCAAAG gaaggAGACG gtctggCGGC ttGAAGAAATT tggacGATT 540  
 gccagcttG aggctcaagg tgcattGGCC aacataGCTG tggacaAAAG ccaacctggAA 600  
 atcatgacAA agcgctccAA ctataCTCG atcaccAAATT aa 642

25 <210> CO585  
 <211> 645  
 <212> DNA  
 <213> Homo sapiens

atgggggaca ccggTCgcAG cttcacCCtG gcctccAGCG agaccGGCGT gggcgCTAGC 60  
 30 ggagggggcg gaagcggCGG aggGGGGGAC acccgaccAC gtttcttggA gcaggTTAAA 120  
 catgagtgtc atttcttcaa cggacggAG cgggtgcggT tcctggacAG atacttctat 180  
 caccaagagg agtacgtgcG cttcgacAGC gacgtggggG agtaccGGGC ggtgacGGAG 240  
 35 ctggggcggc ctgatGCCGA gtactggAAC agccAGAAAG acctcctggA gcagaAGCGG 300  
 gcccgcggTgg acacctaCTg cagacaCAAC tacggggTTg gtgagAGCTt cacagtgcag 360  
 cggcgattcg acgcacCTAG cccactCCCAtCAAAGAAAG aacatgtGAT catccaggCC 420  
 gagttctatC tgaatCCTGA ccaatcAGGC gagtttatGT ttGACTTTGA tggtgatGAG 480  
 40 attttccatG tggatATGGC aaagaAGGAG acggTctGGC ggcttGAAGA atttggacGA 540  
 tttgcCAGCT ttGAGGCTA aggtgcattG gccaacatAG ctgtggacAAAG ccaacacCTG 600  
 gaaatcatGA caaAGCGCTC caactataCT ccgatCACCA ATTAA 645

<210> CO584  
 <211> 642  
 45 <212> DNA  
 <213> Homo sapiens

atgggggaca ccggTCgcAG cttcacCCtG gcctccAGCG agaccGGCGT gggcgCTAGC 60  
 50 ggagggggcg gaagcggCGG aggGGGGGAC acccgaccAC gtttcttggA gcaggTTAAA 120  
 catgagtgtc atttcttcaa cggacggAG cgggtgcggT tcctggacAG atacttctat 180  
 caccaagagg agtacgtgcG cttcgacAGC gacgtggggG agtaccGGGC ggtgacGGAG 240  
 ctggggcggc ctgatGCCGA gtactggAAC agccAGAAAG acctcctggA gcagaAGCGG 300  
 gcccgcggTgg acacctaCTg cagacaCAAC tacggggTTg gtgagAGCTt cacagtgcag 360  
 55 cggcgaaGtG qcggtagtgg cggtAGTATC aaagaAGAAAC atgtgatCAT ccaggCCGAG 420  
 ttctatctGA atcctgacca atcaggcGAG tttatGTTG actttGATGG tgatgAGATT 480  
 ttccatgtgg atatGGCAAAG gaaggAGACG gtctggCGGC ttGAAGAAATT tggacGATT 540  
 gccagcttG aggctcaagg tgcattGGCC aacataGCTG tggacaAAAG ccaacctggAA 600  
 atcatgacAA agcgctccAA ctataCTCG atcaccAAATT aa 642

5       <210> CO583  
 <211> 642  
 <212> DNA  
 <213> Homo sapiens

```

atgggggaca ccggtcgcag cttcaccctg gcctccagcg agaccggcgt gggcgctagc 60
ggagggggcg gaagcggcgg agggggggac acccgaccac gtttcttggaa gcaggttaaa 120
catgagtgtc atttcttcaa cgggacggag cgggtgcgggt tcctggacag atacttctat 180
10      caccaagagg agtacgtgcg cttcgacagc gacgtggggg agtaccgggc ggtgacggag 240
ctggggcggc ctgatgccga gtactggAAC agccagaagg acctcctggaa gcagaagcgg 300
gccgcgggtgg acacctaCTG cagacacaac tacggggTTG gtgagagCTT cacagtgcag 360
cgcgcaacta gtggTggcgg tggcagcatc aaagaagaac atgtgatcat ccagGCCgag 420
15      ttcttatctga atcctgacca atcaggcggag ttatgtttg actttgatgg tgatgagatt 480
ttccatgtgg atatggcaaa gaaggagacg gtctggcggc ttgaagaatt tggacgattt 540
gccagctttg aggctcaagg tgcattggcc aacatagctg tggacaaagc caacctggaa 600
atcatgacaa agcgctccaa ctatactccg atcaccaatt aa 642
  
```

20     <210> CO582  
 <211> 651  
 <212> DNA  
 <213> Homo sapiens

```

atgggggaca ccggtcgcag cttcaccctg gcctccagcg agaccggcgt gggcgctagc 60
ggagggggcg gaagcggcgg agggggggac acccgaccac gtttcttggaa gcaggttaaa 120
catgagtgtc atttcttcaa cgggacggag cgggtgcgggt tcctggacag atacttctat 180
caccaagagg agtacgtgcg cttcgacagc gacgtggggg agtaccgggc ggtgacggag 240
ctggggcggc ctgatgccga gtactggAAC agccagaagg acctcctggaa gcagaagcgg 300
25      gccgcgggtgg acacctaCTG cagacacaac tacggggTTG gtgagagCTT cacagtgcag 360
cgcgaggct ctcctggagg tggaggTCCT ggatctatca aagaagaaca tgtgatcatc 420
caggccgagt tctatctgaa tcctgaccaaa tcaggcgagt ttatgtttga ctggatgg 480
30      gatgagattt tccatgtggaa tatggcaaa aaggagacgg tctggcggct tgaagaattt 540
ggacgatttg ccagctttga ggctcaagggt gcattggcca acatagctgt ggacaaagcc 600
aacctggaaa tcatgacaaa gcgctccaa tatactccgaa tcaccaattt a 651
  
```

35     <210> CO581  
 <211> 651  
 <212> DNA  
 <213> Homo sapiens

```

atgggggaca ccggtcgcag cttcaccctg gcctccagcg agaccggcgt gggcgctagc 60
ggagggggcg gaagcggcgg agggggggac acccgaccac gtttcttggaa gcaggttaaa 120
catgagtgtc atttcttcaa cgggacggag cgggtgcgggt tcctggacag atacttctat 180
45      caccaagagg agtacgtgcg cttcgacagc gacgtggggg agtaccgggc ggtgacggag 240
ctggggcggc ctgatgccga gtactggAAC agccagaagg acctcctggaa gcagaagcgg 300
gccgcgggtgg acacctaCTG cagacacaac tacggggTTG gtgagagCTT cacagtgcag 360
cgcgaggct ctcctcctgg tggaccaccc ggatctatca aagaagaaca tgtgatcatc 420
caggccgagt tctatctgaa tcctgaccaaa tcaggcgagt ttatgtttga ctggatgg 480
50      gatgagattt tccatgtggaa tatggcaaa aaggagacgg tctggcggct tgaagaattt 540
ggacgatttg ccagctttga ggctcaagggt gcattggcca acatagctgt ggacaaagcc 600
aacctggaaa tcatgacaaa gcgctccaa tatactccgaa tcaccaattt a 651
  
```

55     <210> CO580  
 <211> 663  
 <212> DNA  
 <213> Homo sapiens

74

atgggggaca ccggtcgcag cttcacccctg gcctccagcg agaccggcgt gggcgctagc 60  
 ggagggggcg gaagcggcgg agggggggac acccgaccac gtttcttggaa gcaggtaaa 120  
 catgagtgtc atttcttcaa cgggacggag cgggtgcggt tcctggacag atacttctat 180  
 5 cccaagagg agtacgtgcg cttcgacagc gacgtgggg agtaccgggc ggtgacggag 240  
 ctggggcggc ctgatgccga gtactgaaac agccagaagg acctcctgga gcagaagcgg 300  
 gccgcggtgg acacctaactg cagacacaac tacggggttg gtgagagctt cacagtgcag 360  
 cggcggggga gtccaggcgg tggcgggagc ggcgggtggc ctgggagttt caaaagaagaa 420  
 catgtgatca tccaggccga gttctatctg aatcctgacc aatcaggcga gtttatgttt 480  
 10 gacttgatg gtgatgagat ttccatgtg gatatggcaa agaaggagac ggtctggcgg 540  
 cttgaagaat ttggacgatt tgccagcttt gaggctcaag gtgcattggc caacatagct 600  
 gtggacaaaag ccaacctgga aatcatgaca aagcgctcca actatactcc gatcaccaat 660  
 taa 663

15 <210> C0567  
 <211> 663  
 <212> DNA  
 <213> Homo sapiens

20 atgggggaca ccggtcgcag cttcacccctg gcctccagcg agaccggcgt gggcgctagc 60  
 ggagggggcg gaagcggcgg agggggggac acccgaccac gtttcttggaa gcaggtaaa 120  
 catgagtgtc atttcttcaa cgggacggag cgggtgcggt tcctggacag atacttctat 180  
 cccaagagg agtacgtgcg cttcgacagc gacgtgggg agtaccgggc ggtgacggag 240  
 25 ctggggcggc ctgatgccga gtactgaaac agccagaagg acctcctgga gcagaagcgg 300  
 gccgcggtgg acacctaactg cagacacaac tacggggttg gtgagagctt cacagtgcag 360  
 cggcgaacta gtggtggcgg tggcagcggc ggtgggtgtt cctcgagttt caaaagaagaa 420  
 catgtgatca tccaggccga gttctatctg aatcctgacc aatcaggcga gtttatgttt 480  
 gacttgatg gtgatgagat ttccatgtg gatatggcaa agaaggagac ggtctggcgg 540  
 30 cttgaagaat ttggacgatt tgccagcttt gaggctcaag gtgcattggc caacatagct 600  
 gtggacaaaag ccaacctgga aatcatgaca aagcgctcca actatactcc gatcaccaat 660  
 taa 663

35 <210> C0598  
 <211> 213  
 <212> PRT  
 <213> Homo sapiens

Met Gly Asp Thr Gly Arg Ser Phe Thr Leu Ala Ser Ser Glu Thr Gly  
 40 5 10 15

Val Gly Ala Ser Gly Gly Ser Gly Gly Gly Asp Thr Arg  
 20 25 30

45 Pro Arg Phe Leu Glu Gln Val Lys His Glu Cys His Phe Phe Asn Gly  
 35 40 45

Thr Glu Arg Val Arg Phe Leu Asp Arg Tyr Phe Tyr His Gln Glu Glu  
 50 55 60

50 Tyr Val Arg Phe Asp Ser Asp Val Gly Glu Tyr Arg Ala Val Thr Glu  
 65 70 75 80

55 Leu Gly Arg Pro Asp Ala Glu Tyr Trp Asn Ser Gln Lys Asp Leu Leu  
 85 90 95

Glu Gln Lys Arg Ala Ala Val Asp Thr Tyr Cys Arg His Asn Tyr Gly  
 100 105 110

75

	Val	Gly	Glu	Ser	Phe	Thr	Val	Leu	Arg	Arg	Leu	Gly	Gly	Glu	Asp	Asp
	115						120					125				
5	Glu	Ala	Asp	His	His	Val	Ile	Ile	Gln	Ala	Glu	Phe	Tyr	Leu	Asn	Pro
	130					135					140					
	Asp	Gln	Ser	Gly	Glu	Phe	Met	Phe	Asp	Phe	Asp	Gly	Asp	Glu	Ile	Phe
	145					150			155			160				
10	His	Val	Asp	Met	Ala	Lys	Lys	Glu	Thr	Val	Trp	Arg	Leu	Glu	Glu	Phe
						165			170			175				
	Gly	Arg	Phe	Ala	Ser	Phe	Glu	Ala	Gln	Gly	Ala	Leu	Ala	Asn	Ile	Ala
						180			185			190				
15	Val	Asp	Lys	Ala	Asn	Leu	Glu	Ile	Met	Thr	Lys	Arg	Ser	Asn	Tyr	Thr
						195			200			205				
20	Pro	Ile	Thr	Asn												
		210														
	<210> CO597															
	<211> 213															
25	<212> PRT															
	<213> Homo sapiens															
	Met	Gly	Asp	Thr	Gly	Arg	Ser	Phe	Thr	Leu	Ala	Ser	Ser	Glu	Thr	Gly
						5				10				15		
30	Val	Gly	Ala	Ser	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Asp	Thr	Arg	
						20			25				30			
35	Pro	Arg	Phe	Leu	Glu	Gln	Val	Lys	His	Glu	Cys	His	Phe	Phe	Asn	Gly
						35			40			45				
	Thr	Glu	Arg	Val	Arg	Phe	Leu	Asp	Arg	Tyr	Phe	Tyr	His	Gln	Glu	Glu
						50			55			60				
40	Tyr	Val	Arg	Phe	Asp	Ser	Asp	Val	Gly	Glu	Tyr	Arg	Ala	Val	Thr	Glu
						65			70			75			80	
	Leu	Gly	Arg	Pro	Asp	Ala	Glu	Tyr	Trp	Asn	Ser	Gln	Lys	Asp	Leu	Leu
						85			90			95				
45	Glu	Gln	Lys	Arg	Ala	Ala	Val	Asp	Thr	Tyr	Cys	Arg	His	Asn	Tyr	Gly
						100			105			110				
50	Val	Gly	Glu	Ser	Phe	Thr	Val	Gln	Arg	Arg	Gly	Gly	Ser	Gly	Gly	
						115			120			125				
	Ile	Lys	Glu	Glu	His	Val	Ile	Ile	Gln	Ala	Glu	Phe	Tyr	Leu	Asn	Pro
						130			135			140				
55	Asp	Gln	Ser	Gly	Glu	Phe	Met	Phe	Asp	Phe	Asp	Gly	Asp	Glu	Ile	Phe
						145			150			155			160	
	His	Val	Asp	Met	Ala	Lys	Lys	Glu	Thr	Val	Trp	Arg	Leu	Glu	Glu	Phe
						165			170			175				

Gly Arg Phe Ala Ser Phe Glu Ala Gln Gly Ala Leu Ala Asn Ile Ala  
180 185 190

5 Val Asp Lys Ala Asn Leu Glu Ile Met Thr Lys Arg Ser Asn Tyr Thr  
195 200 205

Pro Ile Thr Asn  
210

10

<210> CO596

<211> 212

<212> PRT

15 <213> Homo sapiens

Met Gly Asp Thr Gly Arg Ser Phe Thr Leu Ala Ser Ser Glu Thr Gly  
5 10 15

20 Val Gly Ala Ser Gly Gly Ser Gly Gly Gly Asp Thr Arg  
20 25 30

Pro Arg Phe Leu Glu Gln Val Lys His Glu Cys His Phe Phe Asn Gly  
35 40 45

25 Thr Glu Arg Val Arg Phe Leu Asp Arg Tyr Phe Tyr His Gln Glu Glu  
50 55 60

30 Tyr Val Arg Phe Asp Ser Asp Val Gly Glu Tyr Arg Ala Val Thr Glu  
65 70 75 80

Leu Gly Arg Pro Asp Ala Glu Tyr Trp Asn Ser Gln Lys Asp Leu Leu  
85 90 95

35 Glu Gln Lys Arg Ala Ala Val Asp Thr Tyr Cys Arg His Asn Tyr Gly  
100 105 110

Val Gly Glu Ser Phe Thr Val Gln Arg Arg Gly Gly Ser Ile  
115 120 125

40 Lys Glu Glu His Val Ile Ile Gln Ala Glu Phe Tyr Leu Asn Pro Asp  
130 135 140

45 Gln Ser Gly Glu Phe Met Phe Asp Phe Asp Gly Asp Glu Ile Phe His  
145 150 155 160

Val Asp Met Ala Lys Lys Glu Thr Val Trp Arg Leu Glu Glu Phe Gly  
165 170 175

50 Arg Phe Ala Ser Phe Glu Ala Gln Gly Ala Leu Ala Asn Ile Ala Val  
180 185 190

Asp Lys Ala Asn Leu Glu Ile Met Thr Lys Arg Ser Asn Tyr Thr Pro  
195 200 205

55 Ile Thr Asn  
210

77

&lt;210&gt; CO595

&lt;211&gt; 211

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

5

Met	Gly	Asp	Thr	Gly	Arg	Ser	Phe	Thr	Leu	Ala	Ser	Ser	Glu	Thr	Gly
							5							10	
															15

10

Val	Gly	Ala	Ser	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Asp	Thr	Arg
							20					30	

Pro	Arg	Phe	Leu	Glu	Gln	Val	Lys	His	Glu	Cys	His	Phe	Phe	Asn	Gly
							35					40		45	

15

Thr	Glu	Arg	Val	Arg	Phe	Leu	Asp	Arg	Tyr	Phe	Tyr	His	Gln	Glu	Glu
							50					55		60	

Tyr	Val	Arg	Phe	Asp	Ser	Asp	Val	Gly	Glu	Tyr	Arg	Ala	Val	Thr	Glu
							65					70		75	
															80

20

Leu	Gly	Arg	Pro	Asp	Ala	Glu	Tyr	Trp	Asn	Ser	Gln	Lys	Asp	Leu	Leu
							85					90		95	

25

Glu	Gln	Lys	Arg	Ala	Ala	Val	Asp	Thr	Tyr	Cys	Arg	His	Asn	Tyr	Gly
							100					105		110	

Val	Gly	Glu	Ser	Phe	Thr	Val	Gln	Arg	Arg	Gly	Gly	Gly	Ile	Lys	
							115					120		125	

30

Glu	Glu	His	Val	Ile	Ile	Gln	Ala	Glu	Phe	Tyr	Leu	Asn	Pro	Asp	Gln
							130					135		140	

Ser	Gly	Glu	Phe	Met	Phe	Asp	Phe	Asp	Gly	Asp	Glu	Ile	Phe	His	Val
							145					150		155	
															160

35

Asp	Met	Ala	Lys	Lys	Glu	Thr	Val	Trp	Arg	Leu	Glu	Phe	Gly	Arg	
							165					170		175	

40

Phe	Ala	Ser	Phe	Glu	Ala	Gln	Gly	Ala	Leu	Ala	Asn	Ile	Ala	Val	Asp
							180					185		190	

Lys	Ala	Asn	Leu	Glu	Ile	Met	Thr	Lys	Arg	Ser	Asn	Tyr	Thr	Pro	Ile
							195					200		205	

45

Thr	Asn
	210

50

&lt;210&gt; CO593

&lt;211&gt; 214

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

55

Met	Gly	Asp	Thr	Gly	Arg	Ser	Phe	Thr	Leu	Ala	Ser	Ser	Glu	Thr	Gly
							5					10		15	

Val	Gly	Ala	Ser	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Asp	Thr	Arg	
							20				25		30	

78

Pro Arg Phe Leu Glu Gln Val Lys His Glu Cys His Phe Phe Asn Gly  
 35 40 45

5 Thr Glu Arg Val Arg Phe Leu Asp Arg Tyr Phe Tyr His Gln Glu Glu  
 50 55 60

Tyr Val Arg Phe Asp Ser Asp Val Gly Glu Tyr Arg Ala Val Thr Glu  
 65 70 75 80

10 Leu Gly Arg Pro Asp Ala Glu Tyr Trp Asn Ser Gln Lys Asp Leu Leu  
 85 90 95

Glu Gln Lys Arg Ala Ala Val Asp Thr Tyr Cys Arg His Asn Tyr Gly  
 100 105 110

15 Val Gly Glu Ser Phe Thr Val Gln Arg Arg Val Tyr Pro Glu Val Thr  
 115 120 125

20 Val Ile Lys Glu Glu His Val Ile Ile Gln Ala Glu Phe Tyr Leu Asn  
 130 135 140

Pro Asp Gln Ser Gly Glu Phe Met Phe Asp Phe Asp Gly Asp Glu Ile  
 145 150 155 160

25 Phe His Val Asp Met Ala Lys Lys Glu Thr Val Trp Arg Leu Glu Glu  
 165 170 175

Phe Gly Arg Phe Ala Ser Phe Glu Ala Gln Gly Ala Leu Ala Asn Ile  
 180 185 190

30 Ala Val Asp Lys Ala Asn Leu Glu Ile Met Thr Lys Arg Ser Asn Tyr  
 195 200 205

Thr Pro Ile Thr Asn  
 35 210

<210> CO585

<211> 215

40 <212> PRT

<213> Homo sapiens

Met Gly Asp Thr Gly Arg Ser Phe Thr Leu Ala Ser Ser Glu Thr Gly  
 5 10 15

45 Val Gly Ala Ser Gly Gly Ser Gly Gly Gly Asp Thr Arg  
 20 25 30

50 Pro Arg Phe Leu Glu Gln Val Lys His Glu Cys His Phe Phe Asn Gly  
 35 40 45

Thr Glu Arg Val Arg Phe Leu Asp Arg Tyr Phe Tyr His Gln Glu Glu  
 50 55 60

55 Tyr Val Arg Phe Asp Ser Asp Val Gly Glu Tyr Arg Ala Val Thr Glu  
 65 70 75 80

Leu Gly Arg Pro Asp Ala Glu Tyr Trp Asn Ser Gln Lys Asp Leu Leu  
 85 90 95

79

Glu Gln Lys Arg Ala Ala Val Asp Thr Tyr Cys Arg His Asn Tyr Gly  
100 105 110

5 Val Gly Glu Ser Phe Thr Val Gln Arg Arg Phe Asp Ala Pro Ser Pro  
115 120 125

Leu Pro Ile Lys Glu Glu His Val Ile Ile Gln Ala Glu Phe Tyr Leu  
130 135 140

10 Asn Pro Asp Gln Ser Gly Glu Phe Met Phe Asp Phe Asp Gly Asp Glu  
145 150 155 160

Ile Phe His Val Asp Met Ala Lys Lys Glu Thr Val Trp Arg Leu Glu  
15 165 170 175

Glu Phe Gly Arg Phe Ala Ser Phe Glu Ala Gln Gly Ala Leu Ala Asn  
180 185 190

20 Ile Ala Val Asp Lys Ala Asn Leu Glu Ile Met Thr Lys Arg Ser Asn  
195 200 205

Tyr Thr Pro Ile Thr Asn  
210

25

<210> C0584  
<211> 214  
<212> PRT  
30 <213> Homo sapiens

Met Gly Asp Thr Gly Arg Ser Phe Thr Leu Ala Ser Ser Glu Thr Gly  
5 10 15

35 Val Gly Ala Ser Gly Gly Ser Gly Gly Gly Asp Thr Arg  
20 25 30

Pro Arg Phe Leu Glu Gln Val Lys His Glu Cys His Phe Phe Asn Gly  
35 40 45

40 Thr Glu Arg Val Arg Phe Leu Asp Arg Tyr Phe Tyr His Gln Glu Glu  
50 55 60

Tyr Val Arg Phe Asp Ser Asp Val Gly Glu Tyr Arg Ala Val Thr Glu  
45 65 70 75 80

Leu Gly Arg Pro Asp Ala Glu Tyr Trp Asn Ser Gln Lys Asp Leu Leu  
85 90 95

50 Glu Gln Lys Arg Ala Ala Val Asp Thr Tyr Cys Arg His Asn Tyr Gly  
100 105 110

Val Gly Glu Ser Phe Thr Val Gln Arg Arg Ser Gly Gly Ser Gly Gly  
115 120 125

55 Ser Ile Lys Glu Glu His Val Ile Ile Gln Ala Glu Phe Tyr Leu Asn  
130 135 140

Pro Asp Gln Ser Gly Glu Phe Met Phe Asp Phe Asp Gly Asp Glu Ile

		80		
	145	150	155	160
	Phe His Val Asp Met Ala Lys Lys Glu Thr Val Trp Arg Leu Glu Glu			
	165	170	175	
5	Phe Gly Arg Phe Ala Ser Phe Glu Ala Gln Gly Ala Leu Ala Asn Ile			
	180	185	190	
	Ala Val Asp Lys Ala Asn Leu Glu Ile Met Thr Lys Arg Ser Asn Tyr			
10	195	200	205	
	Thr Pro Ile Thr Asn			
	210			
15	<210> CO583			
	<211> 214			
	<212> PRT			
	<213> Homo sapiens			
20	Met Gly Asp Thr Gly Arg Ser Phe Thr Leu Ala Ser Ser Glu Thr Gly			
	5	10	15	
	Val Gly Ala Ser Gly Gly Ser Gly Gly Gly Asp Thr Arg			
25	20	25	30	
	Pro Arg Phe Leu Glu Gln Val Lys His Glu Cys His Phe Phe Asn Gly			
	35	40	45	
30	Thr Glu Arg Val Arg Phe Leu Asp Arg Tyr Phe Tyr His Gln Glu Glu			
	50	55	60	
	Tyr Val Arg Phe Asp Ser Asp Val Gly Glu Tyr Arg Ala Val Thr Glu			
	65	70	75	80
35	Leu Gly Arg Pro Asp Ala Glu Tyr Trp Asn Ser Gln Lys Asp Leu Leu			
	85	90	95	
	Glu Gln Lys Arg Ala Ala Val Asp Thr Tyr Cys Arg His Asn Tyr Gly			
40	100	105	110	
	Val Gly Glu Ser Phe Thr Val Gln Arg Arg Thr Ser Gly Gly Gly			
	115	120	125	
45	Ser Ile Lys Glu Glu His Val Ile Ile Gln Ala Glu Phe Tyr Leu Asn			
	130	135	140	
	Pro Asp Gln Ser Gly Glu Phe Met Phe Asp Phe Asp Gly Asp Glu Ile			
	145	150	155	160
50	Phe His Val Asp Met Ala Lys Lys Glu Thr Val Trp Arg Leu Glu Glu			
	165	170	175	
	Phe Gly Arg Phe Ala Ser Phe Glu Ala Gln Gly Ala Leu Ala Asn Ile			
55	180	185	190	
	Ala Val Asp Lys Ala Asn Leu Glu Ile Met Thr Lys Arg Ser Asn Tyr			
	195	200	205	

81

Thr Pro Ile Thr Asn  
210

<210> CO581  
<211> 217  
<212> PRT  
<213> *Homo sapiens*

Met Gly Asp Thr Gly Arg Ser Phe Thr Leu Ala Ser Ser Glu Thr Gly  
5 10 15

82

Val Gly Ala Ser Gly Gly Gly Ser Gly Gly Gly Asp Thr Arg  
                   20                  25                  30

5 Pro Arg Phe Leu Glu Gln Val Lys His Glu Cys His Phe Phe Asn Gly  
        35                        40                  45

Thr Glu Arg Val Arg Phe Leu Asp Arg Tyr Phe Tyr His Gln Glu Glu  
        50                        55                  60

10 Tyr Val Arg Phe Asp Ser Asp Val Gly Glu Tyr Arg Ala Val Thr Glu  
       65                        70                  75                  80

Leu Gly Arg Pro Asp Ala Glu Tyr Trp Asn Ser Gln Lys Asp Leu Leu  
 15                                85                  90                  95

Glu Gln Lys Arg Ala Ala Val Asp Thr Tyr Cys Arg His Asn Tyr Gly  
       100                        105                  110

20 Val Gly Glu Ser Phe Thr Val Gln Arg Arg Gly Ser Pro Pro Gly Gly  
       115                        120                  125

Pro Pro Gly Ser Ile Lys Glu Glu His Val Ile Ile Gln Ala Glu Phe  
       130                        135                  140

25 Tyr Leu Asn Pro Asp Gln Ser Gly Glu Phe Met Phe Asp Phe Asp Gly  
       145                        150                  155                  160

Asp Glu Ile Phe His Val Asp Met Ala Lys Lys Glu Thr Val Trp Arg  
 30                                165                  170                  175

Leu Glu Glu Phe Gly Arg Phe Ala Ser Phe Glu Ala Gln Gly Ala Leu  
       180                        185                  190

35 Ala Asn Ile Ala Val Asp Lys Ala Asn Leu Glu Ile Met Thr Lys Arg  
       195                        200                  205

Ser Asn Tyr Thr Pro Ile Thr Asn  
       210                        215

40 <210> CO580  
 <211> 221  
 <212> PRT  
 45 <213> Homo sapiens

Met Gly Asp Thr Gly Arg Ser Phe Thr Leu Ala Ser Ser Glu Thr Gly  
       5                          10                  15

50 Val Gly Ala Ser Gly Gly Gly Ser Gly Gly Gly Asp Thr Arg  
       20                        25                  30

Pro Arg Phe Leu Glu Gln Val Lys His Glu Cys His Phe Phe Asn Gly  
       35                        40                  45

55 Thr Glu Arg Val Arg Phe Leu Asp Arg Tyr Phe Tyr His Gln Glu Glu  
       50                        55                  60

Tyr Val Arg Phe Asp Ser Asp Val Gly Glu Tyr Arg Ala Val Thr Glu

		83		
	65	70	75	80
	Leu Gly Arg Pro Asp Ala Glu Tyr Trp Asn Ser Gln Lys Asp Leu Leu			
	85	90	95	
5	Glu Gln Lys Arg Ala Ala Val Asp Thr Tyr Cys Arg His Asn Tyr Gly			
	100	105	110	
10	Val Gly Glu Ser Phe Thr Val Gln Arg Arg Gly Ser Pro Gly Gly Gly			
	115	120	125	
	Gly Ser Gly Gly Pro Gly Ser Ile Lys Glu Glu His Val Ile Ile			
	130	135	140	
15	Gln Ala Glu Phe Tyr Leu Asn Pro Asp Gln Ser Gly Glu Phe Met Phe			
	145	150	155	160
	Asp Phe Asp Gly Asp Glu Ile Phe His Val Asp Met Ala Lys Lys Glu			
	165	170	175	
20	Thr Val Trp Arg Leu Glu Glu Phe Gly Arg Phe Ala Ser Phe Glu Ala			
	180	185	190	
25	Gln Gly Ala Leu Ala Asn Ile Ala Val Asp Lys Ala Asn Leu Glu Ile			
	195	200	205	
	Met Thr Lys Arg Ser Asn Tyr Thr Pro Ile Thr Asn			
	210	215	220	
30				
	<210> CO567			
	<211> 221			
	<212> PRT			
	<213> Homo sapiens			
35	Met Gly Asp Thr Gly Arg Ser Phe Thr Leu Ala Ser Ser Glu Thr Gly			
	5	10	15	
40	Val Gly Ala Ser Gly Gly Ser Gly Gly Gly Asp Thr Arg			
	20	25	30	
	Pro Arg Phe Leu Glu Gln Val Lys His Glu Cys His Phe Phe Asn Gly			
	35	40	45	
45	Thr Glu Arg Val Arg Phe Leu Asp Arg Tyr Phe Tyr His Gln Glu Glu			
	50	55	60	
	Tyr Val Arg Phe Asp Ser Asp Val Gly Glu Tyr Arg Ala Val Thr Glu			
	65	70	75	80
50	Leu Gly Arg Pro Asp Ala Glu Tyr Trp Asn Ser Gln Lys Asp Leu Leu			
	85	90	95	
55	Glu Gln Lys Arg Ala Ala Val Asp Thr Tyr Cys Arg His Asn Tyr Gly			
	100	105	110	
	Val Gly Glu Ser Phe Thr Val Gln Arg Arg Thr Ser Gly Gly Gly			
	115	120	125	

84

Ser Gly Gly Gly Ser Ser Ser Ile Lys Glu Glu His Val Ile Ile  
 130 135 140

Gln Ala Glu Phe Tyr Leu Asn Pro Asp Gln Ser Gly Glu Phe Met Phe  
 5 145 150 155 160

Asp Phe Asp Gly Asp Glu Ile Phe His Val Asp Met Ala Lys Lys Glu  
 165 170 175

10 Thr Val Trp Arg Leu Glu Glu Phe Gly Arg Phe Ala Ser Phe Glu Ala  
 180 185 190

Gln Gly Ala Leu Ala Asn Ile Ala Val Asp Lys Ala Asn Leu Glu Ile  
 195 200 205

15 Met Thr Lys Arg Ser Asn Tyr Thr Pro Ile Thr Asn  
 210 215 220

I-As MBP. $\beta$ 1 $\beta$ 2 $\alpha$ 1 $\alpha$ 2.Ck nucleotide sequence

20 gcggccgcca ccatggagac agacacactc ctgctatggg tactgctgct ctgggttcca 60  
 gtttccactg gtgacttcaa gaacattgtg acacacctgaa caccacctcc agctagcgga 120  
 gggggcggaa gcggcggagg gggagactcc gaaaggcatt tcgtgttcca gttcaagggc 180  
 gagtgctact tcaccaacgg gacgcagcgc atacgatctg tggacagata catctacaac 240  

25 cgggaggagt acctgcgcgtt cgacagcgc acgtggcgcgtt accgcgcgcgtt gaccgagctg 300  
 gggcggccag accccgagta ctacaataag cagtagctgg agcaaacgcg gccgcgcgtg 360  
 gacacggtgt gcagacacaa ctacgagggg gtggagaccc acacctccct gcggcggcgtt 420  
 gaacagccca atgtcgcat ctccctgtcc aggacagagg ccctcaacca ccacaacact 480  
 ctggtctgtt cagtgcacaga ttcttaccca gccaagatca aagtgcgcgtt gttccggaaat 540  

30 ggccaggagg agacgggtggg ggtctcatcc acacagcttta ttaggaatgg ggactggacc 600  
 ttccagggtcc tggtcatgtt ggagatgacc cctcggcggg gagaggtcta cacctgccac 660  
 gtggagcattt cggcctgaa gagccccatc actgtggagt ggactagtgg tggcgggtggc 720  
 agcggcgggtg gtgggtccgg tggcggcgggt tctggcgggt gcggttcctc gagtgaagac 780  
 gacattgaggccgaccacgtt aggcgtcttat ggtacaactg tatatcagtc tcctggagac 840  

35 attggccagt acacacatga atttgatgtt gatgagttt gttatgttca cttggataag 900  
 aaggagacta tctggatgtt tcctgagttt gccaatttga caagctttga cccccaaggt 960  
 ggactgcaaa acatagctac agaaaaatac accttgggaa tcttgactaa gaggtcaaat 1020  
 tccaccccaag ctaccaatga ggctcctcaa ggcactgtgt tccccaagtc ccctgtgt 1080  

40 ctgggtcagc ccaacacccat catctgtttt gtggacaaca tcttccctcc tgtatcaac 1140  
 atcacatggc tcagaaatag taagtcagtc acagacggcg tttatgagac cagttccctt 1200  
 gtcaaccgtg accattcattt ccacaagctg tcttatactca ccttcatccc ttctgtacgt 1260  
 gatattttatg actgcaaggt ggagcactgg ggcctggagg agccggttct gaaacactgg 1320  
 gctagcggag ggggccccggaa cggcggagggg ggagctgtatg ctgcaccaac tgtatccatc 1380  

45 ttcccaccat ccagtgcacca gttaacatctt ggaggtgcctt cagtcgtgtt ctttttgaac 1440  
 aacttctacc ccaaagacat caatgtcaag tggaaagattt atggcagtta acgacaaaat 1500  
 ggcgtcttca acagttggac tgatcaggac agcaaaagaca gcacccatcag catgagcagc 1560  
 accctcacgt tgaccaagggc cgagtatgaa cgacataaca gctataccctg tgaggccact 1620  
 cacaagacat caacttcacc cattgtcaag agcttcaaca ggaatgagtg tttaggttacc 1680

50 I-As MBP. $\beta$ 1 $\beta$ 2 $\alpha$ 1 $\alpha$ 2.Ck amino acid sequence

Met Glu Thr Asp Thr Leu Leu Trp Val Leu Leu Trp Val Pro  
 5 10 15

55 Gly Ser Thr Gly Asp Phe Lys Asn Ile Val Thr Pro Arg Thr Pro Pro  
 20 25 30

85

Pro Ala Ser Gly Gly Gly Ser Gly Gly Gly Asp Ser Glu Arg  
                   35                        40                        45

5 His Phe Val Phe Gln Phe Lys Gly Glu Cys Tyr Phe Thr Asn Gly Thr  
       50                            55                        60

Gln Arg Ile Arg Ser Val Asp Arg Tyr Ile Tyr Asn Arg Glu Glu Tyr  
    65                            70                        75                    80

10 Leu Arg Phe Asp Ser Asp Val Gly Glu Tyr Arg Ala Val Thr Glu Leu  
       85                            90                        95

Gly Arg Pro Asp Pro Glu Tyr Tyr Asn Lys Gln Tyr Leu Glu Gln Thr  
   15                            100                        105                    110

Arg Ala Glu Leu Asp Thr Val Cys Arg His Asn Tyr Glu Gly Val Glu  
   115                            120                        125

20 Thr His Thr Ser Leu Arg Arg Leu Glu Gln Pro Asn Val Val Ile Ser  
   130                            135                        140

Leu Ser Arg Thr Glu Ala Leu Asn His His Asn Thr Leu Val Cys Ser  
   145                            150                        155                    160

25 Val Thr Asp Phe Tyr Pro Ala Lys Ile Lys Val Arg Trp Phe Arg Asn  
   165                            170                        175

Gly Gln Glu Glu Thr Val Gly Val Ser Ser Thr Gln Leu Ile Arg Asn  
 30                            180                        185                    190

Gly Asp Trp Thr Phe Gln Val Leu Val Met Leu Glu Met Thr Pro Arg  
   195                            200                        205

35 Arg Gly Glu Val Tyr Thr Cys His Val Glu His Pro Ser Leu Lys Ser  
   210                            215                        220

Pro Ile Thr Val Glu Trp Thr Ser Gly Gly Ser Gly Gly Gly  
   225                            230                        235                    240

40 Gly Ser Gly Gly Ser Gly Gly Ser Ser Ser Glu Asp  
   245                            250                        255

Asp Ile Glu Ala Asp His Val Gly Val Tyr Gly Thr Thr Val Tyr Gln  
 45                            260                        265                    270

Ser Pro Gly Asp Ile Gly Gln Tyr Thr His Glu Phe Asp Gly Asp Glu  
   275                            280                        285

50 Trp Phe Tyr Val Asp Leu Asp Lys Lys Glu Thr Ile Trp Met Leu Pro  
   290                            295                        300

Glu Phe Gly Gln Leu Thr Ser Phe Asp Pro Gln Gly Gly Leu Gln Asn  
   305                            310                        315                    320

55 Ile Ala Thr Gly Lys Tyr Thr Leu Gly Ile Leu Thr Lys Arg Ser Asn  
   325                            330                        335

Ser Thr Pro Ala Thr Asn Glu Ala Pro Gln Ala Thr Val Phe Pro Lys

	86			
	340	345	350	
	Ser Pro Val Leu Leu Gly Gln Pro Asn Thr Leu Ile Cys Phe Val Asp			
	355	360	365	
5	Asn Ile Phe Pro Pro Val Ile Asn Ile Thr Trp Leu Arg Asn Ser Lys			
	370	375	380	
10	Ser Val Thr Asp Gly Val Tyr Glu Thr Ser Phe Leu Val Asn Arg Asp			
	385	390	395	400
	His Ser Phe His Lys Leu Ser Tyr Leu Thr Phe Ile Pro Ser Asp Asp			
	405	410	415	
15	Asp Ile Tyr Asp Cys Lys Val Glu His Trp Gly Leu Glu Glu Pro Val			
	420	425	430	
	Leu Lys His Trp Ala Ser Gly Gly Gly Ser Gly Gly Gly Ala			
	435	440	445	
20	Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu			
	450	455	460	
25	Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro			
	465	470	475	480
	Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn			
	485	490	495	
30	Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr			
	500	505	510	
	Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His			
	515	520	525	
35	Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile			
	530	535	540	
	Val Lys Ser Phe Asn Arg Asn Glu Cys			
40	545	550		

<210> CO528-AC

<211> 600

<212> DNA

<213> Homo sapiens

atgggggaca ccggtcgcag cttcacccctg gcctccagcg agaccggcgt gggtggtggc 60

ggttcgcgtc cacgttcttt ggaacagggtt aaacatgagt gtcatttttt caatggacg 120

gaacgcgtgc gttttctgga tcgtaacttt tatcaccaag aggaatacgt acgcctcgac 180

agcgatgtgg gcgaatatcg tgcggtcacg gaactgggtc gtcctgtatgc cgaataactgg 240

aacagtcaga aggacttact ggagcagaaaa cgtgcagcgg tggataccta ttgccgcccac 300

aattacggcg ttggtgaaag cttcacagtc cagcgtcgcg gtggcatcaa agaagagcat 360

gtgattatcc aggccgaatt ctatctgaat ccggatcaat cgggcgaatt catgtttgac 420

ttcgatggtg atgagatttt ccatgttgat atggcaaaga aagaaaacggt ctggcgctta 480

gaggaatttg gccgctttgc ctcgttcgaa gctcaaggcg cattggccaa cattgctgtg 540

gataaagcga acctggaaat catgacaaaaa cgctccaact atactccgat taccaattaa 600

<210> CO608-AC

<211> 642

<212> DNA

5 <213> Homo sapiens

```

atgggggaca ccggtcgcag cttcaccctg gcctccagcg agaccggcgt gggtgcttct 60
ggcgaaaaacg gttcgccggc tgggggtgac acccgccccac gtttcttggaa acaggttaaa 120
catgagtgtc atttttcaaa tggacggaa cgccgtgcgtt ttctggatcg ttacttttat 180
10 caccaggagg aatacgtacg cttcgacagc gatgtggcgt aatatcgtgc ggtcacggaa 240
ctgggtcgctc ctgtatgccga atactggAAC agtcagaagg acttacttggaa gcagaaaacgt 300
gcagcggtgg atacctattt ccggccacaat tacggcggtt gtgaaagcgtt cacagtccag 360
cgtcgcacta gtgggtggcgt tggctctatc aaagaagagc atgtgattat ccaggcggaa 420
ttctatctga atccggatca atcggggcgtt ttcatgtttt acttcgtatgg tgatgagatt 480
15 ttccatgttg atatggcaaa gaaagaaaacg gtctggcgct tagaggaatt tggccgcttt 540
gcctcggtcg aagctcaagg cgcattggcc aacattgtgt tggataaagc gaacctggaa 600
atcatgacaa aacgctccaa ctatactccg attaccaatt aa 642

```

20 <210> CO528

<211> 600

<212> DNA

<213> Homo sapiens

```

25 atgggggaca ccggaaagatc gttcacacactc gcatcatcag agacaggagt aggaggagga 60
ggatcgcgac cacgtttctt ggagcagggtt aaacatgagt gtcatttctt caacgggacg 120
gagcgggtgc ggttcttggaa cagatacttc tatcaccaag aggagtacgt gcgcttcgac 180
agcgcacgtgg gggagttaccg ggcgtgacg gagctgggc ggcctgtatgc cgagacttgg 240
aacagccaga gggacctcct ggagcagaag cggccgcgg tggacaccctt ctgcagacac 300
30 aactacgggg ttggtgagag cttcacagtg cagcggcgag gaggtatcaa agaagaacat 360
gtgatcatcc aggccgagtt ctatctgaat cctgaccaat caggcgagtt tatgtttgac 420
tttgatggtg atgagatttt ccatgtggat atggcaaaaga aggagacggtt ctggcggctt 480
gaagaatttg gacgatttgc cagcttttag gctcaagggtt cattggccaa catagctgtg 540
gacaaagcca acctggaaat catgacaaag cgctccaaact atactccgtt caccattaa 600
35

```

<210> CO608

<211> 630

<212> DNA

40 <213> Homo sapiens

```

ATGGGGGACACCCGCAGCTTCACCCCTGGCCTCCAGCGAGACCGGGGTGGCGCTAGCGGAGGGGGCGGAAGC
GGCGGAGGGGGGCCACGTTCTTGGAGCAGGTAAACATGAGTGTCAATTCTCAACGGGACGGAGCGGGTG
45 CGGTTCTGGACAGATACTTCTATCACCAAGAGGGAGTACGTGCGCTTCGACAGCGACGTGGGGAGTACCGG
GCGGTGACGGAGCTGGGGCGGCCTGATGCCGAGTACTGGAACAGCCAGAAGGACCTCTGGAGCAGAAGCGG
GCCGGGTGGACACCTACTGCAGACACAACCTACGGGGTTGGTAGAGAGCTTCACAGTGCAGCGGCGAAGTGT
GGTGGCGGTGGCAGCATCAAAGAAGAACATGTGATCATCCAGGCCAGTTCTATCTGAATCCTGACAATCA
GGCGAGTTTATGTTGACTTTGATGGTAGAGATTTCATGTGGATATGGCAAAGAAGGAGACGGTCTGG
50 CGGCTTGAAGAATTGGACGATTGCCAGCTTGAGGCTCAAGGTGCATTGCCAACATAGCTGTGGACAAA
GCCAACCTGGAAATCATGACAAGCGCTCCAACACTATACTCCGATACCAATTAA

```

<210> CO 608 variation

<211> 642

55 <212> DNA--CO608

<213> Homo sapiens

```

ATGGGGGACACCCGTGAGCTTCACCCCTGGCCTCCAGCGAGACCGGGGTGGCGCTAGCGGAGGGGGCGGA
AGCGGCGGAGGGGGACACCCGACCACGTTCTTGGAGCAGGTAAACATGAGTGTCAATTCTCAACGGG

```

88

ACGGAGCGGGTGGGTTCTGGACAGATACTTCTATCACCAAGAGGGAGTACGTGCGCTTCGACAGCGACGTG  
GGGGAGTACCGGGCGGTGACGGAGCTGGGCGCCCTGATGCCGAGTACTGGAACAGCCAGAAGGACCTCCTG  
GAGCAGAACGGGGCGGGTGGACACCTACTGCAGACACAACACTACGGGGTGGTGGAGAGCTTCACAGTGCAG  
CGGCGAACTAGTGGTGGCGGTGGCAGCATCAAAGAAGAACATGTGATCATCCAGGCCAGTTCTATCTGAAT  
CCTGACCAATCAGGGAGTTATGTTGACTTTGATGGTGATGAGATTTCCATGTTGGATATGGCAAAGAAG  
GAGACGGTCTGGGGCTTGAAGAATTGGACGATTGCCAGCTTGAGGCTCAAGGTGCAATTGGCCAACATA  
GCTGTGGACAAAGCCAACTGGAAATCATGACAAAGCGCTCCAACATACTCCGATCACCAATTAA

10 <210> CO528-AC  
<211> 200  
<212> PRT  
<213> Homo sapiens

15 Met Gly Asp Thr Gly Arg Ser Phe Thr Leu Ala Ser Ser Glu Thr Gly  
5 10 15

Val Gly Gly Gly Ser Arg Pro Arg Phe Leu Glu Gln Val Lys His  
20 25 30

20 Glu Cys His Phe Phe Asn Gly Thr Glu Arg Val Arg Phe Leu Asp Arg  
                  35                 40                 45

25 Tyr Phe Tyr His Gln Glu Glu Tyr Val Arg Phe Asp Ser Asp Val Gly  
           50               55               60

Glu Tyr Arg Ala Val Thr Glu Leu Gly Arg Pro Asp Ala Glu Tyr Trp  
65 70 75 80

30 Asn Ser Gln Lys Asp Leu Leu Glu Gln Lys Arg Ala Ala Val Asp Thr  
85 90 95

Tyr Cys Arg His Asn Tyr Gly Val Gly Glu Ser Phe Thr Val Gln Arg  
           100           105                   110

35 Arg Gly Gly Ile Lys Glu Glu His Val Ile Ile Gln Ala Glu Phe Tyr  
           115               120               125

40 Leu Asn Pro Asp Gln Ser Gly Glu Phe Met Phe Asp Phe Asp Gly Asp  
40 130 135 140

Glu Ile Phe His Val Asp Met Ala Lys Lys Glu Thr Val Trp Arg Leu  
 145                   150                   155                   160

45 Glu Glu Phe Gly Arg Phe Ala Ser Phe Glu Ala Gln Gly Ala Leu Ala  
165 170 175

Asn Ile Ala Val Asp Lys Ala Asn Leu Glu Ile Met Thr Lys Arg Ser  
           180           185           190

50 Asn Tyr Thr Pro Ile Thr Asn  
195

<210> 55555 118  
<211> 214  
<212> PRT  
<213> *Homo sapiens*

89

90

MGDTGRSFTLASSETGVGASGGGGGGDTRPRFLEQVKHECHFFNGTERVRFLDRYFYHQEEYVRFDSDV  
 GEYRAVTELGRPDAEYWNSQKDLLEQKRAAVDTYCRHNYVGESFTVQRRTSGGGGSIKEEHVIIQAEFYLN  
 PDQSGEFMFDFDGDEIFHVDMAKKETVWRLEEFGRFASFEAQGALANIADKANLEIMTKRSNYTPIT

5

&lt;210&gt; CO528

&lt;211&gt; 200

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

10

Met	Gly	Asp	Thr	Gly	Arg	Ser	Phe	Thr	Leu	Ala	Ser	Ser	Glu	Thr	Gly
							5						10		15

15

Val	Gly	Gly	Gly	Gly	Ser	Arg	Pro	Arg	Phe	Leu	Glu	Gln	Val	Lys	His
							20					25		30	

20

Glu	Cys	His	Phe	Phe	Asn	Gly	Thr	Glu	Arg	Val	Arg	Phe	Leu	Asp	Arg
							35					40		45	

25

Tyr	Phe	Tyr	His	Gln	Glu	Glu	Tyr	Val	Arg	Phe	Asp	Ser	Asp	Val	Gly
							50					55		60	

Glu	Tyr	Arg	Ala	Val	Thr	Glu	Leu	Gly	Arg	Pro	Asp	Ala	Glu	Tyr	Trp
							65					70		75	

30

Asn	Ser	Gln	Arg	Asp	Leu	Leu	Glu	Gln	Lys	Arg	Ala	Ala	Val	Asp	Thr
							85					90		95	

35

Tyr	Cys	Arg	His	Asn	Tyr	Gly	Val	Gly	Glu	Ser	Phe	Thr	Val	Gln	Arg
							100					105		110	

Arg	Gly	Gly	Ile	Lys	Glu	Glu	His	Val	Ile	Ile	Gln	Ala	Glu	Phe	Tyr
							115					120		125	

40

Leu	Asn	Pro	Asp	Gln	Ser	Gly	Glu	Phe	Met	Phe	Asp	Phe	Asp	Gly	Asp
							130					135		140	

Glu	Ile	Phe	His	Val	Asp	Met	Ala	Lys	Lys	Glu	Thr	Val	Trp	Arg	Leu
							145					150		155	

45

Glu	Glu	Phe	Gly	Arg	Phe	Ala	Ser	Phe	Glu	Ala	Gln	Gly	Ala	Leu	Ala
							165					170		175	

Asn	Ile	Ala	Val	Asp	Lys	Ala	Asn	Leu	Glu	Ile	Met	Thr	Lys	Arg	Ser
							180					185		190	

Asn	Tyr	Thr	Pro	Ile	Thr	Asn
						195

50

&lt;210&gt; IAS MBP1-14 CH1.CH2.CH3

&lt;211&gt; 2346

&lt;212&gt; DNA

&lt;213&gt; murine

55

gcggccgcca	ccatggagac	agacacactc	ctgctatggg	tactgctgct	ctgggttcca	60
ggttccactg	gtgacatggc	gtcacagaag	agaccctccc	agaggcacgg	atccaaggct	120
agcggagggg	cgccaagcgg	cggaggggga	gactccgaaa	ggcatttcgt	gttccagttc	180

91

	aaggcgagt	gctacttcac	caacgggacg	cagcgatac	gatctgtgga	cagatacatc	240
	tacaaccggg	aggagtaacct	gcgcattcgac	agcqacgtgg	gcgagttaccg	cgccgggtgacc	300
	gagctggggc	ggccagaccc	cgagtactac	aataaggagt	acctggagca	aacgcgggccc	360
5	cggctgaac	agcccaatgt	cgtcatctcc	ctgtccagga	cagaggccct	caaccaccac	420
	aacactctgg	tctgctcagt	gacagatttc	tacccagcca	agatcaaagt	gcgctgggtc	540
	cggaatggcc	aggaggagac	ggtgggggtc	tcatccacac	agcttattag	aatggggac	600
	tggacattcc	aggtccttgtt	catgctggag	atgaccctc	ggcggggaga	ggtctacacc	660
	tgccacgtgg	agcatccgag	cctgaagagc	cccatcaactg	tggagtggac	tagtgggtgc	720
10	ggggcagcg	gccccgtgg	ttccgggtggc	ggcggtctcg	gcgggtggcgg	ttccctcgagt	780
	gaagacgaca	ttgaggccga	ccacgttaggc	gtctatggta	caactgtata	tcagtctcct	840
	ggagacatttgc	gccagtacac	acatgaattt	gatggtgatg	agtggttcta	tgtggacttg	900
	gataagaagg	agactatctg	gatgcttctt	gagtttggcc	aattgacaag	ctttgaccac	960
15	caaggtggac	tgcaaaaacat	agctacagga	aaatacacct	tgggaatctt	gactaagagg	1020
	tcaaaattcca	ccccagctac	caatgaggct	cctcaagcga	ctgtgttccc	caagtccccct	1080
	gtgctgtgg	gtcagccaa	caccctcatc	tgctttgtgg	acaacatctt	ccctcctgtg	1140
	atcaacatca	catggctcag	aaatagtaag	tcagtcaacag	acggcgttta	tgagaccagc	1200
	ttccttgc	accgtgacca	ttccttccac	aagctgtctt	atctcacctt	catcccttct	1260
	gacgtgata	tttatgactg	caaggtggag	cactggggcc	tggaggagcc	ggttctgaaa	1320
20	cactggcgt	gccccgggg	cggaaacggc	ggagggggag	ccaaaacgac	accccccattt	1380
	gtctatccac	tggcccttgg	atctgctgccc	caaactaact	ccatgggtgac	cctgggatgc	1440
	ctgggtcaagg	gtatattccc	tgagccagtg	acagtgttctt	ggaactctgg	atccctgtcc	1500
	agcgggtgtc	acacccccc	agctgttctg	cagtctgacc	tctacactct	gagcagctca	1560
25	gtgactgtcc	cctccagcac	ctggcccagc	gagaccgtca	cctgcaacgt	tgcccaccccg	1620
	gccagcagca	ccaagggtgga	caagaaaatt	gtgcccaggg	attgtggtttgc	taaggccttgc	1680
	atatgtacag	tcccagaagt	atcatctgtc	ttcatcttcc	ccccaaagcc	caaggatgtg	1740
	ctcaccatttca	ctctgactcc	taaggtcagc	tgtgttgtgg	tagacatcag	caaggatgtat	1800
	cccgagggtcc	agttcagctg	gtttgttagat	gatgtggagg	tgcacacagc	tcagacgcaa	1860
30	ccccggggagg	agcagttcaa	cagcaacttc	cgctcaagtca	gtgaacttcc	catcatgcac	1920
	caggactggc	tcaatggcaa	ggagttcaaa	tgcagggtca	acagtgcagc	ttccctgtcc	1980
	cccatcgaga	aaaccatctc	aaaaacccaaa	ggcagaccga	aggctccaca	ggtgtacacc	2040
	attccacctc	ccaaggagca	gatggccaag	gataaagtca	gtctgacccctg	catgataaca	2100
	gactttttcc	ctgaagacat	tactgtggag	tggcagttga	atgggcagcc	agcggagaac	2160
	tacaagaaca	ctcagcccat	catggacaca	gatggcttca	acttctgtcta	cagcaagctc	2220
35	aatgtgcaga	agagcaactg	ggaggcagga	aataacttca	cctgctctgt	gttacatgag	2280
	ggcctgcaca	accaccatac	tgagaagagc	ctctccact	ctccctggtaa	atgatctgg	2340
	acccctgc						2346

40 &lt;210&gt; IAS MBP 1-14 CH1.H

&lt;211&gt; 1701

&lt;212&gt; DNA

&lt;213&gt; murine

45	gcggccgcca	ccatggagac	agacacactc	ctgctatggg	tactgtgtct	ctgggttcca	60
	ggttccactg	gtgacatggc	gtcacagaag	agaccctccc	agaggcacgg	atccaaaggct	120
	agcggagggg	gccaaggcgg	cggaggggg	gactccaaa	ggcatttcgt	gttccagttc	180
	aaggcgagt	gtacttcac	caacgggacg	cagcgatac	gatctgtgg	cagatacatc	240
	tacaaccggg	aggagtaacct	gcccattcgac	agcgtacgtgg	gcgagttaccg	cgccgggtgacc	300
50	gagctggggc	ggccagaccc	cgagtactac	aataaggagt	acctggagca	aacgcgggccc	360
	gagctggaca	cggtgtgcag	acacaactac	gaggggtgg	agacccacac	ctccctgtgg	420
	cggctgaac	agcccaatgt	cgtcatctcc	ctgtccagga	cagaggccct	caaccaccac	480
	aacactctgg	tctgctcagt	gacagatttc	tacccagcca	agatcaaagt	gcgctgggtc	540
	cggaatggcc	aggaggagac	ggtgggggtc	tcatccacac	agcttattag	aatggggac	600
55	tggacattcc	aggtccttgtt	catgctggag	atgaccctc	ggcggggaga	ggtctacacc	660
	tgccacgtgg	agcatccgag	cctgaagagc	cccatcaactg	tggagtggac	tagtgggtgc	720
	ggggcagcg	gccccgtgg	ttccgggtggc	ggcggtctcg	gcgggtggcgg	ttccctcgagt	780
	gaagacgaca	ttgaggccga	ccacgttaggc	gttotatggta	caactgtata	tcagtctcct	840
	ggagacatttgc	gccagtacac	acatgaatttgc	gatggtgatg	agtggttcta	tgtggacttg	900

92

gataagaagg agactatctg gatgcttcct gagtttggcc aattgacaag ctttgacccc 960  
 caaggtggac tgcaaaaatc agctacagga aaatacacatc tggaaatctt gactaagagg 1020  
 tcaaattcca ccccagctac caatgaggct cctcaagcga ctgtgttccc caagtcccc 1080  
 5 gtgctgtgg gtcagccaa caccctcatc tgctttgtgg acaacatctt ccctccctgtg 1140  
 atcaacatca catggcttag aaatagtaag tcagtcacag acggcggttta tgagaccgc 1200  
 ttccttgtca accgtgacca ttccttccac aagctgtttt atctcacctt catccctct 1260  
 gacgatgata tttatgactg caaggtggag cactggggcc tggaggaggg ggttctgaaa 1320  
 cactgggcta gcggagggggg cgaaagcgcc ggagggggag caaaacgcac acccccatct 1380  
 10 gtctatccac tggcccttgg atctgctgcc caaactaact ccatgggtac cctgggatgc 1440  
 ctggtcaagg gctatccc tgagccagt acagtgcacctt ggaactctgg atccctgtcc 1500  
 agcgggtgtc acacccccc agctgtcctg cagtctgacc tctacactt gagcagctca 1560  
 gtgactgtcc cttccagcac ctggccctgg gagaccgtca cctgcaacgt tgcccaccc 1620  
 gccagcagca ccaaggtgga caagaaaatt gtgcccaggg attgtggttt taaggcttgc 1680  
 atatgtacag tctaaggta c 1701

15

<210> IAS MBP 90-101 CH1.H.CH2  
 <211> 2053  
 <212> DNA  
 20 <213> murine

gcggccgcca ccatggagac agacacactc ctgctatggg tactgctgct ctgggttcca 60  
 ggttcactg gtgacttcaa gaacattgtg acacacccaa caccacctcc agctagcgga 120  
 25 gggggcggaa gcggcggagg gggagactcc gaaaggcatt tcgtgttcca gttcaaggc 180  
 gagtgctact tcaccaacgg gacgcagcgc atacgatctg tggacagata catctacaac 240  
 cgggaggagt acctgcgtt cgacagcgc acgtggcgtt accgcgcggg gaccgagctg 300  
 gggcgccag acccccgagta ctacaataag cagtaacctgg agcaaacgcg gcccagctg 360  
 gacacgggtt gcagacacaa ctacgagggg gtggagaccc acacccccc gccggggctt 420  
 30 gaacagccca atgtcgcat ctccctgtcc aggacagagg ccctcaacca ccacaacact 480  
 ctggctctgct cagtgcacaga ttcttaccca gccaagatca aagtgcgcgt gttccggaaat 540  
 gggcaggagg agacgggtggg ggtctcatcc acacagctt ttaggaatgg ggactggacc 600  
 ttccagggtcc tggtcatgtt ggagatgacc cctcggggg gagaggctta cacctgccac 660  
 gtggagcatc cgagcctgaa gagcccccatt actgtggagt ggactagtgg tggcgggtgc 720  
 35 agcggcgggtg gtgggtccgg tggcggcggt tctggcggt gcggttcctc gatgtggacc 780  
 gacattgggg cggaccacgt aggctgttat ggtacaactt tatatcagtc tcctggagac 840  
 attggccagt acacacatga atttgatggt gatgagttt tctatgttga cttggataag 900  
 aaggagacta tctggatgtt tcctgagttt ggcacattga caagctttga cccccaaggt 960  
 ggactgcata acatagctac agaaaaatac accttggaa tcttgactaa gaggtcaaat 1020  
 40 tccaccccaatcgtt ggcacccaa ggcactgtgt tccctcaactt cccctgtctg 1080  
 ctgggtcagc ccaacacccct catctgtttt gtggacaaca tcttccctcc tggatcaac 1140  
 atcacatggc tcagaaatag taagtcaatc acagacggcg tttatgagac cagttccctt 1200  
 gtcaaccgtg accattccctt ccacaagctg tcttacatca ccttcatccc ttctgacat 1260  
 gatattttatc actgcacagg ggacactgg ggcctggagg agccgggtt gaaacactgg 1320  
 45 gctagcggag gggggcggaa cggcggagggg ggagccaaaa caacaccccc atcagtctat 1380  
 ccactggccc ctgggtgtgg agatacaactt ggttccctcc tgactctggg atgcgtggc 1440  
 aagggtact tccctgagtc agtactgtg acttggaaact ctggctccct gtccagcagt 1500  
 gtgcacaccc tcccacgtt cctgcagttt ggacttccata ctatgagcag ctcagtgtact 1560  
 gtcccttcca gcacccgttcc aagtccatc gtcacccatc gctgttgc tccagccagc 1620  
 50 agcaccacgg tggacaaaaa acttgagccc agcggggccca tttcaacaaat caacccctgt 1680  
 cctccatgca aggagtgtca caaatgccc gtccttaacc tggagggtgg accatccgtc 1740  
 ttcatcttcc ctccaaatat caaggatgtt ctcatgtatc ccctgacacc caaggtcact 1800  
 tgggtgtgg tggatgtgag cgaggatgac ccagacgtcc agatcagctg gtttggaaac 1860  
 aacgttggaaag tacacacacgc tcagacacaa accccatagag aggattacaa cgtactatc 1920  
 55 cgggtgtca gcaccctccc catccagcac caggactggta tgagtggcaa ggagttcaaa 1980  
 tgcaaggtca acaacaaaga cctccatca cccatcgaga gaaccatctc aaaaattaaa 2040  
 taggttaccc cga 2053

&lt;210&gt; IAS MBP 90-101 CH1.H

&lt;211&gt; 1707

&lt;212&gt; DNA

&lt;213&gt; murine

5	gcggccgcca ccatggagac agacacactc ctgctatggg tactgctgct ctgggttcca 60
	gttccactg gtgacttcaa gaacattgtg acacctcgaa caccacctcc agctagcgct 120
	agcggagggg gCGGAAGCGG CGGAGGGGG GACTCCGAAA GGCATTTCGT GTTCAGTTC 180
	aaggcgagt gctacttcac caacgggacg cagcgatac gatctgtgga cagatacatc 240
	tacaaccggg aggagttacct gcgcctcgac agcgacgtgg gcgagttacgg cgccgtgacc 300
10	gagctggggc ggccagaccc cgagttactac aataagcagt acctggagca aacgcggggcc 360
	gagctggaca cggtgtgcag acacaactac gaggggggtgg agacccacac ctccctgcgg 420
	cggctgaac agcccaatgt cgtcatctcc ctgtccagga cagaggccct caaccaccac 480
	aacactctgg tctgctcagt gacagattt taccctggca agatcaaagt ggcgtggttc 540
	cggaatggcc aggaggagac ggtgggggtc tcattccacac agcttatttag gaatggggac 600
15	tggacattcc aggtccttgtt catgctggag atgacccttc ggcggggaga ggtctacacc 660
	tgccacgtgg agcatccgag cctgaagagc cccatcaactg tggagtggac tagtgggtggc 720
	ggtggcagcg gcggtgggtt ttccgggtggc ggcggttctg gcggtggcgg ttccctcgagt 780
	gaagacgaca ttgaggccga ccacgttaggc gtctatggta caactgtata tcagtctcct 840
	ggagacattt gccagttacac acatgaattt gatggtgatg agtggttcta tgtgacttg 900
20	gataagaagg agactatctg gatgcttcctt gagtttggcc aattgacaag cttaaagcttt 960
	gaccggcaag gtggactgca aaacatagct acaggaaaat acaccttggg aatcttact 1020
	aagaggtcaa attccaccccc agctaccaat gaggctcctc aagcgactgt gttccccaag 1080
	tcccctgtgc tgctgggtca gccaacaccc ctcatctgtt ttgtggaca catctccct 1140
	cctgtgatca acatcacatg gtcagaaat agtaagtcag tcacagacgg cggttatgag 1200
25	accagcttcc ttgtcaaccc tgaccattcc ttccacaagc tgcattatct caccttcattc 1260
	ccttctgacg atgatattt tgactgcaag gtggagcact ggggccttggc ggagccgggtt 1320
	ctgaaacact gggcttagcgg agggggcggg agcggcggag ggggagccaa aacgacacccc 1380
	ccatctgtct atccactggc ccctggatct gtcggccaaa ctaactccat ggtgaccctg 1440
	ggatgcctgg tcaagggtta tttccctgag ccagtgcacag tgacctggaa ctctggatcc 1500
30	ctgtccagcg gtgtgcacac cttccctggatct gtcctgcagt ctgacctcta cactctgagc 1560
	agctcagtga ctgtccctc cagcacctgg cccagcggaga cctgcacccctg caacgttgcc 1620
	cacccggcca gcagcaccaa ggtggacaag aaaattgtgc ccaggaggattg tggttgtaa 1680
	ccttgcataat gtacagtcta aggtacc 1707

35

&lt;210&gt; MBP 1-14 CK

&lt;211&gt; 1686

&lt;212&gt; DNA

&lt;213&gt; murine

40

40	gcggccgcca ccatggagac agacacactc ctgctatggg tactgctgct ctgggttcca 60
	gttccactg gtgacatggc gtacacagaag agacccctcc agaggcacgg atccaaaggct 120
	agcggagggg gCGGAAGCGG CGGAGGGGG GACTCCGAAA GGCATTTCGT GTTCAGTTC 180
	aaggcgagt gctacttcac caacgggacg cagcgatac gatctgtgga cagatacatc 240
45	tacaaccggg aggagttacct gcgcctcgac agcgacgtgg gcgagttacgg cgccgtgacc 300
	gagctggggc ggccagaccc cgagttactac aataagcagt acctggagca aacgcggggcc 360
	gagctggaca cggtgtgcag acacaactac gaggggggtgg agacccacac ctccctgcgg 420
	cggctgaac agcccaatgt cgtcatctcc ctgtccagga cagaggccct caaccaccac 480
	aacactctgg tctgctcagt gacagattt taccctggca agatcaaagt ggcgtggttc 540
	cggaatggcc aggaggagac ggtgggggtc tcattccacac agcttatttag gaatggggac 600
	tggacattcc aggtccttgtt catgctggag atgacccttc ggcggggaga ggtctacacc 660
	tgccacgtgg agcatccgag cctgaagagc cccatcaactg tggagtggac tagtgggtggc 720
	ggtggcagcg gcggtgggtt ttccgggtggc ggcggttctg gcggtggcgg ttccctcgagt 780
	gaagacgaca ttgaggccga ccacgttaggc gtctatggta caactgtata tcagtctcct 840
55	ggagacattt gccagttacac acatgaattt gatggtgatg agtggttcta tgtgacttg 900
	gataagaagg agactatctg gatgcttcctt gagtttggcc aattgacaag ctttgacc 960
	caaggtggac tgcaaaaat agctacagga aaatacacct tggaatctt gactaagagg 1020
	tcaaatttcca ccccagctac caatgaggct cctcaagcga ctgtgttccc caagtccct 1080
	gtgctgctgg gtcagccaa caccctcattc tgctttgtgg acaacatctt ccctccctgtg 1140

94

atcaacatca catggctca gaaatagtaag tcagtcacag acggcggttta tgagaccaggc 1200  
 ttccttgtca accgtgacca ttccttccac aagctgtctt atctcacctt catcccttct 1260  
 gacgatgata tttatgactg caaggtggag cactggggcc tggaggagcc ggttctgaaa 1320  
 5 cactgggcta gcggaggggg cgaaagcggc ggagggggag ctgatgctgc accaactgta 1380  
 tccatcttcc caccatccag tgagcagtta acatctggag gtgcctcagt cgttgcttc 1440  
 ttgaacaact tctaccccaa agacatcaat gtcaagtgg aagattgtatgg cagtgaacga 1500  
 caaaatggcg tcctgaacag ttggactgtat caggacagca aagacagcac ctacagcatg 1560  
 agcagcaccc tcacgttgc caaggacag tatgaacgac ataacagcta tacctgttag 1620  
 10 gccactcaca agacatcaac ttcacccatt gtcaagagct tcaacaggaa tgagtgttag 1680  
 ggtacc 1686

&lt;210&gt; MBP 1-14 CH1.H.CH2

&lt;211&gt; 2059

15 <212> DNA  
 <213> murine

gcggccgcca ccatggagac agacacactc ctgctatggg tactgctgct ctgggttcca 60  
 20 gtttccactg gtgacatggc gtacacagaag agacccccc agaggcacgg atccaaggct 120  
 agcggagggg gcgaaagcgg cggagggggg gactccgaaa ggcatttcgt gttcagttc 180  
 aaggggcgagt gctacttcac caacgggacg cagcgcatac gatctgtgga cagatacatc 240  
 tacaaccggg aggagtacct ggcgttcgac agegacgtgg gcgagttaccg cgcgtgacc 300  
 gagctggggc ggccagaccc cgagtactac aataaggagt acctggagca aacgcgggccc 360  
 25 gagctggaca cggtgtgcag acacaactac gagggggtgg agacccacac ctccctgcgg 420  
 cggcttgaac agcccaatgt cgtcatctcc ctgtccagga cagaggccct caaccaccac 480  
 aacactctgg tctgctcagt gacagatttc taccctagcca agatcaaagt ggcgtgggtc 540  
 cggaaatggcc aggaggagac ggtgggggtc tcatccacac agcttattag gaatggggac 600  
 tggacaccttcc aggtccttggt catgtggag atgacccctc ggcggggaga ggtctacacc 660  
 30 tgccacgtgg agcatccgag cctgaagagc cccatcaactg tggagttggac tagtgggtgc 720  
 ggtggcagcg gcggtgggtt ttccgggtggc ggcgggttctg gcggtggcgg ttccctcgagt 780  
 gaagacgaca ttgaggccga ccacgttaggc gtctatggta caactgtata tcagtctcct 840  
 ggagacattt gccagtacac acatgaattt gatggatgtt agtgggttcta tgtgacttg 900  
 gataagaagg agactatctg gatgttccct gagtttggcc aattgacaag ctggaccccc 960  
 35 caagggtggac tgcaaaaacat agtacagga aaatacacct tggaatctt gactaagagg 1020  
 tcaaattcca ccccagctac caatggaggc cctcaagcga ctgtgttccc caagtcccc 1080  
 gtgctgctgg gtcagccaa cacccatc tgctttgtgg acaacatctt ccctccctgt 1140  
 atcaacatca catggctca gaaatagtaag tcagtcacag acggcggttta tgagaccaggc 1200  
 ttccttgtca accgtgacca ttccttccac aagctgtctt atctcacctt catcccttct 1260  
 gacgatgata tttatgactg caaggtggag cactggggcc tggaggagcc ggttctgaaa 1320  
 40 cactgggcta gcggaggggg cgaaagcggc ggagggggag caaaaacaaac acccccatca 1380  
 gtctatccac tggcccccgtt gtgtggagat acaactgggtt cctccgtgac tctggatgc 1440  
 ctggtciaagg gctacttccc tgagtcagtg actgtactt ggaactctgg ctccctgtcc 1500  
 agcagtgtgc acacccccc agtctcctg cagtctggac tctacactat gagcagctca 1560  
 45 gtgactgtcc cctccagcac ctggccaagt cagacccgtca cctgcagcgt tgctcaccctt 1620  
 gcccagcac ccacgggtggc caaaaaactt gagcccagcg gggccatttc aacaatcaac 1680  
 ccctgttcc catgcaagga gtgtcacaaa tgcccaagct ctaacctgga ggggtggacca 1740  
 tccgttccca tcttccctcc aaatatcaag gatgtactca tgatctccct gacaccccaag 1800  
 gtcacgtgtg tgggtggatgatggagc gatgacccag acgtccagat cagctgggtt 1860  
 50 gtgaacaacg tggaaagtaca cacagctca gacacaaaccc atagagagga ttacaacagt 1920  
 actatccggg tggtcagcac cttcccccattt cagcaccagg actggatgag tggcaaggag 1980  
 ttcaaatgca aggtcaacaa caaagacctc ccatcacccca tcgagagaac catctcaaaa 2040  
 attaaatagg gtaccccgaa 2059

55 &lt;210&gt; MBP 90-101 CH1.H.CH2.CH3

&lt;211&gt; 2343

&lt;212&gt; DNA--

&lt;213&gt; murine

95

	gccccggcca	ccatggagac	agacacactc	ctgctatggg	tactgctgt	ctgggttcca	60
	ggttccactg	gtgacttcaa	gaacattgtg	acacacctgaa	caccacccc	agctagcgg	120
	ggggggcgaa	gcggcgagg	gggagactcc	gaaaggcatt	tcgtgttcca	gttcaaggc	180
5	gagtgctact	tcaccaacgg	gacgcagcgc	atacgatctg	tggacagata	catctacaac	240
	cgggaggagt	acctgcgtt	cgacagcgc	gtggggaggt	accgcgcgt	gaccgagctg	300
	gggcggccag	accccgagta	ctacaataag	cagtactgg	agcaaacgcg	ggccgagctg	360
	gacacgacgt	gcagacacaa	ctacgagggg	gtggagaccc	acacctccct	gcggcggtt	420
	gaacagccca	atgtcgcat	ctccctgtcc	aggacagagg	ccctcaacca	ccacaacact	480
10	ctggctctgt	cagtgacaga	tttctaccca	gccaagatca	aagtgcgt	gttccggaaat	540
	ggccaggagg	agacgggtgg	ggtctcatcc	acacagctt	ttaggaatgg	ggactggacc	600
	ttccagggtcc	tggtcatgt	ggagatgacc	cctcggcggg	gagaggtcta	cacctgccc	660
	gtggagcatc	cgagcctgaa	gagcccccatt	actgtggagt	ggactagtgg	tggcgggtgg	720
	agcggcggtg	gtgggtccgg	tggcggcggt	tctggcggt	gcccgttcc	gagtgaagac	780
15	gacattgagg	ccgaccacgt	aggcgtctat	ggtacaactg	tatatcagtc	tcctggagac	840
	attggccagt	acacacatga	atttgatggt	gatgagtgg	tctatgtgga	cttggataag	900
	aaggagacta	tctggatgt	tcctgagttt	ggccaattga	caagcttga	cccccaaggt	960
	ggactgcaaa	acatagctac	agaaaaatac	accttggaa	tcttactaa	gaggtcaaat	1020
	tccacccca	ctaccaatga	ggctcctcaa	gctactgt	tcccaagtc	ccctgtgt	1080
20	ctgggtcagc	ccaacaccc	catctgttt	gtggacaçaca	tcttccctcc	tgtatcaac	1140
	atcacatggc	tcagaaatag	taagtcagtc	acagacggcg	tttatgagac	cagcttcctt	1200
	gtcaaccgtg	accattccctt	ccacaagctg	tcttattctca	ccttcatccc	ttctgacgt	1260
	gatattttatg	actgcaaggt	ggagcactgg	ggcctggagg	agccggttct	gaaacactgg	1320
	gctagcggag	ggggcggaaag	cggcggagga	agcttagcca	aaacgacacc	cccatctgtc	1380
25	tatccactgg	cccctggatc	tgctgccccaa	actaactcca	tggtgaccct	ggatgcctg	1440
	gtcaagggct	atttccctga	gccagtgaca	gtgacctgga	actctggatc	cctgtccagc	1500
	ggtgtgcaca	ccttcccagc	tgtcctgca	tctgacctct	acactctgag	cagctcagt	1560
	actgtccccct	ccagcacctg	gccagcgcag	accgtcacct	gcaacgttgc	ccacccggcc	1620
	agcagcacca	aggtggacaa	gaaaattgtg	cccaggatt	gtgggtgtaa	gccttgata	1680
30	tgtacagtcc	cagaagtatc	atctgtttc	atctcccccc	caaagcccaa	ggatgtgctc	1740
	accattactc	tgactcctaa	ggtcacgtgt	gttgtggtag	acatcagcaa	ggatgatccc	1800
	gaggttccagt	tcagctgtt	tgttagatgt	gtggaggtgc	acacagotca	gacgcaaccc	1860
	cgggaggaggc	agttcaacag	cacttccgc	tcagtcagtg	aaactcccat	catgcaccag	1920
	gactggctca	atggcaagga	gttcaaatgc	agggtcaaca	gtgcagctt	ccctgcccccc	1980
35	atcgagaaaa	ccatctccaa	aaccaaaggc	agaccgaagg	ctccacaggt	gtacaccatt	2040
	ccaccccca	aggagcagat	ggccaaggat	aaagtcaagtc	tgacctgcat	gataacagac	2100
	ttcttccctg	aagacattac	tgtggagtgg	cagtggaaatg	ggcagccagc	ggagaactac	2160
	aagaacactc	agcccatcat	ggacacagat	ggctcttact	tctgtctacag	caagctcaat	2220
	gtgcagaaga	gcaactggga	ggcaggaaat	acttccaccc	gctctgtt	acatgaggc	2280
	ctgcacaacc	accatactga	gaagagcctc	tcccactctc	ctggtaaaatg	atctggtacc	2340
40	tgc						2343

&lt;210&gt; IASMBP 1-14 CH1.CH2.CH3

&lt;211&gt; 679

45 <212> PRT--  
<213> murine

Met	Glu	Thr	Asp	Thr	Lle	Lle	Lle	Trp	Val	Lle	Lle	Trp	Val	Pro
					5				10				15	

50	Gly	Ser	Thr	Gly	Asp	Met	Ala	Ser	Gln	Lys	Arg	Pro	Ser	Gln	Arg	His
					20				25				30			

55	Gly	Ser	Lys	Ala	Ser	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Asp	Ser		
					35			40				45				

Glu	Arg	His	Phe	Val	Phe	Gln	Phe	Lys	Gly	Glu	Cys	Tyr	Phe	Thr	Asn
					50			55			60				

96

Gly Thr Gln Arg Ile Arg Ser Val Asp Arg Tyr Ile Tyr Asn Arg Glu  
 65                   70                   75                   80

5       Glu Tyr Leu Arg Phe Asp Ser Asp Val Gly Glu Tyr Arg Ala Val Thr  
       85                   90                   95

  Glu Leu Gly Arg Pro Asp Pro Glu Tyr Tyr Asn Lys Gln Tyr Leu Glu  
 100                   105                   110

10      Gln Thr Arg Ala Glu Leu Asp Thr Val Cys Arg His Asn Tyr Glu Gly  
       115                   120                   125

  Val Glu Thr His Thr Ser Leu Arg Arg Leu Glu Gln Pro Asn Val Val  
 130                   135                   140

15      Ile Ser Leu Ser Arg Thr Glu Ala Leu Asn His His Asn Thr Leu Val  
       145                   150                   155                   160

20      Cys Ser Val Thr Asp Phe Tyr Pro Ala Lys Ile Lys Val Arg Trp Phe  
       165                   170                   175

  Arg Asn Gly Gln Glu Glu Thr Val Gly Val Ser Ser Thr Gln Leu Ile  
 180                   185                   190

25      Arg Asn Gly Asp Trp Thr Phe Gln Val Leu Val Met Leu Glu Met Thr  
       195                   200                   205

  Pro Arg Arg Gly Glu Val Tyr Thr Cys His Val Glu His Pro Ser Leu  
 210                   215                   220

30      Lys Ser Pro Ile Thr Val Glu Trp Thr Ser Gly Gly Gly Ser Gly  
       225                   230                   235                   240

35      Gly Gly Gly Ser Gly Gly Ser Gly Gly Gly Ser Ser Ser  
       245                   250                   255

  Glu Asp Asp Ile Glu Ala Asp His Val Gly Val Tyr Gly Thr Thr Val  
 260                   265                   270

40      Tyr Gln Ser Pro Gly Asp Ile Gly Gln Tyr Thr His Glu Phe Asp Gly  
       275                   280                   285

  Asp Glu Trp Phe Tyr Val Asp Leu Asp Lys Lys Glu Thr Ile Trp Met  
 290                   295                   300

45      Leu Pro Glu Phe Gly Gln Leu Thr Ser Phe Asp Pro Gln Gly Gly Leu  
       305                   310                   315                   320

50      Gln Asn Ile Ala Thr Gly Lys Tyr Thr Leu Gly Ile Leu Thr Lys Arg  
       325                   330                   335

  Ser Asn Ser Thr Pro Ala Thr Asn Glu Ala Pro Gln Ala Thr Val Phe  
 340                   345                   350

55      Pro Lys Ser Pro Val Leu Leu Gly Gln Pro Asn Thr Leu Ile Cys Phe  
       355                   360                   365

  Val Asp Asn Ile Phe Pro Pro Val Ile Asn Ile Thr Trp Leu Arg Asn  
 370                   375                   380

Ser Lys Ser Val Thr Asp Gly Val Tyr Glu Thr Ser Phe Leu Val Asn  
 385 390 395 400

5 Arg Asp His Ser Phe His Lys Leu Ser Tyr Leu Thr Phe Ile Pro Ser  
 405 410 415

Asp Asp Asp Ile Tyr Asp Cys Lys Val Glu His Trp Gly Leu Glu Glu  
 420 425 430

10 Pro Val Leu Lys His Trp Ala Ser Gly Gly Gly Ser Gly Gly Gly  
 435 440 445

Gly Ala Lys Thr Thr Pro Pro Ser Val Tyr Pro Leu Ala Pro Gly Cys  
 15 450 455 460

Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly Cys Leu Val Lys Gly  
 465 470 475 480

20 Tyr Phe Pro Glu Ser Val Thr Val Thr Trp Asn Ser Gly Ser Leu Ser  
 485 490 495

Ser Ser Val His Thr Phe Pro Ala Leu Leu Gln Ser Gly Leu Tyr Thr  
 500 505 510

25 Met Ser Ser Ser Val Thr Val Pro Ser Ser Thr Trp Pro Ser Gln Thr  
 515 520 525

Val Thr Cys Ser Val Ala His Pro Ala Ser Ser Thr Thr Val Asp Lys  
 30 530 535 540

Lys Leu Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Cys Pro Pro  
 545 550 555 560

35 Cys Lys Glu Cys His Lys Cys Pro Ala Pro Asn Leu Glu Gly Pro  
 565 570 575

Ser Val Phe Ile Phe Pro Pro Asn Ile Lys Asp Val Leu Met Ile Ser  
 580 585 590

40 Leu Thr Pro Lys Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp  
 595 600 605

Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr  
 45 610 615 620

Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Ile Arg Val  
 625 630 635 640

50 Val Ser Thr Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu  
 645 650 655

Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ser Pro Ile Glu Arg  
 660 665 670

55 Thr Ile Ser Lys Ile Lys  
 675

98

&lt;210&gt; IAS MBP 1-14 CH1.H

&lt;211&gt; 677

&lt;212&gt; PRT--

&lt;213&gt; murine

5

Met	Glu	Thr	Asp	Thr	Leu	Leu	Leu	Trp	Val	Leu	Leu	Leu	Trp	Val	Pro
					5				10					15	

Gly	Ser	Thr	Gly	Asp	Phe	Lys	Asn	Ile	Val	Thr	Pro	Arg	Thr	Pro	Pro
					20				25			30			

Pro	Ala	Ser	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Asp	Ser	Glu	Arg		
					35			40			45				

15	His	Phe	Val	Phe	Gln	Phe	Lys	Gly	Glu	Cys	Tyr	Phe	Thr	Asn	Gly	Thr
					50				55			60				

Gln	Arg	Ile	Arg	Ser	Val	Asp	Arg	Tyr	Ile	Tyr	Asn	Arg	Glu	Glu	Tyr
					65			70			75			80	

20	Leu	Arg	Phe	Asp	Ser	Asp	Val	Gly	Glu	Tyr	Arg	Ala	Val	Thr	Glu	Leu
					85				90			95				

25	Gly	Arg	Pro	Asp	Pro	Glu	Tyr	Tyr	Asn	Lys	Gln	Tyr	Leu	Glu	Gln	Thr
					100				105			110				

Arg	Ala	Glu	Leu	Asp	Thr	Val	Cys	Arg	His	Asn	Tyr	Glu	Gly	Val	Glu	
					115			120			125					

30	Thr	His	Thr	Ser	Leu	Arg	Arg	Leu	Glu	Gln	Pro	Asn	Val	Val	Ile	Ser
					130			135			140					

Leu	Ser	Arg	Thr	Glu	Ala	Leu	Asn	His	His	Asn	Thr	Leu	Val	Cys	Ser
					145			150			155			160	

35	Val	Thr	Asp	Phe	Tyr	Pro	Ala	Lys	Ile	Lys	Val	Arg	Trp	Phe	Arg	Asn
					165				170			175				

40	Gly	Gln	Glu	Glu	Thr	Val	Gly	Val	Ser	Ser	Thr	Gln	Leu	Ile	Arg	Asn
					180			185			190					

Gly	Asp	Trp	Thr	Phe	Gln	Val	Leu	Val	Met	Leu	Glu	Met	Thr	Pro	Arg
					195			200			205				

45	Arg	Gly	Glu	Val	Tyr	Thr	Cys	His	Val	Glu	His	Pro	Ser	Leu	Lys	Ser
					210			215			220					

Pro	Ile	Thr	Val	Glu	Trp	Thr	Ser	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly
					225			230			235			240	

50	Gly	Ser	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Ser	Ser	Ser	Ser	Glu	Asp
					245			250					255		

55	Asp	Ile	Glu	Ala	Asp	His	Val	Gly	Val	Tyr	Gly	Thr	Thr	Val	Tyr	Gln
					260			265			270					

Ser	Pro	Gly	Asp	Ile	Gly	Gln	Tyr	Thr	His	Glu	Phe	Asp	Gly	Asp	Glu
					275			280			285				

99

Trp Phe Tyr Val Asp Leu Asp Lys Lys Glu Thr Ile Trp Met Leu Pro  
 290 295 300  
 Glu Phe Gly Gln Leu Thr Ser Phe Asp Pro Gln Gly Gly Leu Gln Asn  
 5 305 310 315 320  
 Ile Ala Thr Gly Lys Tyr Thr Leu Gly Ile Leu Thr Lys Arg Ser Asn  
 325 330 335  
 10 Ser Thr Pro Ala Thr Asn Glu Ala Pro Gln Ala Thr Val Phe Pro Lys  
 340 345 350  
 Ser Pro Val Leu Leu Gly Gln Pro Asn Thr Leu Ile Cys Phe Val Asp  
 355 360 365  
 15 Asn Ile Phe Pro Pro Val Ile Asn Ile Thr Trp Leu Arg Asn Ser Lys  
 370 375 380  
 Ser Val Thr Asp Gly Val Tyr Glu Thr Ser Phe Leu Val Asn Arg Asp  
 20 385 390 395 400  
 His Ser Phe His Lys Leu Ser Tyr Leu Thr Phe Ile Pro Ser Asp Asp  
 405 410 415  
 25 Asp Ile Tyr Asp Cys Lys Val Glu His Trp Gly Leu Glu Pro Val  
 420 425 430  
 Leu Lys His Trp Ala Ser Gly Gly Ser Gly Gly Gly Ala  
 435 440 445  
 30 Lys Thr Thr Pro Pro Ser Val Tyr Pro Leu Ala Pro Gly Cys Gly Asp  
 450 455 460  
 Thr Thr Gly Ser Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe  
 35 465 470 475 480  
 Pro Glu Ser Val Thr Val Thr Trp Asn Ser Gly Ser Leu Ser Ser Ser  
 485 490 495  
 40 Val His Thr Phe Pro Ala Leu Leu Gln Ser Gly Leu Tyr Thr Met Ser  
 500 505 510  
 Ser Ser Val Thr Val Pro Ser Ser Thr Trp Pro Ser Gln Thr Val Thr  
 515 520 525  
 45 Cys Ser Val Ala His Pro Ala Ser Ser Thr Thr Val Asp Lys Lys Leu  
 530 535 540  
 Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Cys Pro Pro Cys Lys  
 50 545 550 555 560  
 Glu Cys His Lys Cys Pro Ala Pro Asn Leu Glu Gly Gly Pro Ser Val  
 565 570 575  
 55 Phe Ile Phe Pro Pro Asn Ile Lys Asp Val Leu Met Ile Ser Leu Thr  
 580 585 590  
 Pro Lys Val Thr Cys Val Val Asp Val Ser Glu Asp Asp Pro Asp  
 595 600 605

100

Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala Gln  
 610 615 620

5 Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Ile Arg Val Val Ser  
 625 630 635 640

Thr Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys  
 645 650 655

10 Cys Lys Val Asn Asn Lys Asp Leu Pro Ser Pro Ile Glu Arg Thr Ile  
 660 665 670

15 Ser Lys Ile Lys  
 675

<210> IAS MBP 90-101 CH1.H.CH2

<211> 563

20 <212> PRT--

<213> murine

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro  
 5 10 15

25 Gly Ser Thr Gly Asp Phe Lys Asn Ile Val Thr Pro Arg Thr Pro Pro  
 20 25 30

30 Pro Ala Ser Ala Ser Gly Gly Gly Ser Gly Gly Gly Asp Ser  
 35 40 45

Glu Arg His Phe Val Phe Gln Phe Lys Gly Glu Cys Tyr Phe Thr Asn  
 50 55 60

35 Gly Thr Gln Arg Ile Arg Ser Val Asp Arg Tyr Ile Tyr Asn Arg Glu  
 65 70 75 80

40 Glu Tyr Leu Arg Phe Asp Ser Asp Val Gly Glu Tyr Arg Ala Val Thr  
 85 90 95

45 Glu Leu Gly Arg Pro Asp Pro Glu Tyr Tyr Asn Lys Gln Tyr Leu Glu  
 100 105 110

Gln Thr Arg Ala Glu Leu Asp Thr Val Cys Arg His Asn Tyr Glu Gly  
 115 120 125

Val Glu Thr His Thr Ser Leu Arg Arg Leu Glu Gln Pro Asn Val Val  
 130 135 140

50 Ile Ser Leu Ser Arg Thr Glu Ala Leu Asn His His Asn Thr Leu Val  
 145 150 155 160

Cys Ser Val Thr Asp Phe Tyr Pro Ala Lys Ile Lys Val Arg Trp Phe  
 165 170 175

55 Arg Asn Gly Gln Glu Glu Thr Val Gly Val Ser Ser Thr Gln Leu Ile  
 180 185 190

Arg Asn Gly Asp Trp Thr Phe Gln Val Leu Val Met Leu Glu Met Thr

	101			
	195	200	205	
	Pro Arg Arg Gly Glu Val Tyr Thr Cys His Val Glu His Pro Ser Leu			
	210	215	220	
5	Lys Ser Pro Ile Thr Val Glu Trp Thr Ser Gly Gly Gly Ser Gly			
	225	230	235	240
	Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Ser Ser			
10	245	250	255	
	Glu Asp Asp Ile Glu Ala Asp His Val Gly Val Tyr Gly Thr Thr Val			
	260	265	270	
15	Tyr Gln Ser Pro Gly Asp Ile Gly Gln Tyr Thr His Glu Phe Asp Gly			
	275	280	285	
	Asp Glu Trp Phe Tyr Val Asp Leu Asp Lys Lys Glu Thr Ile Trp Met			
	290	295	300	
20	Leu Pro Glu Phe Gly Gln Leu Thr Ser Leu Ser Phe Asp Pro Gln Gly			
	305	310	315	320
	Gly Leu Gln Asn Ile Ala Thr Gly Lys Tyr Thr Leu Gly Ile Leu Thr			
25	325	330	335	
	Lys Arg Ser Asn Ser Thr Pro Ala Thr Asn Glu Ala Pro Gln Ala Thr			
	340	345	350	
30	Val Phe Pro Lys Ser Pro Val Leu Leu Gly Gln Pro Asn Thr Leu Ile			
	355	360	365	
	Cys Phe Val Asp Asn Ile Phe Pro Pro Val Ile Asn Ile Thr Trp Leu			
	370	375	380	
35	Arg Asn Ser Lys Ser Val Thr Asp Gly Val Tyr Glu Thr Ser Phe Leu			
	385	390	395	400
	Val Asn Arg Asp His Ser Phe His Lys Leu Ser Tyr Leu Thr Phe Ile			
40	405	410	415	
	Pro Ser Asp Asp Ile Tyr Asp Cys Lys Val Glu His Trp Gly Leu			
	420	425	430	
45	Glu Glu Pro Val Leu Lys His Trp Ala Ser Gly Gly Gly Ser Gly			
	435	440	445	
	Gly Gly Gly Ala Lys Thr Thr Pro Pro Ser Val Tyr Pro Leu Ala Pro			
	450	455	460	
50	Gly Ser Ala Ala Gln Thr Asn Ser Met Val Thr Leu Gly Cys Leu Val			
	465	470	475	480
	Lys Gly Tyr Phe Pro Glu Pro Val Thr Val Thr Trp Asn Ser Gly Ser			
55	485	490	495	
	Leu Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Asp Leu			
	500	505	510	

102

Tyr Thr Leu Ser Ser Ser Val Thr Val Pro Ser Ser Thr Trp Pro Ser  
 515 520 525

5 Glu Thr Val Thr Cys Asn Val Ala His Pro Ala Ser Ser Thr Lys Val  
 530 535 540

Asp Lys Lys Ile Val Pro Arg Asp Cys Gly Cys Lys Pro Cys Ile Cys  
 545 550 555 560

10 Thr Val

<210> IAS MBP 90-101 CH1.H

15 <211> 556

<212> PRT

<213> murine

20 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro  
 5 10 15

Gly Ser Thr Gly Asp Met Ala Ser Gln Lys Arg Pro Ser Gln Arg His  
 20 25 30

25 Gly Ser Lys Ala Ser Gly Gly Gly Ser Gly Gly Gly Asp Ser  
 35 40 45

Glu Arg His Phe Val Phe Gln Phe Lys Gly Glu Cys Tyr Phe Thr Asn  
 50 55 60

30 Gly Thr Gln Arg Ile Arg Ser Val Asp Arg Tyr Ile Tyr Asn Arg Glu  
 65 70 75 80

35 Glu Tyr Leu Arg Phe Asp Ser Asp Val Gly Glu Tyr Arg Ala Val Thr  
 85 90 95

Glu Leu Gly Arg Pro Asp Pro Glu Tyr Tyr Asn Lys Gln Tyr Leu Glu  
 100 105 110

40 Gln Thr Arg Ala Glu Leu Asp Thr Val Cys Arg His Asn Tyr Glu Gly  
 115 120 125

Val Glu Thr His Thr Ser Leu Arg Arg Leu Glu Gln Pro Asn Val Val  
 130 135 140

45 Ile Ser Leu Ser Arg Thr Glu Ala Leu Asn His His Asn Thr Leu Val  
 145 150 155 160

50 Cys Ser Val Thr Asp Phe Tyr Pro Ala Lys Ile Lys Val Arg Trp Phe  
 165 170 175

Arg Asn Gly Gln Glu Glu Thr Val Gly Val Ser Ser Thr Gln Leu Ile  
 180 185 190

55 Arg Asn Gly Asp Trp Thr Phe Gln Val Leu Val Met Leu Glu Met Thr  
 195 200 205

Pro Arg Arg Gly Glu Val Tyr Thr Cys His Val Glu His Pro Ser Leu  
 210 215 220

Lys Ser Pro Ile Thr Val Glu Trp Thr Ser Gly Gly Gly Ser Gly  
 225 230 235 240

5 Gly Gly Gly Ser Gly Gly Ser Gly Gly Ser Ser Ser Ser  
 245 250 255

Glu Asp Asp Ile Glu Ala Asp His Val Gly Val Tyr Gly Thr Thr Val  
 260 265 270

10 Tyr Gln Ser Pro Gly Asp Ile Gly Gln Tyr Thr His Glu Phe Asp Gly  
 275 280 285

Asp Glu Trp Phe Tyr Val Asp Leu Asp Lys Lys Glu Thr Ile Trp Met  
 290 295 300

Leu Pro Glu Phe Gly Gln Leu Thr Ser Phe Asp Pro Gln Gly Gly Leu  
 305 310 315 320

20 Gln Asn Ile Ala Thr Gly Lys Tyr Thr Leu Gly Ile Leu Thr Lys Arg  
 325 330 335

Ser Asn Ser Thr Pro Ala Thr Asn Glu Ala Pro Gln Ala Thr Val Phe  
 340 345 350

25 Pro Lys Ser Pro Val Leu Leu Gly Gln Pro Asn Thr Leu Ile Cys Phe  
 355 360 365

30 Val Asp Asn Ile Phe Pro Pro Val Ile Asn Ile Thr Trp Leu Arg Asn  
 370 375 380

Ser Lys Ser Val Thr Asp Gly Val Tyr Glu Thr Ser Phe Leu Val Asn  
 385 390 395 400

35 Arg Asp His Ser Phe His Lys Leu Ser Tyr Leu Thr Phe Ile Pro Ser  
 405 410 415

Asp Asp Asp Ile Tyr Asp Cys Lys Val Glu His Trp Gly Leu Glu Glu  
 420 425 430

40 Pro Val Leu Lys His Trp Ala Ser Gly Gly Ser Gly Gly Gly  
 435 440 445

45 Gly Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu  
 450 455 460

Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe  
 465 470 475 480

50 Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg  
 485 490 495

Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser  
 500 505 510

55 Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu  
 515 520 525

Arg His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser

	104			
	530	535	540	
	Pro Ile Val Lys Ser Phe Asn Arg Asn Glu Cys			
5	545	550	555	
	<210> IAS MBP 1-14 CK			
	<211> 775			
	<212> PRT			
10	<213> murine			
	Thr Met Glu Thr Asp Thr Leu Leu Leu Trp Val			
	5	10	15	
15	Pro Gly Ser Thr Gly Asp Met Ala Ser Gln Lys Arg Pro Ser Gln Arg			
	20	25	30	
	His Gly Ser Lys Ala Ser Gly Gly Gly Ser Gly Gly Gly Asp			
	35	40	45	
20	Ser Glu Arg His Phe Val Phe Gln Phe Lys Gly Glu Cys Tyr Phe Thr			
	50	55	60	
25	Asn Gly Thr Gln Arg Ile Arg Ser Val Asp Arg Tyr Ile Tyr Asn Arg			
	65	70	75	80
	Glu Glu Tyr Leu Arg Phe Asp Ser Asp Val Gly Glu Tyr Arg Ala Val			
	85	90	95	
30	Thr Glu Leu Gly Arg Pro Asp Pro Glu Tyr Tyr Asn Lys Gln Tyr Leu			
	100	105	110	
	Glu Gln Thr Arg Ala Glu Leu Asp Thr Val Cys Arg His Asn Tyr Glu			
	115	120	125	
35	Gly Val Glu Thr His Thr Ser Leu Arg Arg Leu Glu Gln Pro Asn Val			
	130	135	140	
40	Val Ile Ser Leu Ser Arg Thr Glu Ala Leu Asn His His Asn Thr Leu			
	145	150	155	160
	Val Cys Ser Val Thr Asp Phe Tyr Pro Ala Lys Ile Lys Val Arg Trp			
	165	170	175	
45	Phe Arg Asn Gly Gln Glu Glu Thr Val Gly Val Ser Ser Thr Gln Leu			
	180	185	190	
	Ile Arg Asn Gly Asp Trp Thr Phe Gln Val Leu Val Met Leu Glu Met			
	195	200	205	
50	Thr Pro Arg Arg Gly Glu Val Tyr Thr Cys His Val Glu His Pro Ser			
	210	215	220	
	Leu Lys Ser Pro Ile Thr Val Glu Trp Thr Ser Gly Gly Gly Ser			
55	225	230	235	240
	Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Ser			
	245	250	255	

105

	Ser	Glu	Asp	Asp	Ile	Glu	Ala	Asp	His	Val	Gly	Val	Tyr	Gly	Thr	Thr	
										260	265				270		
5		Val	Tyr	Gln	Ser	Pro	Gly	Asp	Ile	Gly	Gln	Tyr	Thr	His	Glu	Phe	Asp
																285	
										275	280						
		Gly	Asp	Glu	Trp	Phe	Tyr	Val	Asp	Leu	Asp	Lys	Lys	Glu	Thr	Ile	Trp
										290	295			300			
10		Met	Leu	Pro	Glu	Phe	Gly	Gln	Leu	Thr	Ser	Phe	Asp	Pro	Gln	Gly	Gly
																320	
										305	310			315			
		Leu	Gln	Asn	Ile	Ala	Thr	Gly	Lys	Tyr	Thr	Leu	Gly	Ile	Leu	Thr	Lys
																335	
										325			330				
15		Arg	Ser	Asn	Ser	Thr	Pro	Ala	Thr	Asn	Glu	Ala	Pro	Gln	Ala	Thr	Val
																350	
										340			345				
		Phe	Pro	Lys	Ser	Pro	Val	Leu	Leu	Gly	Gln	Pro	Asn	Thr	Leu	Ile	Cys
20																	
										355			360			365	
		Phe	Val	Asp	Asn	Ile	Phe	Pro	Pro	Val	Ile	Asn	Ile	Thr	Trp	Leu	Arg
																380	
										370			375				
25		Asn	Ser	Lys	Ser	Val	Thr	Asp	Gly	Val	Tyr	Glu	Thr	Ser	Phe	Leu	Val
																400	
										385			390				
		Asn	Arg	Asp	His	Ser	Phe	His	Lys	Leu	Ser	Tyr	Leu	Thr	Phe	Ile	Pro
																415	
										405			410				
30		Ser	Asp	Asp	Asp	Ile	Tyr	Asp	Cys	Lys	Val	Glu	His	Trp	Gly	Leu	Glu
																430	
										420			425				
		Glu	Pro	Val	Leu	Lys	His	Trp	Ala	Ser	Gly	Gly	Gly	Ser	Gly	Gly	
35																445	
										435			440				
		Gly	Gly	Ala	Lys	Thr	Thr	Pro	Pro	Ser	Val	Tyr	Pro	Leu	Ala	Pro	Gly
																460	
										450			455				
40		Ser	Ala	Ala	Gln	Thr	Asn	Ser	Met	Val	Thr	Leu	Gly	Cys	Leu	Val	Lys
																480	
										465			470				
		Gly	Tyr	Phe	Pro	Glu	Pro	Val	Thr	Val	Thr	Trp	Asn	Ser	Gly	Ser	Leu
																495	
										485			490				
45		Ser	Ser	Gly	Val	His	Thr	Phe	Pro	Ala	Val	Leu	Gln	Ser	Asp	Leu	Tyr
																510	
										500			505				
		Thr	Leu	Ser	Ser	Ser	Val	Thr	Val	Pro	Ser	Ser	Thr	Trp	Pro	Ser	Glu
50																525	
										515			520				
		Thr	Val	Thr	Cys	Asn	Val	Ala	His	Pro	Ala	Ser	Ser	Thr	Lys	Val	Asp
																540	
										530			535				
55		Lys	Lys	Ile	Val	Pro	Arg	Asp	Cys	Gly	Cys	Lys	Pro	Cys	Ile	Cys	Thr
																560	
										545			550				
		Val	Pro	Glu	Val	Ser	Ser	Val	Phe	Ile	Phe	Pro	Pro	Lys	Pro	Lys	Asp
																575	
										565			570				

106

Val Leu Thr Ile Thr Leu Thr Pro Lys Val Thr Cys Val Val Val Asp  
 580 585 590

5 Ile Ser Lys Asp Asp Pro Glu Val Gln Phe Ser Trp Phe Val Asp Asp  
 595 600 605

Val Glu Val His Thr Ala Gln Thr Gln Pro Arg Glu Glu Gln Phe Asn  
 610 615 620

10 Ser Thr Phe Arg Ser Val Ser Glu Leu Pro Ile Met His Gln Asp Trp  
 625 630 635 640

Leu Asn Gly Lys Glu Phe Lys Cys Arg Val Asn Ser Ala Ala Phe Pro  
 15 645 650 655

Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Arg Pro Lys Ala  
 660 665 670

20 Pro Gln Val Tyr Thr Ile Pro Pro Pro Lys Glu Gln Met Ala Lys Asp  
 675 680 685

Lys Val Ser Leu Thr Cys Met Ile Thr Asp Phe Phe Pro Glu Asp Ile  
 690 695 700

25 Thr Val Glu Trp Gln Trp Asn Gly Gln Pro Ala Glu Asn Tyr Lys Asn  
 705 710 715 720

Thr Gln Pro Ile Met Asp Thr Asp Gly Ser Tyr Phe Val Tyr Ser Lys  
 30 725 730 735

Leu Asn Val Gln Lys Ser Asn Trp Glu Ala Gly Asn Thr Phe Thr Cys  
 740 745 750

35 Ser Val Leu His Glu Gly Leu His Asn His His Thr Glu Lys Ser Leu  
 755 760 765

Ser His Ser Pro Gly Lys  
 770

40 <210> IAS MBP 1-14 CH1.H.CH2  
 <211> 561  
 <212> PRT  
 45 <213> murine

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro  
 5 10 15

50 Gly Ser Thr Gly Asp Met Ala Ser Gln Lys Arg Pro Ser Gln Arg His  
 20 25 30

Gly Ser Lys Ala Ser Gly Gly Ser Gly Gly Gly Gly Asp Ser  
 35 40 45

55 Glu Arg His Phe Val Phe Gln Phe Lys Gly Glu Cys Tyr Phe Thr Asn  
 50 55 60

Gly Thr Gln Arg Ile Arg Ser Val Asp Arg Tyr Ile Tyr Asn Arg Glu

	107			
	65	70	75	80
	Glu Tyr Leu Arg Phe Asp Ser Asp Val Gly Glu Tyr Arg Ala Val Thr			
	85		90	95
5	Glu Leu Gly Arg Pro Asp Pro Glu Tyr Tyr Asn Lys Gln Tyr Leu Glu			
	100		105	110
10	Gln Thr Arg Ala Glu Leu Asp Thr Val Cys Arg His Asn Tyr Glu Gly			
	115		120	125
	Val Glu Thr His Thr Ser Leu Arg Arg Leu Glu Gln Pro Asn Val Val			
	130		135	140
15	Ile Ser Leu Ser Arg Thr Glu Ala Leu Asn His His Asn Thr Leu Val			
	145		150	155
	Cys Ser Val Thr Asp Phe Tyr Pro Ala Lys Ile Lys Val Arg Trp Phe			
	165		170	175
20	Arg Asn Gly Gln Glu Glu Thr Val Gly Val Ser Ser Thr Gln Leu Ile			
	180		185	190
25	Arg Asn Gly Asp Trp Thr Phe Gln Val Leu Val Met Leu Glu Met Thr			
	195		200	205
	Pro Arg Arg Gly Glu Val Tyr Thr Cys His Val Glu His Pro Ser Leu			
	210		215	220
30	Lys Ser Pro Ile Thr Val Glu Trp Thr Ser Gly Gly Gly Ser Gly			
	225		230	235
	Gly Gly Ser Gly Gly Ser Gly Gly Gly Ser Ser Ser			
	245		250	255
35	Glu Asp Asp Ile Glu Ala Asp His Val Gly Val Tyr Gly Thr Thr Val			
	260		265	270
	Tyr Gln Ser Pro Gly Asp Ile Gly Gln Tyr Thr His Glu Phe Asp Gly			
40	275		280	285
	Asp Glu Trp Phe Tyr Val Asp Leu Asp Lys Lys Glu Thr Ile Trp Met			
	290		295	300
45	Leu Pro Glu Phe Gly Gln Leu Thr Ser Phe Asp Pro Gln Gly Gly Leu			
	305		310	315
	Gln Asn Ile Ala Thr Gly Lys Tyr Thr Leu Gly Ile Leu Thr Lys Arg			
	325		330	335
50	Ser Asn Ser Thr Pro Ala Thr Asn Glu Ala Pro Gln Ala Thr Val Phe			
	340		345	350
	Pro Lys Ser Pro Val Leu Leu Gly Gln Pro Asn Thr Leu Ile Cys Phe			
55	355		360	365
	Val Asp Asn Ile Phe Pro Pro Val Ile Asn Ile Thr Trp Leu Arg Asn			
	370		375	380

108

Ser Lys Ser Val Thr Asp Gly Val Tyr Glu Thr Ser Phe Leu Val Asn  
 385 390 395 400

5 Arg Asp His Ser Phe His Lys Leu Ser Tyr Leu Thr Phe Ile Pro Ser  
 405 410 415

Asp Asp Asp Ile Tyr Asp Cys Lys Val Glu His Trp Gly Leu Glu Glu  
 420 425 430

10 Pro Val Leu Lys His Trp Ala Ser Gly Gly Gly Ser Gly Gly Gly  
 435 440 445

Gly Ala Lys Thr Thr Pro Pro Ser Val Tyr Pro Leu Ala Pro Gly Ser  
 450 455 460

15 Ala Ala Gln Thr Asn Ser Met Val Thr Leu Gly Cys Leu Val Lys Gly  
 465 470 475 480

20 Tyr Phe Pro Glu Pro Val Thr Val Thr Trp Asn Ser Gly Ser Leu Ser  
 485 490 495

Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr  
 500 505 510

25 Leu Ser Ser Val Thr Val Pro Ser Ser Thr Trp Pro Ser Glu Thr  
 515 520 525

Val Thr Cys Asn Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys  
 530 535 540

30 Lys Ile Val Pro Arg Asp Cys Gly Cys Lys Pro Cys Ile Cys Thr Val  
 545 550 555 560

35 <210> IAS MBP 90-101 CH1.H.CH2.CH3  
 <211> 773  
 <212> PRT  
 <213> murine

40 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro  
 5 10 15

Gly Ser Thr Gly Asp Phe Lys Asn Ile Val Thr Pro Arg Thr Pro Pro  
 20 25 30

45 Pro Ala Ser Gly Gly Ser Gly Gly Gly Asp Ser Glu Arg  
 35 40 45

50 His Phe Val Phe Gln Phe Lys Gly Glu Cys Tyr Phe Thr Asn Gly Thr  
 50 55 60

Gln Arg Ile Arg Ser Val Asp Arg Tyr Ile Tyr Asn Arg Glu Glu Tyr  
 65 70 75 80

55 Leu Arg Phe Asp Ser Asp Val Gly Glu Tyr Arg Ala Val Thr Glu Leu  
 85 90 95

Gly Arg Pro Asp Pro Glu Tyr Tyr Asn Lys Gln Tyr Leu Glu Gln Thr  
 100 105 110

109

Arg Ala Glu Leu Asp Thr Thr Cys Arg His Asn Tyr Glu Gly Val Glu  
 115 120 125

5 Thr His Thr Ser Leu Arg Arg Leu Glu Gln Pro Asn Val Val Ile Ser  
 130 135 140

Leu Ser Arg Thr Glu Ala Leu Asn His His Asn Thr Leu Val Cys Ser  
 145 150 155 160

10 Val Thr Asp Phe Tyr Pro Ala Lys Ile Lys Val Arg Trp Phe Arg Asn  
 165 170 175

Gly Gln Glu Glu Thr Val Gly Val Ser Ser Thr Gln Leu Ile Arg Asn  
 15 180 185 190

Gly Asp Trp Thr Phe Gln Val Leu Val Met Leu Glu Met Thr Pro Arg  
 195 200 205

20 Arg Gly Glu Val Tyr Thr Cys His Val Glu His Pro Ser Leu Lys Ser  
 210 215 220

Pro Ile Thr Val Glu Trp Thr Ser Gly Gly Gly Ser Gly Gly Gly  
 225 230 235 240

25 Gly Ser Gly Gly Ser Gly Gly Ser Ser Ser Glu Asp  
 245 250 255

Asp Ile Glu Ala Asp His Val Gly Val Tyr Gly Thr Thr Val Tyr Gln  
 30 260 265 270

Ser Pro Gly Asp Ile Gly Gln Tyr Thr His Glu Phe Asp Gly Asp Glu  
 275 280 285

35 Trp Phe Tyr Val Asp Leu Asp Lys Lys Glu Thr Ile Trp Met Leu Pro  
 290 295 300

Glu Phe Gly Gln Leu Thr Ser Phe Asp Pro Gln Gly Gly Leu Gln Asn  
 305 310 315 320

40 Ile Ala Thr Gly Lys Tyr Thr Leu Gly Ile Leu Thr Lys Arg Ser Asn  
 325 330 335

Ser Thr Pro Ala Thr Asn Glu Ala Pro Gln Ala Thr Val Phe Pro Lys  
 45 340 345 350

Ser Pro Val Leu Leu Gly Gln Pro Asn Thr Leu Ile Cys Phe Val Asp  
 355 360 365

50 Asn Ile Phe Pro Pro Val Ile Asn Ile Thr Trp Leu Arg Asn Ser Lys  
 370 375 380

Ser Val Thr Asp Gly Val Tyr Glu Thr Ser Phe Leu Val Asn Arg Asp  
 385 390 395 400

55 His Ser Phe His Lys Leu Ser Tyr Leu Thr Phe Ile Pro Ser Asp Asp  
 405 410 415

Asp Ile Tyr Asp Cys Lys Val Glu His Trp Gly Leu Glu Pro Val

		110		
	420		425	430
	Leu Lys His Trp Ala Ser Gly Gly Gly Gly Ser Gly Gly Ser Leu			
	435		440	445
5	Ala Lys Thr Thr Pro Pro Ser Val Tyr Pro Leu Ala Pro Gly Ser Ala			
	450		455	460
	Ala Gln Thr Asn Ser Met Val Thr Leu Gly Cys Leu Val Lys Gly Tyr			
10	465		470	475
	Phe Pro Glu Pro Val Thr Val Thr Trp Asn Ser Gly Ser Leu Ser Ser			
	485		490	495
15	Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu			
	500		505	510
	Ser Ser Ser Val Thr Val Pro Ser Ser Thr Trp Pro Ser Glu Thr Val			
	515		520	525
20	Thr Cys Asn Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys			
	530		535	540
	Ile Val Pro Arg Asp Cys Gly Cys Lys Pro Cys Ile Cys Thr Val Pro			
25	545		550	555
	Glu Val Ser Ser Val Phe Ile Phe Pro Pro Lys Pro Lys Asp Val Leu			
	565		570	575
30	Thr Ile Thr Leu Thr Pro Lys Val Thr Cys Val Val Val Asp Ile Ser			
	580		585	590
	Lys Asp Asp Pro Glu Val Gln Phe Ser Trp Phe Val Asp Asp Val Glu			
	595		600	605
35	Val His Thr Ala Gln Thr Gln Pro Arg Glu Glu Gln Phe Asn Ser Thr			
	610		615	620
	Phe Arg Ser Val Ser Glu Leu Pro Ile Met His Gln Asp Trp Leu Asn			
40	625		630	635
	Gly Lys Glu Phe Lys Cys Arg Val Asn Ser Ala Ala Phe Pro Ala Pro			
	645		650	655
45	Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Arg Pro Lys Ala Pro Gln			
	660		665	670
	Val Tyr Thr Ile Pro Pro Pro Lys Glu Gln Met Ala Lys Asp Lys Val			
	675		680	685
50	Ser Leu Thr Cys Met Ile Thr Asp Phe Phe Pro Glu Asp Ile Thr Val			
	690		695	700
	Glu Trp Gln Trp Asn Gly Gln Pro Ala Glu Asn Tyr Lys Asn Thr Gln			
55	705		710	715
	Pro Ile Met Asp Thr Asp Gly Ser Tyr Phe Val Tyr Ser Lys Leu Asn			
	725		730	735

111

Val Gln Lys Ser Asn Trp Glu Ala Gly Asn Thr Phe Thr Cys Ser Val  
740 745 750

5      Leu His Glu Gly Leu His Asn His His Thr Glu Lys Ser Leu Ser His  
       755                  760                  765

Ser Pro Gly Lys  
770

10 <210> pCRC203  
<211> 609  
<212> DNA  
<213> Murine

<210> pCRC201  
<211> 614  
30 <212> DNA  
<213> Murine

```

<400> 2
catatgttca agaacattgt gacacctcgaa caccaccctc caggaggagg atccggagac 60
tcggaaaaggc attcgtgtt ccagttcaag ggcgagtgtct acttcaccaa cgggacgcag 120
cgcataacgat ctgtggacag atacatctac aaccgggagg agtacctgcg cttgcacagc 180
gacgtggcg agtaccgcgc ggtgaccgag ctggggcgcc cagaccccga gtactacaat 240
aagcagtacc tggagcaaac gcggggccgag ctggacacgg tgtcagaca caactacgag 300
ggggtgtggaga cccacacccctc cctggggcggtt cttggaggtt aagacgcacat tgaggccgac 360
cacgttaggcg ttatggtac aactgtat cagtctcttg gagacattgg ccagtacaca 420
catgaatttg atggtgatga gtggttctat gtggacttgg ataagaagga gactatctgg 480
atgcttcctg agtttggcca attgacaagc tttgaccccc aaggtggact gcaaaacata 540
gctacaggaa aatacacacccctt ggaaatcttg actaagaggt caaattccac cccagctacc 600
aattaagcgg ccgc                                              614

```

45 <210> pCRC19  
<211> 642  
<212> DNA  
<213> Murine

```
<400> 3
catatgttca agaacattgt gacacctcgaa acaccaccc cagctagcgg agggggcggaa 60
agcggcggagg ggggagactc cgaaaaggcat ttcgtgttcc agtttaaagg cgagtgtac 120
ttcaccaacg ggacgcagcg catacgatct gtggacagat acatctacaa ccggggaggag 180
tacctgcgct tcgacagcga cgtggcgag taccgcgcgg tgaccgagct gggggcggcca 240
gaccccgagt actacaataa gcagtacctg gagcaaacgc gggccgagct ggacacggtg 300
tgcagacaca actacgaggg ggtggagacc cacacacctcc tgcggcggtct tactagtgg 360
ggcggtgttca gcgaaagacgaa cattgaggcc gaccacgttag cgtcttatgg tacaactgtaa 420
tatcaqtctc ctqqaqacat tqqccaqtac acacatgaat ttgatggtga tgagtggttc 480
```

112

tatgtggact tggataagaa ggagactatc tggatgcttc ctgagtttg ccaattgaca 540  
 agctttgacc cccaagggtgg actgcaaaaac atagctacag gaaaatacac cttggaaatc 600  
 ttgactaaga ggtcaaattc cacccagct accaatctcg ag 642

5 <210> pCRC197  
 <211> 647  
 <212> DNA  
 <213> Murine

10 <400> 4  
 catatgttca agaacattgt gacacctcg aacaccaccc cagctagccg agggggcgg 60  
 agcggcggag ggggagactc cgaaaggcat ttcgtttcc agtttaagg cgagtgtac 120  
 ttcaccaacg ggacgcagcg catacgatct gtggacagat acatctacaa ccgggaggag 180  
 tacctgcgtc tcgacagcga cgtggcggag taccgcgcgg tgaccgagct gggcggcca 240  
 15 gaccccgagt actacaataa gcagtacactg gagcaaaacgc gggccgagct ggacacgggt 300  
 tgcagacaca actacgaggg ggtggagacc cacacccccc tgccggcggt tactagtgt 360  
 ggcgggtggca gcbaagacga cattgaggcc gaccacgtg gctgttatgg tacaactgt 420  
 tatcagtctc ctggagacat tggccagtagtac acacatgaat ttgatggta tgagtggttc 480  
 tatgtggact tggataagaa ggagactatc tggatgcttc ctgagtttg ccaattgaca 540  
 20 agctttgacc cccaagggtgg actgcaaaaac atagctacag gaaaatacac cttggaaatc 600  
 ttgactaaga ggtcaaattc cacccagct accaattaag cggccgc 647

<210> pCRC188  
 <211> 1698  
 25 <212> DNA  
 <213> Murine

<400> 5  
 30 gcggccgcca ccatggctct gcagatcccc agcctcctcc tctcggctgc tgtgggtgg 60  
 ctgatggtgc tgagcagccc aggacttag ggcttaaga acattgtgac acctcgaaca 120  
 ccacccctccag ctagcggagg gggcggaaagc ggccgggggg gagaactccga aaggcatttc 180  
 gtgttccagt tcaagggcga gtgtacttc accaacggga cgcagcgcac acgatctgt 240  
 gacagataca tctacaaccc ggaggagtagtac ctgcgttccg acagcgcacgt gggcgagtagt 300  
 cgcgcgtga ccgagctggg gcccggccagac cccgagtagt actaataagca gtacactggag 360  
 35 caaacgcggg ccgagctgga cacgggtgtc agacacaact acgagggggt ggagacccac 420  
 acctccctgc ggcggcttga acagcccaat gtcgtcatct ccctgtccag gacagaggcc 480  
 ctcaaccacc acaacactct ggtctgtca gtgacagatt tctaccacca caagatcaaa 540  
 gtgcgttgtt tccggaatgg ccaggaggag acgggtgggg tctcatccac acagcttatt 600  
 40 aggaatgggg actggacattt ccaggtcctg gtcgtactgg agatgacccc tcggcgggg 660  
 gaggtctaca cctgccacgt ggagcatccg agcctgaaga gcccacatcac tgtggagtgg 720  
 actagtggtg gcggtggcag cggcgggtgg gttccgggtg gccgcgggtc tggcgggtggc 780  
 ggttccctcga gtgaagacga cattgaggcc gaccacgtg gctgttatgg tacaactgt 840  
 tatcagtctc ctggagacat tggccagtagtac acacatgaat ttgatggta tgagtggttc 900  
 tatgtggact tggataagaa ggagactatc tggatgcttc ctgagtttg ccaattgaca 960  
 45 agctttgacc cccaagggtgg actgcaaaaac atagctacag gaaaatacac cttggaaatc 1020  
 ttgactaaga ggtcaaattc cacccagct accaattgagg ctccctcaagc gactgtgttc 1080  
 cccaaatccc ctgtgtctgc gggcagccc aacaccctca tctgctttgt ggacaacatc 1140  
 ttccctccctg tgatcaacat cacatggctc agaaaatagta agtcagtcac agacggcggt 1200  
 tatgagacca gttcccttgt caaccgtgac cattccctcc acaagctgtc ttatctcacc 1260  
 50 ttcatccctt ctgacgtga tatttatgac tgcaagggtgg agcactgggg cctggaggag 1320  
 ccgggtctga aacactgggc tagcggagggg ggcggaaagcg gcgggggggg agctgatgt 1380  
 gcaccaactg tatccatctt cccaccatcc agtgagcagt taacatctgg aggtgcctca 1440  
 gtcgtgtgtc tcttgaacaa ctttacccca aaagacatca atgtcaagtg gaagattgt 1500  
 55 ggcagtgaac gacaaaatgg cgtcctgaac agttggactg atcaggacag caaagacacg 1560  
 acctacagca tgagcagcac cctcacgttg accaaggacg agtatgaacg acataacacg 1620  
 tataacctgtg aggccactca caagacatca acttcaccca ttgtcaagag cttcaacagg 1680  
 aatgagtgtt agggtacc 1698

<210> pCRC187

&lt;211&gt; 1662

&lt;212&gt; DNA

&lt;213&gt; Murine

5 <400> 6  
 gcggccgcca ccatggctct gcagatcccc agcctoctcc tctcggtgc tgggtggtg 60  
 ctgatggtgc tgagcagccc aggactgag ggcgctagcg gagggggcgg aagccgcgg 120  
 gggggagact ccgaaaaggca tticgtgtc cagttcaagg gcgagtgcata cttcaccaac 180  
 gggacgcagc gcatacgcatt tggacaga tacatctaca accgggagga gtacctgcgc 240  
 10 ttcgcacagcg acgtggcga gtaccgcgcg gtgaccgagc tggggcggcc agaccccgag 300  
 tactacaata agcagtaacct ggagcaaacg cggggccgagc tggacacgggt gtgcagacac 360  
 aactacgagg gggtgagac ccacacctcc ctgcggcgc ttgaacaggg caatgtcgtc 420  
 atctccctgt ccaggacaga ggcctcaac caccacaaca ctctggtctg ctcagtgaca 480  
 gatttctacc cagccaaagat caaagtgcgc tggttccgga atggccaggaa ggagacggtg 540  
 15 ggggtctcat ccacacagct tatttagaat ggggactgga cttccaggt cctggtcatg 600  
 ctggagatga cccctcgccg gggagaggc tacacotgcc acgtggagca tccgagccctg 660  
 aagagccccca tcactgtggta gtggactagt ggtggcggtg gcagcggcgg tgggggttcc 720  
 ggtggcgccg gttctggcgg tggcggttcc tggatgtggaa acgacattga ggcggaccac 780  
 20 gtagggcgtct atggtaaac tggatatacg tccctggag acattggcca gtacacacat 840  
 gaatttgatg gtatgatgt gttctatgt gacttggata agaaggagac tatctggatg 900  
 cttccctgagt ttggccaaatt gacaagctt gacccccaag gtggactgca aaacatagct 960  
 acaggaaaat acacccctggg aatcttgcact aagaggcttcaaa attccacccca agctaccaat 1020  
 gaggctccctc aagcgcactgt gttcccaag tccctgtgc tgctgggtca gcccacacc 1080  
 25 ctcatctgct ttgtggacaa catctccct cctgtgatca acatcacatg gtcagaaat 1140  
 agtaagtccat tcacagacgg cgtttatgag accagottcc ttgtcaaccc tgaccattcc 1200  
 ttccacaaggc tggatctatct cacccttcatt cttctgtacg atgatattta tgactgcaag 1260  
 gtggagcact ggggcctgga ggagccgggtt ctgaaacact gggctagccg agggggcgg 1320  
 agcggcgag ggggagctga tgctgcacca actgtatcca tcttcccacc atccagtggag 1380  
 30 cagttAACAT ctggagggtgc ctcaatcgatg tgcttcttgc acaacttcta ccccaaagac 1440  
 atcaatgtca agtggaaagat tggatggcactt gaaacacaaa atggcgtctt gaaacagtgg 1500  
 actgtatcagg acagcaaaaga cagcacctac agcatgagca gcaccctcac gttgaccaag 1560  
 gacgagttatg aacgacataa cagctatacc tggatggcactt ctcacaagac atcaacttca 1620  
 cccattgtca agagcttcaa caggaatggatcc tggatggta cc 1662

35 <210> pCB229  
 <211> 1085  
 <212> DNA  
 <213> Murine

40 <400> 7  
 gaattcggta ccaccatggc tctgcagatc cccagcctcc tcctctcgcc tgctgtggtg 60  
 gtgctgatgg tgctgagcag cccaggact gagggttca agaacattgt gacacctcg 120  
 acaccaccc tcagctagccg agggggcggg agcggccggag ggggagactc cggaaaggcat 180  
 45 ttcgtgttcc agttcaaggg cgagtgcata ttccacaacg ggacgcagcg catacgatct 240  
 gtggacagat acatctacaa ccgggaggag tacctgcgc tgcacagcg cgtggcgag 300  
 taccgcgcgg tgaccgcact gggcggccca gaccccgagt actacaataa gcagtaccc 360  
 gagcaaacgc gggcccgagct ggacacgggtg tgcagacaca actacgaggg ggtggagacc 420  
 cacacccccc tgcggcggtc tgaacagccc aatgtcgatc tccctctgtc caggacagag 480  
 50 gcccctaacc accacaacac tctggatctgc tcagtgcacg atttctaccc agccaagatc 540  
 aaagtgcgtt ggttccggaa tggccaggag gagacgggtgg gggcttcattc cacacagtt 600  
 attaggaatg gggactggac cttccaggat ctggatgc tggagatgac ccctcgccgg 660  
 ggagaggtct acacctgca cgtggagcat ccgagcctga agagccccc cactgtggag 720  
 tggagggcac agtctgatgc tgcccgagc ggatccgctg atgctgcacc aactgtatcc 780  
 atcttcccac catccatgtca gcaatgttaca tctggatggatc ctcagtcgt gtgcttcttg 840  
 55 aacaacttct accccaaaga catcaatgtc aagtggaaaga ttgatggcag tgaacgacaa 900  
 aatggcgtcc tgaacagttg gactgatcag gacagcaaag acagcaccta cagcatgagc 960  
 agcaccctca cgttgcacca ggacgagttt gaaacacata acagctatac ctgtgaggcc 1020  
 actcacaaga catcaacttc acccattgtc aagagcttca acaggaatgaa gtgtttaggcg 1080  
 gccgc 1085

5           <210> pCB223  
 <211> 1676  
 <212> DNA  
 <213> Murine

10          <400> 8  
 gaattccgta ccatggctct gcagatcccc agcctcctcc tctcggtgc tgggtggtg 60  
 ctgatggtc tgaggcagccc aggactgag ggcgaagacg acattgaggc cgaccacgta 120  
 ggcgtctatg gtacaactgt atatcagtct cctggagaca ttggccagta cacacatgaa 180  
 tttgatggtg atgagtggtt ctatgtggac ttggataaga aggagactat ctggatgctt 240  
 cctgagttt gccaatttgc aagctttgc ccccaaggtg gactgcaaaa catactaca 300  
 ggaaaataca ccttgggaat cttgactaag aggtcaattt ccaccccccagc taccaatgag 360  
 gctccctcaag cgactgtgtt ccccaagtcc cctgtgtgc tgggtcagcc caacaccctc 420  
 15          atctgtttt tggacaacat cttccctctt gtgatcaaca tcacatggct cagaatagt 480  
 aagtcaagtca cagacggcgt ttatgagacc agtttcctt tcaaccgtga ccattccttc 540  
 cacaagctgt cttatctcac cttcatccct tctgacgatg atatttatga ctgcaaggtg 600  
 gagcactggg gcctggagga gcccgttctg aaacactggg aacctgagat tccagcccc 660  
 atgtcagaag gatctgccaa aacaacagcc ccatcggtct atccactggc ccctgtgtgt 720  
 20          ggagatacaa ctggctcctc ggtgactcta ggatgcctgg tcaagggtta tttccctgag 780  
 ccagtgaccc tggaccttggaa ctctggatcc ctgtccaggc gtgtgcacac cttcccaagct 840  
 gtcctgcagt ctgacctcta caccctcagc agctcagtga ctgtAACCTC gagcacctgg 900  
 cccagccagt ccatcacctg caatgtggcc daccggcaa gcaagcaccaa ggtggacaag 960  
 aaaattgagc ccagagggcc cacaatcaag ccctgttctc catgcaaatg cccagcacct 1020  
 25          aaccttctgg gtggaccatc cgctttcattc ttccctccaa agatcaagga tgtactcatg 1080  
 atctccctga gccccatagt cacatgtgtg gtgggtggatg tgagcgagga tgaccaggat 1140  
 gtccagatca gctggtttgtt gaaacaacgtg gaagtacaca cagctcagac acaaaccat 1200  
 agagaggatt acaacagttac tctccgggtg gtcagtgcctt tccccatcca gcaccaggac 1260  
 tggatgagtg gcaaggagtt caaatgcaag gtcaacaaca aagacctccc agcggccatc 1320  
 30          gagagaacca tctcaaaacc caaagggtca gtaagagtc cacaggtata tgtcttgct 1380  
 ccaccagaag aagagatgac taagaaacag gtcactctga cctgcattgtt cacagacttc 1440  
 atgcctgaag acatttacgt ggagtggacc aacaacggga aaacagagct aaactacaag 1500  
 aacactgaac cagtccttgg cttctgtgtt tcttacttca tgtacagcaa gctgagagtg 1560  
 gaaaaagaaga actgggttggaa aagaaaatagc tactccctgtt cagtggtcca cgagggtctg 1620  
 35          cacaatcacc acacgactaa gagttctcc cggactccgg gtaaatgagc ggccgc 1676

40          <210> pCB212  
 <211> 773  
 <212> DNA  
 <213> Murine

45          <400> 9  
 ccatgggtaa gaaacagacc gctgttgcattcgctctggc gtcctggct ctttctatga 60  
 cccccggcgtt cgtttcaag aacattgtgacacctcgaac accacctcca gctagcggag 120  
 gggggcggaaag cggcggaggg ggagactccg aaaggcattt cgtgttccag tttaaaggcg 180  
 agtgcgtactt caccacacggg acgcacgcac tacgatctgt ggacagatac atctacaacc 240  
 gggaggagta cctgcgttgc gacagcgcacg tggcgagta cccgcgcggg accgagctgg 300  
 ggcggccaga ccccgagttac tacaataagc agtaccttgc gcaaaacgcgg gccgagctgg 360  
 acacgggtgtt cagacacaaac tacgaggggg tggagaccca cacctccctg cggcggcttg 420  
 50          gtggccgtgg cagcggcggtt ggtgggttccg gtggcgccgg ttctggcggtt ggcgggttccg 480  
 gtggccgtgg cagcgaagac gacattgagg ccgaccacgtt aggcgtctat ggtacaactg 540  
 tatatcagtc ttctggagac attggccagt acacacatga atttgatgtt gatgagtggt 600  
 tctatgtggaa cttggataag aaggagacta tctggatgtc ttctggatgtt ggccaatttga 660  
 55          caagcttgc cccccaaggtt ggactgcacaa acatagctac agggaaaatac accttggaa 720  
 tcttgcgttcaaa gaggtcaaat tccaccccgatcataccaattt aggtacccggatcc 773

<210> pCB214  
 <211> 702  
 <212> DNA

115

&lt;213&gt; Murine

&lt;400&gt; 10

5 atgttcaaga acattgtgac acctcgaaca ccacacctccag ctagcgagg gggcggaagc 60  
 ggcggagggg gagactccga aaggcatttc gtgttccagt ttaaaggcga gtgctacttc 120  
 accaacggga cgccgcgcac acgatctgtg gacagataca tctacaaccg ggaggagttac 180  
 ctgcgcgttcg acagcgacgt gggcgagttac cgccgcgtga cccgagctggg gcggccagac 240  
 cccgagttac acaaataagca gtacactggag caaacccggg cccgagctggc cacgtgtgc 300  
 agacacaact acgagggggtt ggagacccac acctccctgc ggcggcttgg tggcggtggc 360  
 10 agcggcggtg gtgggtccgg tggcggtgt tctggcggtg gcggttccgg tggcggtggc 420  
 agcgaagacg acatttgaggc cgaccacgtt ggcgtctatg gtacaactgt atatcagtct 480  
 cctggagaca ttggccagta cacacatgaa tttgatgggt atgagtgggt ctatgtggac 540  
 ttggataaga aggagactat ctggatgttt cctgagttt gccaatttgc aagctttgac 600  
 15 ccccaagggtg gactgcaaaa catagctaca ggaaaatatac ccttgggaat cttgactaag 660  
 aggtcaaatt ccaccccccac taccaattaa ggtaccggat cc 702

&lt;210&gt; pCB220

&lt;211&gt; 1013

&lt;212&gt; DNA

20 &lt;213&gt; Murine

&lt;400&gt; 11

25 gaattccgtt ccatggctct gcagatcccc agcctcctcc tctcggtgc tgggtgggt 60  
 ctgtatggtgc tgagcagccc aggactgag ggcgaagacg acattgaggc cgaccacgtt 120  
 ggcgtctatg gtacaactgt atatcagtct octggagaca ttggccagta cacacatgaa 180  
 tttgatgggt atgagtgggtt ctatgtggac ttggataaga aggagactat ctggatgttt 240  
 cctgagttt gccaatttgc aagctttgac ccccaagggtg gactgcaaaa catagctaca 300  
 ggaaaatatac ctttgggaat cttgactaag aggtcaaattt ccaccccccac taccaatgag 360  
 gctcctcaag cgactgtgtt ccccaagtcc cctgtgtgc tgggtcagcc caacaccctc 420  
 30 atctgctttg tggacaacat cttcccttcgtt gatcaaca tcacatggc cagaaatagt 480  
 aagtcaagtca cagacggcgt ttatgagacc agcttccttg tcaaccgttgc ccatttcctc 540  
 cacaagctgt ttatctcac cttcatccct tctgacgtt atatttatgta ctgcaagggtg 600  
 gagcactggg gcctggagga gcccgttctg aaacactggg aacctgagat tccagcccc 660  
 35 atgtcagaag gatccgcacaa aacaacagcc ccatcggttct atccactggc ccctgtgtgt 720  
 ggagatacaa ctggctctc ggtgactcta ggtgcttgc tcaagggttta ttcccttgag 780  
 ccagtgaccc ttgacctggaa ctctggatct ctgtccagtg gtgtgcacac cttccagct 840  
 gtcctgcagt ctgacctcta caccctcagc agctcaagtta ctgttaacctc gagcacctgg 900  
 cccagccagt ccatcacccgtt caatgtggcc caccggcaaa gcagcaccaaa ggtggacaag 960  
 aaaatttggac ccagaggggcc cacaatcaag ccctgtgtgc cataggcggc cgc 1013

40

&lt;210&gt; pCRC203

&lt;211&gt; 207

&lt;212&gt; PRT

45 &lt;213&gt; Murine

&lt;400&gt; 12

Met	Phe	Lys	Asn	Ile	Val	Thr	Pro	Arg	Thr	Pro	Pro	Gly	Gly
5												15	

50

Ser	Gly	Asp	Ser	Glu	Arg	His	Phe	Val	Phe	Gln	Phe	Lys	Gly	Glu	Cys
20												30			

Tyr	Phe	Thr	Asn	Gly	Thr	Gln	Arg	Ile	Arg	Ser	Val	Asp	Arg	Tyr	Ile
35												45			

55

Tyr	Asn	Arg	Glu	Glu	Tyr	Leu	Arg	Phe	Asp	Ser	Asp	Val	Gly	Glu	Tyr
50												60			

Arg	Ala	Val	Thr	Glu	Leu	Gly	Arg	Pro	Asp	Pro	Glu	Tyr	Tyr	Asn	Lys
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

	65	70	75	80
	Gln Tyr Leu Glu Gln Thr Arg Ala Glu Leu Asp Thr Val Cys Arg His			
	85	90		95
5	Asn Tyr Glu Gly Val Glu Thr His Thr Ser Leu Arg Arg Leu Gly Gly			
	100	105		110
10	Glu Asp Asp Ile Glu Ala Asp His Val Gly Val Tyr Gly Thr Thr Val			
	115	120		125
	Tyr Gln Ser Pro Gly Asp Ile Gly Gln Tyr Thr His Glu Phe Asp Gly			
	130	135		140
15	Asp Glu Trp Phe Tyr Val Asp Leu Asp Lys Lys Glu Thr Ile Trp Met			
	145	150	155	160
	Leu Pro Glu Phe Gly Gln Leu Thr Ser Phe Asp Pro Gln Gly Gly Leu			
	165	170		175
20	Gln Asn Ile Ala Thr Gly Lys Tyr Thr Leu Gly Ile Leu Thr Lys Arg			
	180	185		190
25	Ser Asn Ser Thr Pro Ala Thr Asn His His His His His His His			
	195	200		205
	<210> pCRC201			
	<211> 201			
30	<212> PRT			
	<213> Murine			
	<400> 13			
35	Met Phe Lys Asn Ile Val Thr Pro Arg Thr Pro Pro Pro Gly Gly Gly			
	5	10		15
	Ser Gly Asp Ser Glu Arg His Phe Val Phe Gln Phe Lys Gly Glu Cys			
	20	25		30
40	Tyr Phe Thr Asn Gly Thr Gln Arg Ile Arg Ser Val Asp Arg Tyr Ile			
	35	40	45	
	Tyr Asn Arg Glu Glu Tyr Leu Arg Phe Asp Ser Asp Val Gly Glu Tyr			
	50	55	60	
45	Arg Ala Val Thr Glu Leu Gly Arg Pro Asp Pro Glu Tyr Tyr Asn Lys			
	65	70	75	80
50	Gln Tyr Leu Glu Gln Thr Arg Ala Glu Leu Asp Thr Val Cys Arg His			
	85	90		95
	Asn Tyr Glu Gly Val Glu Thr His Thr Ser Leu Arg Arg Leu Gly Gly			
	100	105		110
55	Glu Asp Asp Ile Glu Ala Asp His Val Gly Val Tyr Gly Thr Thr Val			
	115	120	125	
	Tyr Gln Ser Pro Gly Asp Ile Gly Gln Tyr Thr His Glu Phe Asp Gly			
	130	135		140

117

Asp Glu Trp Phe Tyr Val Asp Leu Asp Lys Lys Glu Thr Ile Trp Met  
 145 150 155 160

5 Leu Pro Glu Phe Gly Gln Leu Thr Ser Phe Asp Pro Gln Gly Gly Leu  
 165 170 175

Gln Asn Ile Ala Thr Gly Lys Tyr Thr Leu Gly Ile Leu Thr Lys Arg  
 180 185 190

10 Ser Asn Ser Thr Pro Ala Thr Asn  
 195 200

15 <210> pCRC199  
 <211> 218  
 <212> PRT  
 <213> Murine

20 <400> 14  
 Met Phe Lys Asn Ile Val Thr Pro Arg Thr Pro Pro Pro Ala Ser Gly  
 5 10 15

Gly Gly Gly Ser Gly Gly Gly Asp Ser Glu Arg His Phe Val Phe  
 25 20 25 30

Gln Phe Lys Gly Glu Cys Tyr Phe Thr Asn Gly Thr Gln Arg Ile Arg  
 35 40 45

30 Ser Val Asp Arg Tyr Ile Tyr Asn Arg Glu Glu Tyr Leu Arg Phe Asp  
 50 55 60

Ser Asp Val Gly Glu Tyr Arg Ala Val Thr Glu Leu Gly Arg Pro Asp  
 65 70 75 80

35 Pro Glu Tyr Tyr Asn Lys Gln Tyr Leu Glu Gln Thr Arg Ala Glu Leu  
 85 90 95

Asp Thr Val Cys Arg His Asn Tyr Glu Gly Val Glu Thr His Thr Ser  
 40 100 105 110

Leu Arg Arg Leu Thr Ser Gly Gly Ser Glu Asp Asp Ile Glu  
 115 120 125

45 Ala Asp His Val Gly Val Tyr Gly Thr Thr Val Tyr Gln Ser Pro Gly  
 130 135 140

Asp Ile Gly Gln Tyr Thr His Glu Phe Asp Gly Asp Glu Trp Phe Tyr  
 145 150 155 160

50 Val Asp Leu Asp Lys Lys Glu Thr Ile Trp Met Leu Pro Glu Phe Gly  
 165 170 175

Gln Leu Thr Ser Phe Asp Pro Gln Gly Leu Gln Asn Ile Ala Thr  
 55 180 185 190

Gly Lys Tyr Thr Leu Gly Ile Leu Thr Lys Arg Ser Asn Ser Thr Pro  
 195 200 205

118

Ala Thr Asn His His His His His His  
 210                                   215

5   <210> pCRC197  
 <211> 212  
 <212> PRT  
 <213> Murine

10   <400> 15  
 Met Phe Lys Asn Ile Val Thr Pro Arg Thr Pro Pro Pro Ala Ser Gly  
       5                              10                                   15

Gly Gly Gly Ser Gly Gly Gly Asp Ser Glu Arg His Phe Val Phe  
 15                                   20                              25                           30

Gln Phe Lys Gly Glu Cys Tyr Phe Thr Asn Gly Thr Gln Arg Ile Arg  
       35                            40                              45

20   Ser Val Asp Arg Tyr Ile Tyr Asn Arg Glu Glu Tyr Leu Arg Phe Asp  
       50                            55                              60

Ser Asp Val Gly Glu Tyr Arg Ala Val Thr Glu Leu Gly Arg Pro Asp  
       65                            70                              75                           80

25   Pro Glu Tyr Tyr Asn Lys Gln Tyr Leu Glu Gln Thr Arg Ala Glu Leu  
       85                            90                              95

Asp Thr Val Cys Arg His Asn Tyr Glu Gly Val Glu Thr His Thr Ser  
 30                                   100                           105                           110

Leu Arg Arg Leu Thr Ser Gly Gly Ser Glu Asp Asp Ile Glu  
       115                            120                           125

35   Ala Asp His Val Gly Val Tyr Gly Thr Thr Val Tyr Gln Ser Pro Gly  
       130                            135                           140

Asp Ile Gly Gln Tyr Thr His Glu Phe Asp Gly Asp Glu Trp Phe Tyr  
       145                            150                           155                           160

40   Val Asp Leu Asp Lys Lys Glu Thr Ile Trp Met Leu Pro Glu Phe Gly  
       165                            170                           175

Gln Leu Thr Ser Phe Asp Pro Gln Gly Gly Leu Gln Asn Ile Ala Thr  
 45                                   180                           185                           190

Gly Lys Tyr Thr Leu Gly Ile Leu Thr Lys Arg Ser Asn Ser Thr Pro  
       195                            200                           205

50   Ala Thr Asn  
       210

55   <210> pCRC188  
 <211> 548  
 <212> PRT  
 <213> Murine

&lt;400&gt; 16

119

	Met Ala Leu Gln Ile Pro Ser Leu	Leu	Leu Ser Ala Ala Val Val Val	
	5		10	15
5	Leu Met Val Leu Ser Ser Pro Gly	Thr	Glu Gly Ala Ser Gly Gly Gly	
	20	25	30	
	Gly Ser Gly Gly Gly Asp Ser Glu Arg His Phe Val Phe Gln Phe			
	35	40	45	
10	Lys Gly Glu Cys Tyr Phe Thr Asn Gly	Thr	Gln Arg Ile Arg Ser Val	
	50	55	60	
	Asp Arg Tyr Ile Tyr Asn Arg Glu Glu Tyr	Leu	Arg Phe Asp Ser Asp	
	65	70	75	80
15	Val Gly Glu Tyr Arg Ala Val Thr Glu	Leu	Gly Arg Pro Asp Pro Glu	
	85	90	95	
20	Tyr Tyr Asn Lys Gln Tyr Leu Glu Gln	Thr	Arg Ala Glu Leu Asp Thr	
	100	105	110	
	Val Cys Arg His Asn Tyr Glu Gly Val Glu Thr His	Thr	Ser Leu Arg	
	115	120	125	
25	Arg Leu Glu Gln Pro Asn Val Val Ile Ser	Leu	Ser Arg Thr Glu Ala	
	130	135	140	
	Leu Asn His His Asn Thr Leu Val Cys Ser Val	Thr	Asp Phe Tyr Pro	
	145	150	155	160
30	Ala Lys Ile Lys Val Arg Trp Phe Arg Asn Gly	Gln	Glu Glu Thr Val	
	165	170	175	
35	Gly Val Ser Ser Thr Gln Leu Ile Arg Asn Gly	Asp Trp	Thr Phe Gln	
	180	185	190	
	Val Leu Val Met Leu Glu Met Thr Pro Arg Arg	Gly	Glu Val Tyr Thr	
	195	200	205	
40	Cys His Val Glu His Pro Ser Leu Lys Ser Pro	Ile	Thr Val Glu Trp	
	210	215	220	
	Thr Ser Gly Gly Gly Ser Gly Gly Gly	Ser Gly	Gly Gly Gly Gly	
	225	230	235	240
45	Ser Gly Gly Gly Ser Ser Ser Glu Asp Asp Ile	Glu Ala	Asp His	
	245	250	255	
50	Val Gly Val Tyr Gly Thr Thr Val Tyr Gln	Ser Pro Gly Asp Ile	Gly	
	260	265	270	
	Gln Tyr Thr His Glu Phe Asp Gly Asp Glu Trp	Phe Tyr Val Asp	Leu	
	275	280	285	
55	Asp Lys Lys Glu Thr Ile Trp Met Leu Pro	Glu Phe Gly	Gln Leu Thr	
	290	295	300	
	Ser Phe Asp Pro Gln Gly Gly Leu Gln Asn Ile	Ala Thr Gly	Lys Tyr	
	305	310	315	320

120

	Thr Leu Gly Ile Leu Thr Lys Arg Ser Asn Ser Thr Pro Ala Thr Asn			
	325	330	335	
5	Glu Ala Pro Gln Ala Thr Val Phe Pro Lys Ser Pro Val Leu Leu Gly			
	340	345	350	
	Gln Pro Asn Thr Leu Ile Cys Phe Val Asp Asn Ile Phe Pro Pro Val			
	355	360	365	
10	Ile Asn Ile Thr Trp Leu Arg Asn Ser Lys Ser Val Thr Asp Gly Val			
	370	375	380	
15	Tyr Glu Thr Ser Phe Leu Val Asn Arg Asp His Ser Phe His Lys Leu			
	385	390	395	400
	Ser Tyr Leu Thr Phe Ile Pro Ser Asp Asp Asp Ile Tyr Asp Cys Lys			
	405	410	415	
20	Val Glu His Trp Gly Leu Glu Glu Pro Val Leu Lys His Trp Ala Ser			
	420	425	430	
	Gly Gly Gly Ser Gly Gly Gly Ala Asp Ala Ala Pro Thr Val			
	435	440	445	
25	Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly Gly Ala Ser			
	450	455	460	
30	Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile Asn Val Lys			
	465	470	475	480
	Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu Asn Ser Trp			
	485	490	495	
35	Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser Ser Thr Leu			
	500	505	510	
	Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr Thr Cys Glu			
	515	520	525	
40	Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser Phe Asn Arg			
	530	535	540	
45	Asn Glu Cys			
	545			
	<210> pCRC187			
	<211> 253			
50	<212> PRT			
	<213> Murine			
	<400> 17			
55	Met Gly Lys Lys Gln Thr Ala Val Ala Phe Ala Leu Ala Leu Ala			
	5	10	15	
	Leu Ser Met Thr Pro Ala Tyr Ala Phe Lys Asn Ile Val Thr Pro Arg			
	20	25	30	

121

Thr Pro Pro Pro Ala Ser Gly Gly Gly Gly Ser Gly Gly Gly Asp  
                   35                  40                  45  
  
 5   Ser Glu Arg His Phe Val Phe Gln Phe Lys Gly Glu Cys Tyr Phe Thr  
       50                  55                  60  
  
 Asn Gly Thr Gln Arg Ile Arg Ser Val Asp Arg Tyr Ile Tyr Asn Arg  
   65                  70                  75                  80  
  
 10   Glu Glu Tyr Leu Arg Phe Asp Ser Asp Val Gly Glu Tyr Arg Ala Val  
       85                  90                  95  
  
 Thr Glu Leu Gly Arg Pro Asp Pro Glu Tyr Tyr Asn Lys Gln Tyr Leu  
   100                  105                  110  
  
 15   Glu Gln Thr Arg Ala Glu Leu Asp Thr Val Cys Arg His Asn Tyr Glu  
       115                  120                  125  
  
 Gly Val Glu Thr His Thr Ser Leu Arg Arg Leu Gly Gly Gly Ser  
 20   130                  135                  140  
  
 Gly Gly Gly Ser Gly Gly Ser Gly Gly Gly Ser Gly  
   145                  150                  155                  160  
  
 25   Gly Gly Gly Ser Glu Asp Asp Ile Glu Ala Asp His Val Gly Val Tyr  
       165                  170                  175  
  
 Gly Thr Thr Val Tyr Gln Ser Pro Gly Asp Ile Gly Gln Tyr Thr His  
   180                  185                  190  
  
 30   Glu Phe Asp Gly Asp Glu Trp Phe Tyr Val Asp Leu Asp Lys Lys Glu  
       195                  200                  205  
  
 Thr Ile Trp Met Leu Pro Glu Phe Gly Gln Leu Thr Ser Phe Asp Pro  
 35   210                  215                  220  
  
 Gln Gly Gly Leu Gln Asn Ile Ala Thr Gly Lys Tyr Thr Leu Gly Ile  
   225                  230                  235                  240  
  
 40   Leu Thr Lys Arg Ser Asn Ser Thr Pro Ala Thr Asn  
       245                  250  
  
  
 45   <210> pCB229  
 <211> 354  
 <212> PRT  
 <213> Murine  
  
 <400> 18  
 50   Met Ala Leu Gln Ile Pro Ser Leu Leu Ser Ala Ala Val Val Val  
       5                  10                  15  
  
 Leu Met Val Leu Ser Ser Pro Gly Thr Glu Gly Phe Lys Asn Ile Val  
   20                  25                  30  
  
 55   Thr Pro Arg Thr Pro Pro Ala Ser Gly Gly Gly Ser Gly Gly  
       35                  40                  45  
  
 Gly Gly Asp Ser Glu Arg His Phe Val Phe Gln Phe Lys Gly Glu Cys

		122		
	50	55	60	
	Tyr Phe Thr Asn Gly Thr Gln Arg Ile Arg Ser Val Asp Arg Tyr Ile			
	65	70	75	80
5	Tyr Asn Arg Glu Glu Tyr Leu Arg Phe Asp Ser Asp Val Gly Glu Tyr			
	85	90		95
10	Arg Ala Val Thr Glu Leu Gly Arg Pro Asp Pro Glu Tyr Tyr Asn Lys			
	100	105		110
	Gln Tyr Leu Glu Gln Thr Arg Ala Glu Leu Asp Thr Val Cys Arg His			
	115	120		125
15	Asn Tyr Glu Gly Val Glu Thr His Thr Ser Leu Arg Arg Leu Glu Gln			
	130	135		140
	Pro Asn Val Val Ile Ser Leu Ser Arg Thr Glu Ala Leu Asn His His			
	145	150	155	160
20	Asn Thr Leu Val Cys Ser Val Thr Asp Phe Tyr Pro Ala Lys Ile Lys			
	165	170		175
25	Val Arg Trp Phe Arg Asn Gly Gln Glu Glu Thr Val Gly Val Ser Ser			
	180	185		190
	Thr Gln Leu Ile Arg Asn Gly Asp Trp Thr Phe Gln Val Leu Val Met			
	195	200		205
30	Leu Glu Met Thr Pro Arg Arg Gly Glu Val Tyr Thr Cys His Val Glu			
	210	215		220
	His Pro Ser Leu Lys Ser Pro Ile Thr Val Glu Trp Arg Ala Gln Ser			
	225	230	235	240
35	Glu Ser Ala Arg Ser Gly Ser Ala Asp Ala Ala Pro Thr Val Ser Ile			
	245	250		255
40	Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly Gly Ala Ser Val Val			
	260	265		270
	Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys			
	275	280		285
45	Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu Asn Ser Trp Thr Asp			
	290	295		300
	Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu			
	305	310	315	320
50	Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr Thr Cys Glu Ala Thr			
	325	330		335
55	His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser Phe Asn Arg Asn Glu			
	340	345		350
	Cys			

123

<210> p/cb223  
 <211> 552  
 <212> PRT  
 5 <213> Murine

<400> 19  
 Met Ala Leu Gln Ile Pro Ser Leu Leu Leu Ser Ala Ala Val Val Val  
                       5                         10                         15

10 Leu Met Val Leu Ser Ser Pro Gly Thr Glu Gly Glu Asp Asp Ile Glu  
    20                         25                         30

15 Ala Asp His Val Gly Val Tyr Gly Thr Thr Val Tyr Gln Ser Pro Gly  
    35                         40                         45

Asp Ile Gly Gln Tyr Thr His Glu Phe Asp Gly Asp Glu Trp Phe Tyr  
    50                         55                         60

20 Val Asp Leu Asp Lys Lys Glu Thr Ile Trp Met Leu Pro Glu Phe Gly  
    65                         70                         75                         80

Gln Leu Thr Ser Phe Asp Pro Gln Gly Gly Leu Gln Asn Ile Ala Thr  
    85                         90                         95

25 Gly Lys Tyr Thr Leu Gly Ile Leu Thr Lys Arg Ser Asn Ser Thr Pro  
    100                         105                         110

30 Ala Thr Asn Glu Ala Pro Gln Ala Thr Val Phe Pro Lys Ser Pro Val  
    115                         120                         125

Leu Leu Gly Gln Pro Asn Thr Leu Ile Cys Phe Val Asp Asn Ile Phe  
    130                         135                         140

35 Pro Pro Val Ile Asn Ile Thr Trp Leu Arg Asn Ser Lys Ser Val Thr  
    145                         150                         155                         160

Asp Gly Val Tyr Glu Thr Ser Phe Leu Val Asn Arg Asp His Ser Phe  
    165                         170                         175

40 His Lys Leu Ser Tyr Leu Thr Phe Ile Pro Ser Asp Asp Ile Tyr  
    180                         185                         190

45 Asp Cys Lys Val Glu His Trp Gly Leu Glu Glu Pro Val Leu Lys His  
    195                         200                         205

Trp Glu Pro Glu Ile Pro Ala Pro Met Ser Glu Gly Ser Ala Lys Thr  
    210                         215                         220

50 Thr Ala Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr  
    225                         230                         235                         240

Gly Ser Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu  
    245                         250                         255

55 Pro Val Thr Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His  
    260                         265                         270

Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser

	124		
	275	280	285
	Val Thr Val Thr Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn		
	290	295	300
5	Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro		
	305	310	315
	Arg Gly Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro		
10	325	330	335
	Asn Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys		
	340	345	350
15	Asp Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val		
	355	360	365
	Asp Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn		
	370	375	380
20	Asn Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr		
	385	390	395
	Asn Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp		
25	405	410	415
	Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu		
	420	425	430
30	Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg		
	435	440	445
	Ala Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys		
	450	455	460
35	Lys Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp		
	465	470	475
	480		
40	Ile Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys		
	485	490	495
	Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser		
	500	505	510
45	Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser		
	515	520	525
	Cys Ser Val Val His Glu Gly Leu His Asn His His Thr Thr Lys Ser		
	530	535	540
50	Phe Ser Arg Thr Pro Gly Lys		
	545	550	
55	<210> pCB212		
	<211> 331		
	<212> PRT		
	<213> Murine		

125

&lt;400&gt; 20

Met Ala Leu Gln Ile Pro Ser Leu Leu Leu Ser Ala Ala Val Val Val	5	10	15
---	---	----	----

5 Leu Met Val Leu Ser Ser Pro Gly Thr Glu Gly Glu Asp Asp Ile Glu	20	25	30
---	----	----	----

Ala Asp His Val Gly Val Tyr Gly Thr Thr Val Tyr Gln Ser Pro Gly	35	40	45
---	----	----	----

10 Asp Ile Gly Gln Tyr Thr His Glu Phe Asp Gly Asp Glu Trp Phe Tyr	50	55	60
--	----	----	----

15 Val Asp Leu Asp Lys Lys Glu Thr Ile Trp Met Leu Pro Glu Phe Gly	65	70	75	80
--	----	----	----	----

Gln Leu Thr Ser Phe Asp Pro Gln Gly Gly Leu Gln Asn Ile Ala Thr	85	90	95
---	----	----	----

20 Gly Lys Tyr Thr Leu Gly Ile Leu Thr Lys Arg Ser Asn Ser Thr Pro	100	105	110
--	-----	-----	-----

Ala Thr Asn Glu Ala Pro Gln Ala Thr Val Phe Pro Lys Ser Pro Val	115	120	125
---	-----	-----	-----

25 Leu Leu Gly Gln Pro Asn Thr Leu Ile Cys Phe Val Asp Asn Ile Phe	130	135	140
--	-----	-----	-----

30 Pro Pro Val Ile Asn Ile Thr Trp Leu Arg Asn Ser Lys Ser Val Thr	145	150	155	160
--	-----	-----	-----	-----

Asp Gly Val Tyr Glu Thr Ser Phe Leu Val Asn Arg Asp His Ser Phe	165	170	175
---	-----	-----	-----

35 His Lys Leu Ser Tyr Leu Thr Phe Ile Pro Ser Asp Asp Ile Tyr	180	185	190
--	-----	-----	-----

Asp Cys Lys Val Glu His Trp Gly Leu Glu Glu Pro Val Leu Lys His	195	200	205
---	-----	-----	-----

40 Trp Glu Pro Glu Ile Pro Ala Pro Met Ser Glu Gly Ser Ala Lys Thr	210	215	220
--	-----	-----	-----

45 Thr Ala Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr	225	230	235	240
--	-----	-----	-----	-----

Gly Ser Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu	245	250	255
---	-----	-----	-----

50 Pro Val Thr Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His	260	265	270
--	-----	-----	-----

Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser	275	280	285
---	-----	-----	-----

55 Val Thr Val Thr Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn	290	295	300
--	-----	-----	-----

Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro
---

	126		
* 305	310	315	320
	Arg Gly Pro Thr Ile Lys Pro Cys Ala Ala		
	325	330	
5			
	<210> pCB214		
	<211> 234		
	<212> PRT		
10	<213> Murine		
	<400> 21		
	Met Phe Lys Asn Ile Val Thr Pro Arg Thr Pro Pro Pro Ala Ser Gly		
	5	10	15
15	Gly Gly Gly Ser Gly Gly Gly Asp Ser Glu Arg His Phe Val Phe		
	20	25	30
	Gln Phe Lys Gly Glu Cys Tyr Phe Thr Asn Gly Thr Gln Arg Ile Arg		
20	35	40	45
	Ser Val Asp Arg Tyr Ile Tyr Asn Arg Glu Glu Tyr Leu Arg Phe Asp		
	50	55	60
25	Ser Asp Val Gly Glu Tyr Arg Ala Val Thr Glu Leu Gly Arg Pro Asp		
	65	70	75
	Pro Glu Tyr Tyr Asn Lys Gln Tyr Leu Glu Gln Thr Arg Ala Glu Leu		
	85	90	95
30	Asp Thr Val Cys Arg His Asn Tyr Glu Gly Val Glu Thr His Thr Ser		
	100	105	110
	Leu Arg Arg Leu Gly Gly Ser Gly Gly Gly Ser Gly Gly		
35	115	120	125
	Gly Gly Ser Gly Gly Ser Gly Gly Gly Ser Glu Asp Asp		
	130	135	140
40	Ile Glu Ala Asp His Val Gly Val Tyr Gly Thr Thr Val Tyr Gln Ser		
	145	150	155
	Pro Gly Asp Ile Gly Gln Tyr Thr His Glu Phe Asp Gly Asp Glu Trp		
	165	170	175
45	Phe Tyr Val Asp Leu Asp Lys Lys Glu Thr Ile Trp Met Leu Pro Glu		
	180	185	190
	Phe Gly Gln Leu Thr Ser Phe Asp Pro Gln Gly Gly Leu Gln Asn Ile		
50	195	200	205
	Ala Thr Gly Lys Tyr Thr Leu Gly Ile Leu Thr Lys Arg Ser Asn Ser		
	210	215	220
55	Thr Pro Ala Thr Asn Gly Thr Gly Ser		
	225		

<210> pCB220

127

<211> 560

<212> PRT

<213> Murine

5 <400> 22  
 Met Ala Leu Gln Ile Pro Ser Leu Leu Leu Ser Ala Ala Val Val Val  
           5                                     10                                 15  
 10 Leu Met Val Leu Ser Ser Pro Gly Thr Glu Gly Phe Lys Asn Ile Val  
       20                                     25                                 30  
 15 Thr Pro Arg Thr Pro Pro Pro Ala Ser Gly Gly Gly Ser Gly Gly  
       35                                     40                                 45  
 20 Gly Gly Asp Ser Glu Arg His Phe Val Phe Gln Phe Lys Gly Glu Cys  
       50                                     55                                 60  
 25 Tyr Phe Thr Asn Gly Thr Gln Arg Ile Arg Ser Val Asp Arg Tyr Ile  
       65                                     70                                 80  
 30 Tyr Asn Arg Glu Glu Tyr Leu Arg Phe Asp Ser Asp Val Gly Glu Tyr  
       85                                     90                                 95  
 35 Arg Ala Val Thr Glu Leu Gly Arg Pro Asp Pro Glu Tyr Tyr Asn Lys  
       100                                    105                                110  
 40 Gln Tyr Leu Glu Gln Thr Arg Ala Glu Leu Asp Thr Val Cys Arg His  
       115                                    120                                125  
 45 Asn Tyr Glu Gly Val Glu Thr His Thr Ser Leu Arg Arg Leu Glu Gln  
       130                                    135                                140  
 50 Pro Asn Val Val Ile Ser Leu Ser Arg Thr Glu Ala Leu Asn His His  
       145                                    150                                160  
 55 Asn Thr Leu Val Cys Ser Val Thr Asp Phe Tyr Pro Ala Lys Ile Lys  
       165                                    170                                175  
 60 Val Arg Trp Phe Arg Asn Gly Gln Glu Glu Thr Val Gly Val Ser Ser  
       180                                    185                                190  
 65 Thr Gln Leu Ile Arg Asn Gly Asp Trp Thr Phe Gln Val Leu Val Met  
       195                                    200                                205  
 70 Leu Glu Met Thr Pro Arg Arg Gly Glu Val Tyr Thr Cys His Val Glu  
       210                                    215                                220  
 75 His Pro Ser Leu Lys Ser Pro Ile Thr Val Glu Trp Thr Ser Gly Gly  
       225                                    230                                240  
 80 Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Gly  
       245                                    250                                255  
 85 Gly Ser Ser Ser Glu Asp Asp Ile Glu Ala Asp His Val Gly Val Tyr  
       260                                    265                                270  
 90 Gly Thr Thr Val Tyr Gln Ser Pro Gly Asp Ile Gly Gln Tyr Thr His  
       275                                    280                                285

128

Glu Phe Asp Gly Asp Glu Trp Phe Tyr Val Asp Leu Asp Lys Lys Glu  
290 295 300

5 Thr Ile Trp Met Leu Pro Glu Phe Gly Gln Leu Thr Ser Phe Asp Pro  
305 310 315 320

Gln Gly Gly Leu Gln Asn Ile Ala Thr Gly Lys Tyr Thr Leu Gly Ile  
325 330 335

10 Leu Thr Lys Arg Ser Asn Ser Thr Pro Ala Thr Asn Glu Ala Pro Gln  
340 345 350

Ala Thr Val Phe Pro Lys Ser Pro Val Leu Leu Gly Gln Pro Asn Thr  
355 360 365

15 Leu Ile Cys Phe Val Asp Asn Ile Phe Pro Pro Val Ile Asn Ile Thr  
370 375 380

20 Trp Leu Arg Asn Ser Lys Ser Val Thr Asp Gly Val Tyr Glu Thr Ser  
385 390 395 400

Phe Leu Val Asn Arg Asp His Ser Phe His Lys Leu Ser Tyr Leu Thr  
405 410 415

25 Phe Ile Pro Ser Asp Asp Asp Ile Tyr Asp Cys Lys Val Glu His Trp  
420 425 430

Gly Leu Glu Glu Pro Val Leu Lys His Trp Ala Ser Gly Gly Gly  
435 440 445

30 Ser Gly Gly Gly Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro  
450 455 460

35 Pro Ser Ser Glu Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe  
465 470 475 480

Leu Asn Asn Phe Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp  
485 490 495

40 Gly Ser Glu Arg Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp  
500 505 510

Ser Lys Asp Ser Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys  
515 520 525

45 Asp Glu Tyr Glu Arg His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys  
530 535 540

50 Thr Ser Thr Ser Pro Ile Val Lys Ser Phe Asn Arg Asn Glu Cys  
545 550 555

WHAT IS CLAIMED IS:

- 1           1. A multimeric complex comprising a first recombinant single chain  
2 MHC class II molecule and a second recombinant single chain MHC class II molecule,  
3 wherein the first and the second single chain MHC class II molecule each comprise an  $\alpha 1$   
4 domain and a  $\beta 1$  domain linked via an amino acid linker and a multimerization domain,  
5 and wherein the first and the second single chain MHC class II molecule are linked via  
6 the multimerization domain to form a multimeric complex.
- 1           2. The multimeric complex of claim 1, wherein the first and the  
2 second single chain MHC class II molecules are each linked to an antigenic peptide via an  
3 amino acid linker.
- 1           3. The multimeric complex of claim 2, wherein the peptides are the  
2 same.
- 1           4. The multimeric complex of claim 2, wherein the peptides are from  
2 the same antigen.
- 1           5. The multimeric complex of claim 2, wherein the peptides are from  
2 different antigens.
- 1           6. The multimeric complex of claim 2, wherein the peptides are  
2 selected from the group consisting of MBP83-102Y83, PLP 40-60, PLP 89-106, PLP 95-  
3 117, and PLP 185-206.
- 1           7. The multimeric complex of claim 1, wherein the first and the  
2 second MHC class II molecules are from the same MHC class II allele.
- 1           8. The multimeric complex of claim 1, wherein the first and the  
2 second MHC class II molecules are from different MHC class II alleles.
- 1           9. The multimeric complex of claim 7 or 8, wherein the alleles are  
2 selected from the group consisting of DRB1\*1501 and DRB5\*0101.

1               10.     The multimeric complex of claim 7 or 8, wherein the first and the  
2     second single chain MHC class II molecules are each linked to an antigenic peptide via an  
3     amino acid linker.

1               11.     The multimeric complex of claim 10, wherein the peptides are the  
2     same.

1               12.     The multimeric complex of claim 10, wherein the peptides are  
2     from the same antigen.

1               13.     The multimeric complex of claim 10, wherein the peptides are  
2     from different antigens.

1               14.     The multimeric complex of claim 10, wherein the peptides are  
2     selected from the group consisting of MBP83-102Y83, PLP 40-60, PLP 89-106, PLP 95-  
3     117, and PLP 185-206.

1               15.     The multimeric complex of claim 1, wherein the first and second  
2     MHC class II molecules are from a human.

1               16.     The multimeric complex of claim 1, wherein the multimerization  
2     domains are covalently linked.

1               17.     The multimeric complex of claim 1, wherein the multimerization  
2     domains are non-covalently linked.

1               18.     The multimeric complex of claim 1, wherein the multimerization  
2     domain is a leucine zipper domain.

1               19.     The multimeric complex of claim 1, wherein the multimerization  
2     domain is an immunoglobulin domain.

1               20.     The multimeric complex of claim 19, wherein the immunoglobulin  
2     domain is a light chain constant domain or a heavy chain constant domain.

1           21. The multimeric complex of claim 1, wherein the first or the second  
2 MHC class II molecule is selected from the group consisting of I-As MBP. $\beta$ 1 $\beta$ 2 $\alpha$ 1 $\alpha$ 2.C $\kappa$ ,  
3 I-As MBP. $\beta$ 1 $\beta$ 2 $\alpha$ 1 $\alpha$ 2.CH1.H, I-As MBP. $\beta$ 1 $\beta$ 2 $\alpha$ 1 $\alpha$ 2.CH1.H.CH2, and I-As  
4 MBP. $\beta$ 1 $\beta$ 2 $\alpha$ 1 $\alpha$ 2.CH1.H.CH2.CH3.

1           22. The multimeric complex of claim 1, further comprising a third and  
2 a fourth MHC class II molecule, wherein the third and the fourth MHC class II molecule  
3 each comprise an  $\alpha$ 1 domain and a  $\beta$ 1 domain linked via an amino acid linker and a  
4 multimerization domain, and wherein the first, second, third and fourth single chain MHC  
5 class II molecules are linked via the multimerization domain to form a multimeric  
6 complex.

1           23. The multimeric complex of claim 1, wherein the first and the  
2 second MHC class II molecules comprise  $\beta$ 1  $\beta$ 2 domains and  $\alpha$ 1  $\alpha$ 2 domains linked via an  
3 amino acid linker.

1           24. The multimeric complex of claim 1 or 2, wherein the linker is  
2 selected from the group consisting of GG, GGGG, GGGGS, GGGSG, ASGGGSAGGG,  
3 TSGGGGSAGGGSSS, GSPGGGSAGGGPGS, GSPPGGPPGS, GSPGGGGPGS,  
4 TSGGGGS, SGGSGGS, FDAPSPLP, and VYPEVTV.

1           25. The multimeric complex of claim 1 or 2, wherein the linker is from  
2 a CD4 molecule.

1           26. The multimeric complex of claim 25, wherein the linker is selected  
2 from the group consisting of RNGQEEKAGVVSTGLI, RNGQETKAGVVSTGLI,  
3 YNQEEKAGGVSTGLI, FRNGQEEKAGVVSTGLI, FRNGQETKAGVVSTGLI,  
4 FYNQEEKAGGVSTGLI, and LNGQEEKAGMVSTGLI.

1           27. The multimeric complex of claim 1, wherein the first or the second  
2 MHC class II molecule is selected from the group consisting of CO523, CO543, CO563,  
3 CO567, CO580, CO581, CO582, CO583, CO584, CO585, CO586, CO587, CO588,  
4 CO589, CO590, CO591, CO592, CO593, CO594, CO595, CO596, CO597, and CO608.

1               28. The multimeric complex of claim 1, wherein the first and the  
2 second MHC class II molecule are independently selected from the group consisting of  
3 CO523, CO543, CO563, CO567, CO580, CO581, CO582, CO583, CO584, CO585,  
4 CO586, CO587, CO588, CO589, CO590, CO591, CO592, CO593, CO594, CO595,  
5 CO596, CO597, and CO608.

1               29. The multimeric complex of claim 1, wherein the first MHC class II  
2 or the second MHC class II molecule is encoded by a nucleic acid that codons optimized  
3 for prokaryotic expression.

1               30. The multimeric complex of claim 29, wherein the prokaryote is *E.*  
2 *coli.*

1               31. The multimeric complex of claim 29, wherein the nucleic acid  
2 encoding the first or the second MHC class II molecule is selected from the group  
3 consisting of CO528-AC and CO608-AC.

1               32. A pharmaceutical composition comprising the multimeric complex  
2 of claim 2.

1               33. The pharmaceutical composition of claim 32, further comprising an  
2 adjuvant.

1               34. A method of treating autoimmune disease in a subject, the method  
2 comprising administering an immunogenically effective amount of a pharmaceutical  
3 composition comprising the multimeric complex of claim 2.

1               35. The method of claim 34, wherein the subject is a human.

1               36. A recombinant nucleic acid encoding a single chain MHC class II  
2 molecule comprising an  $\alpha$ 1 domain and a  $\beta$ 1 domain linked via an amino acid linker,  
3 wherein the linker is selected from the group consisting of GG, GGGG, GGGGS,  
4 GGGSG, ASGGGSAGGG, TSAGGGSGGGSSS, GSPAGGGSGGGPGS,  
5 GSPPGGPPGS, GSPAGGGPGS, TSAGGGGS, SGGSGGS, FDAPSPLP, and VYPEVTV.

1           37. The nucleic acid of claim 36, wherein the MHC class II molecule is  
2 selected from the group consisting of CO523, CO543, CO563, CO567, CO580, CO581,  
3 CO582, CO583, CO584, CO585, CO586, CO587, CO588, CO589, CO590, CO591,  
4 CO592, CO593, CO594, CO595, CO596, CO597, and CO608.

1           38. A recombinant nucleic acid encoding a single chain MHC class II  
2 molecule comprising an  $\alpha_1$  domain and a  $\beta_1$  domain linked via an amino acid linker,  
3 wherein the linker is wherein the linker is from a CD4 molecule.

1           39. The nucleic acid of claim 38, wherein the linker is selected from  
2 the group consisting of RNGQEEKAGVVSTGLI, RNGQETKAGVVSTGLI,  
3 YNQQEEKAGGVSTGLI, FRNGQEEKAGVVSTGLI, FRNGQETKAGVVSTGLI,  
4 FYNQQEEKAGGVSTGLI, and LNGQEEKAGMVSTGLI.

1           40. A recombinant nucleic acid encoding a single chain MHC class II  
2 molecule selected from the group consisting of CO528-AC and CO608-AC.

1           41. A recombinant nucleic acid encoding a single chain MHC class II  
2 molecule selected from the group consisting I-As MBP. $\beta_1\beta_2\alpha_1\alpha_2.C\kappa$ , I-As  
3 MBP. $\beta_1\beta_2\alpha_1\alpha_2.CH1.H$ , I-As MBP. $\beta_1\beta_2\alpha_1\alpha_2.CH1.H.CH2$ , and I-As  
4 MBP. $\beta_1\beta_2\alpha_1\alpha_2.CH1.H.CH2.CH3$ .

1           42. A recombinant nucleic acid encoding a single chain MHC class II  
2 molecule selected from the group consisting CO523, CO543, CO563, CO567, CO580,  
3 CO581, CO582, CO583, CO584, CO585, CO586, CO587, CO588, CO589, CO590,  
4 CO591, CO592, CO593, CO594, CO595, CO596, CO597, and CO608.

1 / 14






I-AS<sub>MBP</sub>. $\beta_1\beta_2\alpha_1\alpha_2$ .CK


FIG. 1.


2/14



3/14



**FIG. 4.**

**FIG. 4.** (Continued)

6/14




FIG. 5.




FIG. 6.

7/14




FIG. 7.

8/14




FIG. 8.

EAE induction Day 0 and 7	Treatment Day 1, 4, 7 & 11 10ug/injection i.v.	Incidence of disease (%)
Myelin 2 mg/mouse in CFA s.c.	none	12/16 (75%)
Myelin 2 mg/mouse in CFA s.c.	Monomer	2/12 (16%)
Myelin 2 mg/mouse in CFA s.c.	Dimer	2/6 (33%)
Myelin 2 mg/mouse in CFA s.c.	Tetramer	3/14 (21%)
Myelin 2 mg/mouse in CFA s.c.	Monomer Pool	2/16 (12%)
Myelin 2 mg/mouse in CFA s.c.	Half Anergix	2/16 (12%)
Myelin 2 mg/mouse in CFA s.c.	I-As peptide	9/16 (56%)
Myelin 2 mg/mouse in CFA s.c.	Empty Half Anergix	10/16 (62%)

9/14

**FIG. 9.**

10/14







FIG. 10.

Native IAS beta 1 . PRO  
 mCO608 . PRO  
 mCO608 A . pro  
 mCO608 B . pro  
 pCRC197 . pro  
 pCRC199 . pro

MGSERFKNITPRTPPPASGGGGGGG-----[GDSE.RHFVQFQFKG] 13  
 M-----[FKNITPRTPPPASGGGGGGG-----[HFVFQFQFKG] 35  
 M-----[FKNITPRTPPPASGGGGGGG-----[HFVFQFQFKG] 31  
 M-----[FKNITPRTPPPASGGGGGGG-----[SERHFVQFQFKG] 35  
 M-----[FKNITPRTPPPASGGGGGGGGDSE.RHFVQFQFKG] 36  
 M-----[FKNITPRTPPPASGGGGGGGGDSE.RHFVQFQFKG] 36

Native IAS beta 1 . PRO  
 mCO608 . PRO  
 mCO608 A . pro  
 mCO608 B . pro  
 pCRC197 . pro  
 pCRC199 . pro

KCYFTNGTQRIRSVDRYIYNREEYLRFDSDVGEYRAVTEL 53  
 KCYFTNGTQRIRSVDRYIYNREEYLRFDSDVGEYRAVTEL 75  
 KCYFTNGTQRIRSVDRYIYNREEYLRFDSDVGEYRAVTEL 71  
 KCYFTNGTQRIRSVDRYIYNREEYLRFDSDVGEYRAVTEL 75  
 KCYFTNGTQRIRSVDRYIYNREEYLRFDSDVGEYRAVTEL 76  
 KCYFTNGTQRIRSVDRYIYNREEYLRFDSDVGEYRAVTEL 76

Native IAS beta 1 . PRO  
 mCO608 . PRO  
 mCO608 A . pro  
 mCO608 B . pro  
 pCRC197 . pro  
 pCRC199 . pro

GRDPPEYYNKQYLEQTRAELDTVCRHNYEGVETHTSIRR 92  
 GRDPPEYYNKQYLEQTRAELDTVCRHNYEGVETHTSIRR 115  
 GRDPPEYYNKQYLEQTRAELDTVCRHNYEGVETHTSIRR 111  
 GRDPPEYYNKQYLEQTRAELDTVCRHNYEGVETHTSIRR 115  
 GRDPPEYYNKQYLEQTRAELDTVCRHNYEGVETHTSIRR 116  
 GRDPPEYYNKQYLEQTRAELDTVCRHNYEGVETHTSIRR 116

Native IAS beta 1 . PRO  
 mCO608 . PRO  
 mCO608 A . pro  
 mCO608 B . pro  
 pCRC197 . pro  
 pCRC199 . pro

TSGGGGSEDDIEADHVGVYGTIVYQSPGDIGQYTTHEFDGD 115  
 TSGGGGSEDDIEADHVGVYGTIVYQSPGDIGQYTTHEFDGD 151  
 TSGGGGSEDDIEADHVGVYGTIVYQSPGDIGQYTTHEFDGD 155  
 TSGGGGSEDDIEADHVGVYGTIVYQSPGDIGQYTTHEFDGD 156  
 TSGGGGSEDDIEADHVGVYGTIVYQSPGDIGQYTTHEFDGD 156

**FIG. 11.**

12/14

Native IAs beta 1 . PRO	92
mCO608 . PRO	EWFYVDLDKKETIWM.LPEFGQLTSFDQGGILQNIATGKYT
mCO608 A .pro	EWFYVDLDKKETIWM.LPEFGQLTSFDQGGILQNIATGKYT
mCO608 B .pro	EWFYVDLDKKETIWM.LPEFGQLTSFDQGGILQNIATGKYT
PCRC197 .pro	EWFYVDLDKKETIWM.LPEFGQLTSFDQGGILQNIATGKYT
PCRC199 .pro	EWFYVDLDKKETIWM.LPEFGQLTSFDQGGILQNIATGKYT
Native IAs beta 1 . PRO	93
mCO608 . PRO	LGILT KRSN STPATN.
mCO608 A .pro	LGILT KRSN STPATN.
mCO608 B .pro	LGILT KRSN STPATN.
PCRC197 .pro	LGILT KRSN STPATN.
PCRC199 .pro	LGILT KRSN STPATNHHHHHH.

**FIG. 11. (CONTINUED)**

13/14

Native IAS beta 1.PRO CO561.pro pCRC201.pro pCRC203.pro	-GDSERHFVFFQFKGECYFTN 19 MGSERFKNIVTPRTPPGGGS-----HFFVFFQFKGECYFTN 35 M-----FKNIVTPRTPPGGGGSDSERHFVFFQFKGECYFTN 36 M-----FKNIVTPRTPPGGGGSDSERHFVFFQFKGECYFTN 36
Native IAS beta 1.PRO CO561.pro pCRC201.pro pCRC203.pro	GTQRIRSVVDRYIYNREEEYLREFDSDVGEYRAVTELGRPDPF 59 GTQRIRSVVDRYIYNREEEYLREFDSDVGEYRAVTELGRPDPF 75 GTQRIRSVVDRYIYNREEEYLREFDSDVGEYRAVTELGRPDPF 76 GTQRIRSVVDRYIYNREEEYLREFDSDVGEYRAVTELGRPDPF 76
Native IAS beta 1.PRO CO561.pro pCRC201.pro pCRC203.pro	YNNKQYLEQTRAELDTVCRHNYEGVETHTSIIRR----- 92 YNNKQYLEQTRAELDTVCRHNYEGVETHTSIIRRRLGGEDDI 115 YNNKQYLEQTRAELDTVCRHNYEGVETHTSIIRRRLGGEDDI 116 YNNKQYLEQTRAELDTVCRHNYEGVETHTSIIRRRLGGEDDI 116
Native IAS beta 1.PRO CO561.pro pCRC201.pro pCRC203.pro	----- 92 EADHVGVYGTIVYQSPGDTIGQYTHEFDGDEWFYVDLDDKKE 155 EADHVGVYGTIVYQSPGDTIGQYTHEFDGDEWFYVDLDDKKE 156 EADHVGVYGTIVYQSPGDTIGQYTHEFDGDEWFYVDLDDKKE 156

**FIG. 12.**

14/14

Native IAS beta 1.PRO	92
CO561.pro	TIWMILPEFGQLTSDPQGGIQLQNIATGKYTLGILTGILTKRSNST
PCRC201.pro	TIWMILPEFGQLTSDPQGGIQLQNIATGKYTLGILTGILTKRSNST
PCRC203.pro	TIWMILPEFGQLTSDPQGGIQLQNIATGKYTLGILTGILTKRSNST
Native IAS beta 1.PRO	93
PCRC201.pro	200
PCRC203.pro	L
	PATN.
	PATNHHHHH.
	201
	207

**FIG. 12. (CONTINUED)**

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US2001/09616

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 35/28

US CL : 514/8, 903; 530/395, 402, 403; 424/88

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/8, 903; 530/395, 402, 403; 424/88

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAPLUS EMBASE BIOSIS MEDLINE WEST

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,194,425 A (SHARMA et al.) 16 March 1993, entire patent	1-42
Y	US 5,284,935 A (CLARK et al.) 08 February 1994, entire patent	1-42
Y	US 6,015,884 A (SCHNECK et al.) 18 January 2000, entire patent	1-20

Further documents are listed in the continuation of Box C.  See patent family annex.

*	Special categories of cited documents:	
"A"	document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E"	earlier document published on or after the international filing date	"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P"	document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search  
16 JULY 2001

Date of mailing of the international search report  
05 SEP 2001

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231  
Facsimile No. (703) 305-3230

Authorized officer  
AMY DECLoux  
Telephone No. (703) 308-0196